

1 **Statin uses and skeletal muscle-related phenotypes: insights from**
2 **epidemiological and Mendelian randomization analyses**

3 **Running title: Statin Uses and Skeletal Muscle-related Phenotypes**

4 Fan Tang^{1†}, Zhanchao Chen^{2,3†}, Hongbing Qiu¹, Yige Liu^{2,3}, Yanjiao Shen^{4,5},
5 Yiying Zhang^{1*}, Shanjie Wang^{2,3*}, Bo Yu^{2,3}

6 ¹Department of Epidemiology and Biostatistics, School of Public Health, Jiamusi
7 University, Jiamusi, China.

8 ² Department of Cardiology, Second Affiliated Hospital of Harbin Medical
9 University;

10 ³ The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education;
11 National Key Laboratory of Frigid Zone Cardiovascular Diseases, Harbin, China;

12 ⁴ Innovation Institute for Integration of Medicine and Engineering, Chinese
13 Evidence-Based Medicine Center, West China Hospital, Sichuan University,
14 Chengdu, Sichuan, 610041, P.R. China;

15 ⁵ Department of Health Research Methods, Evidence, and Impact, McMaster
16 University, Hamilton, Ontario, Canada.

17 [†] Contributed equally to this article.

18 ^{*} Corresponding authors: Yiying Zhang, 258 Xuefu Road, Xiangyang District,
19 154007 Jiamusi, China. Tel: 15245488123, Email: zhangyiying@jmsu.edu.cn; Shanjie
20 Wang, 246 Xuefu Road, Nangang District, 150086 Harbin, China. Tel: +86 451 8660
21 5180, Fax: +86 451 8660 5180, Email: shanjie_wang@hrbmu.edu.cn; ORCID:
22 <https://orcid.org/0000-0002-1148-1570>

23 Fan Tang, Hongbing Qiu, Yiying Zhang District: 154007 Jiamusi, China

24 Zhanchao Chen, Yige Liu, Shanjie Wang, Bo Yu District, 150086 Harbin, China.

25 The category of the manuscript: Original Articles

26 Word counts:3890

27 Number of tables: 4 plus 11 supplementary tables

28 Number of figures: 1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 **Abstract:**

30 **Background:**

31 The association between statin use and skeletal muscle-related side effects is
32 always controversial. This study aimed to comprehensively investigate the
33 associations between statin use and muscle-related phenotypes including sarcopenia,
34 sarcopenic obesity, serum lactate dehydrogenase (LDH), and musculoskeletal pain
35 symptoms among adults with indications for statin use for secondary prevention
36 (cardiovascular disease, diabetes, or hyperlipidemia).

37 **Methods:**

38 This cross-sectional study included 22,549 patients aged ≥ 20 years with
39 cardiovascular disease, diabetes, or hyperlipidemia. Weighted generalized linear
40 regression analysis and propensity score matching methods were used to estimate the
41 associations between the use of statins or other lipid-lowering agents and skeletal
42 muscle-related phenotypes. Mendelian randomization (MR) analysis was additionally
43 used to verify the causal relationship between statin use and skeletal muscle-related
44 phenotypes.

45 **Results:**

46 The weighted mean age was 59 years, 50.3% were male, and 37.6% (n=8,481)
47 received statin treatment. In the unadjusted model, compared with adults without any
48 lipid-lowering drugs, statin use was associated with a higher likelihood of sarcopenia
49 (appendicular skeletal muscle mass [ASM]/Body mass index [BMI] OR 1.35 (95%CI
50 1.12 to 1.62, $p < 0.001$), ASM/weight [Wt] OR 1.86 (95%CI 1.62 to 2.13, $p <$
51 0.001), max HGS β -3.01 (95% CI -3.97 to -2.06, $p < 0.001$), relative HGS β -0.23

52 (95% CI -0.30 to -0.17, $p < 0.001$) and combined HGS β -5.90 (95% CI -7.86 to -3.93,
53 $p < 0.001$), sarcopenic obesity (ASM/height squared [Ht^2] and body fat percentage
54 definition [OR 1.36 (95% CI 1.13 to 1.63, $p < 0.001$]). After multivariable adjustment
55 or propensity score match, the independent associations of statin use with sarcopenia,
56 sarcopenic obesity, HGS, LDH, and musculoskeletal pain became nonsignificant.
57 Stepwise regression suggested that age was the predominant confounding factor for
58 the associations. MR analysis also revealed no significant causality between statin use
59 and skeletal muscle-related phenotypes.

60 **Conclusions:**

61 Our epidemiological and MR analyses did not support the causality between
62 statin use and skeletal muscle-related phenotypes. A higher likelihood of skeletal
63 muscle-related adverse phenotypes in statin users may be attributed to age. Future
64 studies should further explore the biological factors that may affect statin-related
65 muscle phenotypes to provide evidence for the safety of statins.

66 **Keywords:**

67 Statins, sarcopenia, sarcopenic obesity, handgrip strength, lactate dehydrogenase,
68 musculoskeletal pain

69

70 1. Introduction

71 Statins are the first-line prescribed drugs that lower lipid levels by inhibiting 3-
72 hydroxy-3-methylglutaryl-CoA reductase[1]. Numerous studies demonstrated the
73 cornerstone status of statins in preventing the risk of atherosclerotic cardiovascular
74 disease (ASCVD) and relevant mortality[2, 3]. Thus, current clinical guidelines
75 underline the importance of statin use in cardiovascular disease, diabetes, and
76 hyperlipidemia[2, 4, 5].

77 Despite the significant benefits of statins, the controversy surrounding Statin-
78 associated muscle symptoms (SAMS) persists. The potential adverse effects of statin
79 use remain a significant subject of discussion, prompting concerns among patients and
80 physicians [6, 7]. SAMS, encompassing muscle-related symptoms such as myalgia,
81 tenderness, stiffness, cramps, and weakness, with or without elevated creatine kinase
82 levels, are frequently reported as the predominant side effects. These symptoms can
83 lead to causes medication nonadherence, potentially leading to suboptimal
84 cardiovascular management [8, 9]. Statin discontinuation related to SAMS has been
85 shown to cause a nearly 3-fold increased risk of cardiovascular events[10]. Most
86 randomized controlled trials indicate that the risk of SAMS is minimal or insignificant
87 compared with a placebo[11]. A study showed[2]that older adults receiving statins for
88 primary and secondary prevention do not have an increased risk of myopathy. A
89 recent systematic review showed[12]that statin use was not significantly related to the
90 risk of SAMS and relevant mortality among older statin users. A cross-sectional study

91 showed no correlation between statin use and musculoskeletal pain in arthritis
92 patients[13]. However, it is important to note that previous trials and meta-analyses
93 may have several limitations. For example, study points by self-reported symptoms
94 may be subjective; severe myopathy and rhabdomyolysis, both are rare in humans as
95 statin-related musculoskeletal disorders; and the study population may lack
96 representativeness due to small sample sizes and potential selection bias[12].

97 Sarcopenia is an age-related syndrome characterized by loss of muscle mass,
98 strength, and function[14]. Dual-energy X-ray absorptiometry (DXA) is employed for
99 assessing total body lean tissue mass or appendicular skeletal muscle mass[15].
100 However, the relationship between statins and muscle mass or sarcopenia has not been
101 reported. Handgrip strength (HGS) serves as another indicator for assessing skeletal
102 muscle function[16]. Only two studies reported inconsistent results on the association
103 between statins and muscle function (e.g., grip strength, and gait speed) in older
104 adults[17, 18]. Overall, there's a lack of large-scale studies comprehensively
105 examining the association between statin use and instrument-based muscle
106 characteristics. Mendelian randomization (MR) analysis is acknowledged as a
107 complementary method to imitate randomized controlled trials, which is increasingly
108 recognized as an emerging epidemiological approach that utilizes genetic factors to
109 evaluate the causal impact of exposure on a particular outcome[19]. Therefore, this
110 study combined a large-scale observational study in the National Nutrition Health and
111 Nutrition Examination Survey (1999-2020) 1999–2020, and a two-sample MR

112 analysis was conducted to evaluate the relationships between statin use and muscle-
113 related phenotypes including sarcopenia, sarcopenic obesity, serum lactate
114 dehydrogenase (LDH), and musculoskeletal pain among adults with the indications
115 for statin use for secondary prevention (cardiovascular disease, diabetes, or
116 hyperlipidemia).

117 2. Methods

118 2.1 Study Population

119 As we have previously reported[20], the National Nutrition Health and Nutrition
120 Examination Survey employs a stratified, multistage probability sampling method to
121 represent the noninstitutionalized population of the United States. In this study,
122 datasets from 11 two-year cycles of the National Nutrition Health and Nutrition
123 Examination Survey (from 1999–2000 to 2017–2020). The data from the 11 cycles
124 were standardized and combined, using interview weights consistent with the
125 recommendations from the National Center for Health Statistics.

126 A total of 116,876 participants were involved in the survey over two cycles. We
127 excluded individuals aged < 20 years (n = 52,563), those without assessment for
128 cardiovascular disease (CVD), diabetes, or hyperlipidemia (n = 37,051), and those
129 lacking data on muscle-related phenotypes (n = 4,713). In total, 22,549 subjects were
130 analyzed, including 13,474 non-statin users, 8,481 statin users, and 594 users of lipid-
131 lowering drugs other than statins (**Figure 1**). The study was approved by the research
132 ethics review board of the Centers for Disease Control and Prevention, and all
133 participants provided informed consent.

134 CVD was defined as a self-reported history of coronary heart disease, heart
135 failure, or stroke. Diabetes was defined as a physician-reported diagnosis, plasma
136 HbA1c \geq 6.5%, or fasting blood glucose \geq 7.0 mmol/L[21]. Hyperlipidemia was
137 defined as a physician-reported diagnosis in the primary analysis. In sensitivity
138 analyses, hyperlipidemia is defined as total cholesterol 200 mg/dL, triglycerides 150

139 mg/dL, HDL 40 mg/dL in men, 50 mg/dL in women, or hypolipidemia—high-density
140 lipoprotein cholesterol 130 mg/dL[22]. Additionally, individuals reporting the use of
141 cholesterol-lowering medications were also categorized as having hyperlipidemia.

142 Two-sample MR was performed to evaluate the causal effects between s statin
143 use and muscle-related phenotypes (**Figure 1**). The current MR research is based on
144 three main assumptions[23]. First, the selected SNPs were associated with statins;
145 second, the SNPs were not associated with other confounding factors; third, the SNPs
146 only affected sarcopenia-related indicators and the risk of LDH through statins,
147 without affecting other pathways. Detailed information about the data downloading
148 and screening processes is displayed in **Table S1** and **Table S2**.

149 **2.2 The use of statins and lipid-lowering agents**

150 At baseline, during a personal interview, participants were asked about the
151 prescription medications they had taken in the past 30 days. The prescription drug
152 names are recorded on the drug container label. Each drug is associated with a
153 standardized generic prescription drug name[20]. **Table S3** contains a list of statins
154 and lipid-lowering drugs.

155 **2.3 Definition of skeletal muscle-related phenotypes**

156 **2.3.1 Sarcopenia and sarcopenic obesity**

157 The survey provides an accurate set of muscle mass data, assessed by dual-
158 energy X-ray absorptiometry (DEXA). Appendicular skeletal muscle mass (ASM
159 (kg)) was defined as the sum of the muscle mass of the four limbs. The skeletal

160 muscle index was calculated as the appendicular skeletal muscle mass divided by the
161 body mass index (BMI) or weight (Wt). In this study, the cutoff value for sarcopenia
162 was defined by BMI-adjusted ASM according to the Foundation for National
163 Institutes of Health (FNIH) criteria[24], male < 0.789 , female < 0.512 . The cutoff for
164 sarcopenia was defined by a weight-adjusted ASM of 29.76% for males and 22.31%
165 for females[25]. The appendicular skeletal mass index (ASMI) was defined as the
166 ASM divided by the square of the height(ht^2). According to the European Working
167 Group on Sarcopenia in Older Population(EWGSOP2)[26], sarcopenia was defined as
168 an ASMI $< 7 \text{ kg/m}^2$ in men or $< 5.5 \text{ kg/m}^2$ in women[27]. Subjects were classified as
169 obese using standard BMI categories ($\geq 30 \text{ kg/m}^2$) or a body fat percentage $\geq 25\%$ for
170 men and $\geq 35\%$ for women. If the subject met the criteria for both sarcopenia and
171 obesity using these definitions, a diagnosis of sarcopenic obesity was considered.

172 The muscle strength/grip strength was assessed by isometric HGS using a
173 handgrip dynamometer[28]. Grip strength testing is typically conducted with
174 participants in a standing position unless they have physical constraints. Muscle
175 strength was measured in three indicators: maximum HGS, combined HGS, and
176 relative HGS. Participants underwent three HGS tests for both their left and right
177 hands. The study selected the highest value from the three tests for maximum HGS;
178 combined HGS was calculated as the sum of the highest readings from each hand.
179 Relative grip strength was defined as the sum of the highest readings from each hand,
180 divided by BMI.

181 **2.3.2 Lactate dehydrogenase**

182 The survey measures serum LDH levels at baseline in all adult participants using
183 an enzymatic rate method; more information on LDH analysis techniques can be
184 found in the Laboratory Procedure Manual[29]

185 **2.3.3 Musculoskeletal pain in different anatomical regions**

186 Participants were asked, ‘In the past month, have you had problems with pain
187 that lasted for more than 24 hours?’ Those who answered ‘yes’ were asked to specify
188 the location of the pain. We assessed reports of pain in the neck or upper back, upper
189 extremities, lower back, and lower extremities. Musculoskeletal pain was defined as
190 pain in one of these areas.

191 **2.4 Other variables**

192 The covariates included age, sex, race/ethnicity, education level, income-to-
193 poverty ratio, marital status, alcohol use status, smoking status, physical activity,
194 BMI, hypertension, cardiovascular disease, diabetes, hyperlipidemia, chronic kidney
195 disease, chronic obstructive pulmonary disease, and cancer. The poverty income ratio
196 was categorized into three categories: 1.5, 1.5-3.5, and >3.5[30]. BMI categories of
197 <25 kg/m², 25 to 30 kg/m², and >30 kg/m² were established. Hypertension,
198 cardiovascular disease, diabetes, hyperlipidemia, chronic obstructive pulmonary
199 disease, and cancer were defined based on self-reported prior diagnoses.

200 **2.5 Propensity score matching**

201 Propensity score matching was used to balance baseline differences in
202 cardiovascular disease, diabetes, and hyperlipidemia between the statin and non-statin

203 groups. Propensity scores were calculated for individuals using logistic regression,
204 including all covariates. Paired patients were selected using the nearest neighbor
205 matching algorithm without replacement, with a caliper size of 0.2 standard
206 deviations of the propensity score logit[20]. In addition, standardized differences were
207 used after matching to assess the balance of covariates between the two groups;
208 covariates with standardized differences less than 0.01 were considered well-
209 balanced.

210 **2.6 Statistical analysis**

211 Statistical analyses were performed according to the analysis guidelines for the
212 dataset. Because the amount of missing data in the covariates was small (<5%), we
213 used multivariate interpolation with chained equations to handle the missing data[31].
214 The baseline characteristics of the participants were summarized via descriptive
215 analysis according to their statin use status. Chi-square tests and t-tests were used to
216 compare categorical and continuous data[30]. Weighted generalized linear regression
217 analyses were used to estimate the associations between statin or lipid-lowering drug
218 use and sarcopenic, sarcopenic obesity, HGS, LDH, and musculoskeletal pain.
219 Multivariate models were adjusted for covariates included in propensity score
220 matching. We further redefined the population with hyperlipidemia to examine the
221 association between statin or lipid-lowering drug use and low muscle mass, grip
222 strength, or musculoskeletal pain. Other analyses were limited to patients aged 65
223 years or older with cardiovascular disease, diabetes, or hyperlipidemia.

224 We performed two-sample MR analyses to assess the causal relationships
225 between statin use and appendicular lean mass, hand grip strength (left and right), low
226 hand grip strength, walking pace, and LDH. Handling missing values using multiple
227 imputations. In the main analyses, we used a random-effects inverse variance
228 weighted (IVW) approach to estimate causal effects. In addition, sensitivity analyses
229 using weighted median, MR-Egger, and MR-pleiotropic residuals and outliers (MR-
230 PRESSO) methods were performed to assess the robustness of the IVW results. We
231 considered two-sided p-values less than 0.05 as statistically significant. Stata (version
232 15.0) and R (version 4.1.2) were used for all analyses.

233

234 **3. Results**

235 **3.1 Participant characteristics**

236 This cross-sectional study included 22,549 individuals diagnosed with
237 cardiovascular disease, diabetes, or hyperlipidemia at baseline between 1999 - 2020.
238 Overall, 37.6% of patients (n=8481) were taking statins at baseline. The mean age of
239 all subjects was 59 ± 15 years, and 50.3% were male. Those taking statins were more
240 likely to be older, have a greater body mass index, and were less likely to smoke ($P <$
241 0.05) (Table 1). Adults without any lipid-lowering drugs had a higher proportion of
242 chronic diseases such as hypertension, chronic kidney disease, or cancer ($P < 0.05$)
243 (Table 1). We also matched statin and non-statin users separately (Table S4).

244 **3.2 Relationship between statin use and muscle-related phenotypes.**

245 Table 2 shows the relationships between statin use and muscle-related
246 phenotypes including sarcopenia, sarcopenic obesity, and LDH. Compared with adults
247 without any lipid-lowering drugs, statin user was associated with a higher likelihood
248 of muscle-related phenotypes, ASM/BMI (OR=1.35, 95% CI: 1.12 to 1.62), ASM/Wt
249 (OR=1.86, 95% CI: 1.62 to 2.13), maximum HGS ($\beta = -3.01$, 95% CI: -3.97 to -2.06),
250 relative HGS ($\beta = -0.23$, 95% CI: -0.30 to -0.17), and combined HGS ($\beta = -5.90$, 95% CI:
251 -7.86 to -3.93), ASM/Ht² and body fat percentage defined as sarcopenic obesity
252 (OR=1.36, 95% CI: 1.13 to 1.63) in the unadjusted model.

253 Multivariate linear regression analysis revealed that compared with adults
254 without any lipid-lowering drugs, statin user was not associated with a higher
255 likelihood of muscle-related phenotypes including ASM/BMI (OR=1.31, 95% CI:

256 0.99 to 1.74), ASM/Wt (OR=1.23, 95% CI: 0.99 to 1.54), ASM/Ht² (OR=1.11, 95%
257 CI: 0.77 to 1.60), maximum HGS (β =-3.01, 95% CI: -3.97 to -2.06), relative HGS (β
258 =-0.23 95% CI: -0.30 to -0.17), and combined HGS (β =-5.90 95% CI: -7.86 to -3.93),
259 ASM/Ht² and body fat percentage defined as sarcopenic obesity (OR= 1.32, 95% CI:
260 1.00 to 1.75), ASM and BMI defined as sarcopenic obesity (OR=0.92, 95% CI: 0.51
261 to 1.66).

262 We further performed propensity score-matched analyses (**Table 2**) to account
263 for possible confounding factors that may have contributed to the protective
264 associations between statin use and muscle-related phenotypes. Statin user was not
265 associated with a higher likelihood of muscle-related phenotypes including ASM/BMI
266 (OR=1.25, 95% CI: 1.00 to 1.55), ASM/Wt (OR=1.14, 95% CI: 0.97 to 1.34),
267 ASM/Ht² (OR=0.87, 95% CI: 0.64 to 1.18), maximum HGS (β =-0.13 95% CI: -0.66
268 to 0.40), relative HGS (β = -0.01 95% CI: -0.04 to 0.03), combined HGS (β =-0.32
269 95% CI: -1.32 to 0.67), or LDH (β =-0.57, 95% CI: -1.72 to 0.58), ASM/Ht² and body
270 fat percentage defined as sarcopenic obesity (OR= 1.26, 95% CI: 1.00 to 1.56), ASM
271 and BMI defined as sarcopenic obesity (OR=0.74, 95% CI: 0.23 to 2.44).

272 **Table 3** shows the adjusted and unadjusted odds ratios for musculoskeletal pain
273 and statin use. Multivariate linear regression analysis revealed that compared with
274 without any lipid-lowering drugs, statin user was not associated with a higher
275 likelihood of musculoskeletal pain including any regional pain (OR=1.15, 95% CI:
276 0.88 to 1.50), neck/upper back pain (OR= 0.96, 95% CI: 0.64 to 1.44), upper
277 extremities pain (OR=1.11, 95% CI: 0.81 to 1.51), lower back pain (OR=1.05, 95%

278 CI: 0.77 to 1.45) or lower extremities pain (OR=1.12, 95% CI: 0.83 to 1.51). We
279 further performed propensity score-matched analyses (**Table 3**) to account for
280 possible confounding factors that may have contributed to the protective association
281 between statin use and musculoskeletal pain. Compared without any lipid-lowering
282 drugs, statin user was not associated with any regional pain (OR=1.09, 95% CI: 0.91
283 to 1.31), neck/upper back pain (OR=0.94, 95% CI: 0.67 to 1.32), upper extremities
284 pain (OR=1.13, 95% CI: 0.93 to 1.39), lower back pain (OR=1.05, 95% CI: 0.79 to
285 1.39) or lower extremities pain (OR=1.08, 95% CI: 0.84 to 1.41).

286 We conducted a stepwise regression analysis to observe the association between
287 statin use and muscle-related phenotypes and found that the associations were
288 substantially attenuated after adjustment for age (**Table S5**).

289 **3.3 MR analysis**

290 There was moderate heterogeneity in the estimated effects of statins on the
291 sarcopenia-related indicators appendicular lean mass, hand grip strength, and LDH (P
292 of Cochran's Q < 0.05) but no pleiotropy (intercept > P of 0.05) (**Table S6**). Overall
293 IVW MR analysis (**Table 4**) revealed that compared without a statin, statin user was
294 not associated with a higher likelihood of muscle-related phenotypes including
295 appendicular lean mass ($\beta=-0.060$, 95% CI: -0.153 to 0.033), right-hand grip strength
296 ($\beta=-0.014$, 95% CI: -0.039 to 0.012), left-hand grip strength ($\beta=-0.216$, 95% CI: -
297 0.044 to 0.001), low hand grip strength (OR=1.042, 95% CI: 0.889 to 1.221), walking
298 pace ($\beta=0.001$, 95% CI: -0.010 to 0.011), and LDH ($\beta=-0.080$, 95% CI: -0.230 to
299 0.053).

300 3.4 Sensitivity analysis

301 Sensitivity analysis revealed that among the population aged 65 and over (**Table**
302 **S7**), population with cardiovascular disease (**Table S8**), population with diabetes
303 (**Table S9**), and population with hyperlipidemia (**Table S10**), statin user was not
304 associated with a higher likelihood of muscle-related phenotypes.

305 **Table S11** shows the relationships between statin use and muscle-related
306 phenotypes in the redefined hyperlipidemic population. Propensity score matching
307 revealed that statin user was not associated with a higher likelihood of muscle-related
308 phenotypes including ASM/BMI (OR=1.25, 95% CI: 0.99 to 1.59), ASM/Ht²
309 (OR=0.94, 95% CI: 0.66 to 1.33), maximum HGS (β =- 0.45, 95% CI: -1.04 to 0.14),
310 relative HGS(β =-0.03, 95% CI: -0.07 to 0.01), combined HGS (β =-2.33, 95% CI: -
311 5.47 to 0.81), ASM/Ht² and body fat percentage defined as sarcopenic obesity
312 (OR=1.23, 95% CI: 0.96 to 1.57), ASM and BMI defined as sarcopenic obesity
313 (OR=0.85, 95% CI: 0.53 to 1.34), LDH (β =- 0.62, 95% CI: -4.69 to 3.46), any region
314 pain (OR=1.10, 95% CI: 0.89 to 1.35), neck/upper back pain (OR=0.89, 95% CI: 0.61
315 to 1.30).

316 **4. Discussion**

317 In this nationally representative cross-sectional study with 22,549 patients with a
318 history of cardiovascular disease, diabetes, or hyperlipidemia, 8,481 (37.6%)
319 participants used statin. We found that in the unadjusted model, compared with adults
320 not using any lipid-lowering drugs, statin use was associated with a higher likelihood
321 of sarcopenia, sarcopenic obesity, lower HGS, and combined HGS. However, after
322 multivariable adjustment or propensity score match, the independent associations of
323 statin use with sarcopenia, sarcopenic obesity, HGS, LDH, and musculoskeletal pain
324 became nonsignificant. Stepwise regression suggested that age was the predominant
325 confounding factor for these associations. MR analysis also showed no significant
326 causality between statin use and skeletal muscle-related phenotypes including
327 appendicular lean mass, hand grip strength (left and right), low hand grip strength,
328 walking pace, or LDH.

329 Our results are inconsistent with previous studies, in which we found no
330 association between statin use and skeletal muscle-related phenotypes. Chronic heart
331 failure resulting from various cardiovascular diseases may contribute to secondary
332 sarcopenia related to disease in patients with cardiovascular disease[32]. Notably,
333 sarcopenia is associated with worse quality of life and increased mortality in patients
334 with CVD[32]. A meta-analysis found significant differences in myopathic symptoms
335 and muscle pain between patients on low- and high-intensity statin therapy. However,
336 only 57% of myopathy symptoms and 16% of muscle pain were dose-related[33]. In a
337 large observational study of 46,249 participants, statin users exhibited higher rates of

338 arthropathy, musculoskeletal injuries, and pain compared to controls matched for age,
339 sex, and comorbidities[34]. While this study found no association between statin use
340 and increased likelihood of musculoskeletal pain among individuals with
341 cardiovascular disease, diabetes, or hyperlipidemia, another observational study
342 reported a significantly higher incidence of musculoskeletal pain in various regions,
343 including the lower back and lower extremities, among statin users without
344 arthritis[13]. The study revealed that statin user was not associated with a higher
345 likelihood of maximum HGS, relative HGS, or combined HGS, and other
346 observational results conflicted. For instance, findings from the Hertfordshire cohort
347 study indicated that calcium channel blockers and fibrates were linked to reduced grip
348 strength in women, whereas statins showed no such association[17].

349 There is no evidence of an increased likelihood of muscle-related phenotypes in
350 the population receiving statins. Data from RCTs on the efficacy of statins in patients
351 aged 65 years and older showed that[35] although older adults are at a higher risk for
352 cardiovascular disease and are most likely to benefit from lipid-lowering therapy, they
353 are the group least likely to receive statins[36]. This suggests that statins are still
354 underutilized, with patients >65 years less likely to receive a statin prescription than
355 younger patients[37]. This phenomenon primarily stems from concerns among older
356 adults regarding myopathy as an adverse reaction linked to statin therapy. However,
357 this cross-sectional study revealed statin user was not associated with a higher
358 likelihood of muscle-related phenotypes including sarcopenia, HGS, or LDH in the
359 population over 65 years of age, indicating that in terms of adverse muscle effects,

360 statins may play a role in cardiovascular disease, diabetes, or relative safety in
361 patients with hyperlipidemia.

362 Our results found that the association between statin use and muscle-related
363 phenotypes was significantly attenuated after adjustment for age. Muscle complaints
364 are commonly reported by older adults and can stem from various causes, including
365 sarcopenia, increased physical activity, diseases that predispose to or exacerbate
366 muscle issues, and medications known for their myotoxic effects. This
367 misinterpretation could lead to a significant number of older adults avoiding statin
368 therapy, thereby missing out on potential cardiovascular benefits and experiencing
369 more unintended events. One randomized controlled trial revealed that 90% of the
370 symptoms experienced while taking statins also occurred while taking a placebo[38].
371 Furthermore, a recent systematic review revealed that between 38% and 78% of
372 individuals reported statin-related muscle symptoms[39]. A recent meta-analysis
373 proposed a “nocebo effect”, which occurs when subjective adverse effects, such as
374 aches and pains, result from patients' anticipation of harm from statin therapy due to
375 their awareness of and concern about potential side effects. A meta-analysis of
376 randomized clinical trials on statins indicated comparable rates of adverse events
377 between participants assigned to statins or placebo, suggesting no notable increase in
378 adverse event rates associated with statin use[39]. However, many researchers argue
379 that because trial populations are often healthier than real-world clinical populations,
380 observational studies can more accurately estimate the frequency of adverse events in
381 clinical practice.

382 The findings of our study demonstrate the long-term safety of statin use, which
383 can enhance patient compliance and address the concerns of both users and healthcare
384 providers. Concurrently, the aging of the population will undoubtedly increase the
385 incidence of musculoskeletal disorders closely associated with aging, including
386 sarcopenia, osteoporosis, and osteopenia[40], therefore muscle-related symptoms
387 should be examined through the lens of the aging process. Our study provides a
388 convincing supplement to the current small sample RCTs, which are insufficient in
389 terms of generalizability and outreach.

390 **4.1 Limitations and Strengths**

391 The strengths of the present study include its large and representative sample,
392 facilitating adjustment for numerous confounding factors and thereby enhancing the
393 reliability of the results. Furthermore, propensity score matching was employed to
394 balance confounding factors related to key medications, thereby reducing potential
395 drug interactions. The main strength of this study lies in combining observational data
396 from the National Nutrition Health and Nutrition Examination Survey 1999–2020
397 with the MR approach.

398 Our study has several limitations. First, the cross-sectional design prevents us
399 from establishing causality or accounting for individuals who may have initiated or
400 ceased statin use due to skeletal muscle adverse events, which were assessed using
401 MR analysis to explore causal relationships. Second, we assessed statin use only for
402 the month before the interview, so we could not determine the duration of statin use or
403 whether non-users had recently stopped taking statins. Additionally, our study faced

404 limitations in obtaining enough statin users to evaluate the effects of various types of
405 statins on outcomes. We also lacked dosage information to investigate potential
406 associations with high statin doses, which contribute to statin-induced muscle-related
407 side effects[13]. Future studies should gather comprehensive medication use histories,
408 including dosage details from prescription labels, frequency, duration of use, and
409 discontinuation patterns. This would enhance the robustness of the study findings.
410 Third, due to the absence of creatine kinase level data, we were unable to investigate
411 the association between statin or other lipid-lowering drug use and creatine kinase
412 levels. These data, combined with longitudinal follow-up, could provide further
413 insights into the musculoskeletal side effects of statins, despite this study utilizing
414 LDH as a muscle damage marker. Moreover, our study sample was representative of
415 the U.S. population, primarily comprising self-reported non-Hispanic White
416 participants. However, data on individuals of Asian descent were not captured. This
417 detail is crucial as research suggests that individuals of Asian descent may exhibit
418 higher susceptibility to statin-induced musculoskeletal side effects compared to other
419 demographic groups. Fourth, this study only focused on skeletal muscle-related
420 phenotypes. Other side effects such as diabetes, cognition, and liver damage require
421 special research. Furthermore, data exclude hospitalized patients, who typically
422 exhibit poorer health statuses, multiple comorbidities, and potentially heightened
423 susceptibility to adverse drug reactions. Last, in this observational study, despite
424 efforts to control for numerous critical confounding factors, residual and unmeasured
425 confounders may have constrained the findings.

426 **4.2 Conclusions**

427 Our epidemiological and MR analyses did not support the causality between
428 statin use and skeletal muscle-related phenotypes. A higher likelihood of skeletal
429 muscle-related adverse phenotypes in statin users may be attributed to age. Future
430 studies should further explore the biological factors that may affect the statin-related
431 muscle phenotype. These findings will provide evidence for the drug safety of statin
432 therapy for the secondary prevention of cardiovascular disease, diabetes, or
433 hyperlipidemia.

Ethical Standards Disclosure: This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving research study participants were approved by the [NCHS]. Written informed consent was obtained from all subjects.

Consent for publication: Not applicable.

Availability of data and materials: The datasets supporting the conclusions of this article are available in the National Health and Nutrition Examination Survey repository, unique persistent identifier and hyperlink to the dataset in <https://wwwn.cdc.gov/nchs/nhanes/default.aspx>.

Competing interests: The authors declare that they have no competing interests.

Sources of Funding: SW was funded by the National Natural Science Foundation of China (82200396), Natural Science Foundation of Heilongjiang Province of China (YQ2022H006), New era Longjiang outstanding doctoral key project (LJYXL2022-013), Cultivation Project of Second Affiliated Hospital of Harbin Medical University (PYMS2023-3); YZ was funded by the Gout Etiology and Functional Food Research Innovation Team, the North Medicine and Functional Food Characteristic Subject Project in Heilongjiang Province (HLJTSXK-2022-03), Postdoctoral Science Foundation of Heilongjiang Province of China (LBH-Q21047), National Fund Cultivation Program of Jiamusi University (JMSUGPZR2022-022), Scientific and Technological Innovation Team of Jiamusi University (cxt202101).

Authors contributions: FT, ZC, and SW conceived and designed the study. FT, HQ, YL, ZH, and BY organized all data. FT, ZC, and SW analyzed and visualized the

results. FT, YS, and SW contributed to the manuscript. Reviewed and edited the manuscript, YZ and SF take responsibility for the integrity and accuracy of this analysis. All authors reviewed and edited the manuscript.

Acknowledgments: The authors thank all the participants and staff in the National Health and Nutrition Examination Survey for their substantial contributions.

References:


- [1] Bose S, Steussy CN, Lopez-Perez D, Schmidt T, Kulathunga SC and Seleem MN. Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor. *Commun Biol* 2023; 6: 360.
- [2] Collins R, Reith C, Emberson J, Armitage J, Baigent C and Blackwell L. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* 2016; 388: 2532-2561.
- [3] Sarzani R, Allevi M, Giulietti F, Sarnari S, Scorcella S, and Di Agostini A. Patient-reported muscle symptoms and their characterization in a hypertensive population eligible for statin therapy: an exploratory study. *Nutr Metab Cardiovasc Dis* 2024; 34: 136-144.
- [4] Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, and Barnes EH. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: a meta-analysis of individual data from 27 randomized trials. *Lancet* 2012; 380: 581-590.
- [5] Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ and Ray KK. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J* 2015; 36: 1012-1022.
- [6] Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J and Genest J. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). *Can J Cardiol* 2016; 32: S35-S65.
- [7] Saxon DR and Eckel RH. Statin Intolerance: a Literature Review and Management Strategies. *Prog Cardiovasc Dis* 2016; 59: 153-164.
- [8] Doganer YC, Aydogan U, Kaplan U, Gormel S, Rohrer JE and Yuksel UC. Statin adherence in patients with high cardiovascular risk: a cross-sectional study. *Postgrad Med* 2023; 135: 361-369.
- [9] Onaisi R, Dumont R, Hasselgard-Rowe J, Safar D, Haller DM and Maisonneuve H. Multimorbidity and statin prescription for primary prevention of cardiovascular diseases: a cross-sectional study in general practice in France. *Front Med (Lausanne)* 2022; 9: 1089050.
- [10] Aivo J, Ruuskanen JO, Tornio A, Rautava P and Kyto V. Lack of Statin Therapy and Outcomes After Ischemic Stroke: a Population-Based Study. *Stroke* 2023; 54: 781-790.
- [11] Irwin JC, Khalesi S, Fenning AS and Vella RK. The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: a systematic review and meta-analysis. *Pharmacol Res* 2018; 128: 264-273.
- [12] Iwere RB and Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. *Br J Clin Pharmacol* 2015; 80: 363-371.
- [13] Buettner C, Rippberger MJ, Smith JK, Leveille SG, Davis RB and Mittleman MA. Statin use and musculoskeletal pain among adults with and without arthritis. *Am J Med* 2012; 125: 176-182.
- [14] Bruno RR, Rosa FC, Nahas PC, de Branco F and de Oliveira EP. Serum alpha-carotene, but Not Other Antioxidants, is Positively Associated with Muscle Strength in Older Adults: NHANES 2001-2002. *Antioxidants (Basel)* 2022; 11.
- [15] Masanes F, Rojano ILX, Salva A, Serra-Rexach JA, Artaza I and Formiga F. Cut-off Points for Muscle Mass - Not Grip Strength or Gait Speed - Determine Variations in Sarcopenia

- Prevalence. *J Nutr Health Aging* 2017; 21: 825-829.
- [16] Wang YC, Bohannon RW, Li X, Sindhu B, and Kapellusch J. Hand-Grip Strength: Normative Reference Values and Equations for Individuals 18 to 85 Years of Age Residing in the United States. *J Orthop Sports Phys Ther* 2018; 48: 685-693.
- [17] Ashfield TA, Syddall HE, Martin HJ, Dennison EM, Cooper C and Aihie SA. Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study. *Age Ageing* 2010; 39: 185-191.
- [18] Veddeng S, Madland H, Molden E, Wyller TB and Romskaug R. Association between statin use and physical performance in home-dwelling older patients receiving polypharmacy: cross-sectional study. *BMC Geriatr* 2022; 22: 242.
- [19] Skrivankova VW, Richmond RC, Woolf B, Yarmolinsky J, Davies NM and Swanson SA. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: the STROBE-MR Statement. *JAMA* 2021; 326: 1614-1621.
- [20] Cai HX, Liang CC, Wang SJ, Guo JC, Wang Y, and Yu B. Renin-angiotensin system antagonists and mortality due to pneumonia, influenza, and chronic lower respiratory disease in patients with hypertension. *J Geriatr Cardiol* 2022; 19: 511-521.
- [21] Kramer H, Boucher RE, Leehey D, Fried L, Wei G and Greene T. Increasing Mortality in Adults with Diabetes and Low Estimated Glomerular Filtration Rate in the Absence of Albuminuria. *Diabetes Care* 2018; 41: 775-781.
- [22] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002; 106: 3143-3421.
- [23] Zhu Y, Zhu F, Guo X, Huang S, Yang Y, and Zhang Q. Appendicular lean mass and the risk of stroke and Alzheimer's disease: a mendelian randomization study. *BMC Geriatr* 2024; 24: 438.
- [24] Studenski SA, Peters KW, Alley DE, Cawthon PM, Mclean RR and Harris TB. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. *J Gerontol A Biol Sci Med Sci* 2014; 69: 547-558.
- [25] Peng P, Wu J, Fang W, Tian J, He M and Xiao F. Association between sarcopenia and osteoarthritis among the US adults: a cross-sectional study. *Sci Rep* 2024; 14: 296.
- [26] Van Ancum JM, Alcazar J, Meskers C, Nielsen BR, Suetta C and Maier AB. Impact of using the updated EWGSOP2 definition in diagnosing sarcopenia: a clinical perspective. *Arch Gerontol Geriatr* 2020; 90: 104125.
- [27] Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, and Cederholm T. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019; 48: 16-31.
- [28] Liang Y, Wang J, Wang T, Li H, Yin C, and Liu J. Moderate selenium mitigates hand grip strength impairment associated with elevated blood cadmium and lead levels in middle-aged and elderly individuals: insights from NHANES 2011-2014. *Front Pharmacol* 2023; 14: 1324583.
- [29] Huang L, Lu Z, Zhou X, He L, You X and Chen C. U-Shaped Relationship Between Serum Lactate Dehydrogenase with All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. *Int J Chron Obstruct Pulmon Dis* 2023; 18: 305-316.
- [30] Wang S, Tian W, Liu Y, Yan G, Fang S and Wang Y. Temporal trend of circulating trans-fatty acids and risk of long-term mortality in the general population. *Clin Nutr* 2021; 40:

- 1095-1101.
- [31] Mera-Gaona M, Neumann U, Vargas-Canas R and Lopez DM. Evaluating the impact of multivariate imputation by MICE in feature selection. *PLoS One* 2021; 16: e0254720.
- [32] Suzuki T, Palus S and Springer J. Skeletal muscle wasting in chronic heart failure. *ESC Heart Fail* 2018; 5: 1099-1107.
- [33] Finegold JA, Manisty CH, Goldacre B, Barron AJ and Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. *Eur J Prev Cardiol* 2014; 21: 464-474.
- [34] Mansi I, Frei CR, Pugh MJ, Makris U and Mortensen EM. Statins and musculoskeletal conditions, arthropathies, and injuries. *JAMA Intern Med* 2013; 173: 1-10.
- [35] Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM and Cobbe SM. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. *Lancet* 2002; 360: 1623-1630.
- [36] Szadkowska I, Stanczyk A, Aronow WS, Kowalski J, Pawlicki L and Ahmed A. Statin therapy in the elderly: a review. *Arch Gerontol Geriatr* 2010; 50: 114-118.
- [37] Alexander KP, Blazing MA, Rosenson RS, Hazard E, Aronow WS and Smith SJ. Management of hyperlipidemia in older adults. *J Cardiovasc Pharmacol Ther* 2009; 14: 49-58.
- [38] Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM and Arnold AD. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. *J Am Coll Cardiol* 2021; 78: 1210-1222.
- [39] Penson PE, Mancini G, Toth PP, Martin SS, Watts GF and Sahebkar A. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. *J Cachexia Sarcopenia Muscle* 2018; 9: 1023-1033.
- [40] Cheng KY, Bao Z, Long Y, Liu C, Huang T and Cui C. Sarcopenia and Ageing. *Subcell Biochem* 2023; 103: 95-120.

Figure and tables

Figure 1 Flow of study



Abbreviations: NHANES, National Health and Nutrition Examination Survey; CVD, cardiovascular disease; HLP, hyperlipidemia; SNP, Single Nucleotide Polymorphism; LDH, Lactate Dehydrogenase.

A: Flow of study.

B: Two-sample Mendelian randomization study design.

Arrows represent associations.

Dashed lines with “X” in the middle represent genetic variants applied as instrumental variables

for Statins that should not be associated with potential confounding factors and do not exert an effect on sarcopenia-related traits and LDH via other pathways in assumptions 2 and 3, respectively.

Abbreviations: SNP, Single nucleotide polymorphism; IVW, Inverse variance weighted; MR-PRESSO, MR-pleiotropy residual sum and outlier; LDH, Lactic dehydrogenase.

Table 1 Baseline characteristics of patients with cardiovascular disease, diabetes, or hyperlipidemia

	Statin drug use			
	Nonuse (13,474)	Statin drugs (8,481)	Lipid-lowering drugs other than statins(n=594)	p
Age, (year)	55.4 ± 0.1	65.7 ± 0.1	63.3 ± 0.5	<0.001
Male, (%)	48.2	53.5	52.2	<0.001
Race/ethnicity, (%)				
Hispanic-Mexican	17.8	11.4	14.5	<0.001
Other Ethnicity	18.2	16.2	18.0	<0.001
Non-Hispanic White	42.2	52.3	54.0	<0.001
Non-Hispanic Black	21.8	20.2	13.5	<0.001
Education status, (%)				<0.001
Less than high school	29.9	28.2	30.6	
High school	22.1	24.9	23.6	
More than high school	48.1	46.9	45.8	
Marital status, (%)				<0.001
Married	56.2	59.9	62.3	
Never married	16.2	8.3	8.9	
other	27.6	31.8	28.8	
PIR, (%)				<0.001
< 1.3	31.5	27.4	30.6	
1.3-3.5	37.8	39.7	38.7	
> 3.5	30.7	32.9	30.8	
BMI, kg/m ²				0.003
18.5-25	21.3	18.1	18.4	
25-30	34.5	36.2	33.9	
≥ 30	44.3	45.7	47.7	
Alcohols status, (%)				<0.001
=0, g/d	38.5	44.2	45.3	
< 5, g/d	42.5	39.1	40.4	
5-30, g/d	16.3	15.1	13.0	
> 30, g/d	2.7	1.7	1.3	
Smoking status, (%)				<0.001
Never smoking	52.0	46.8	46.6	
Former smoker	28.2	39.4	37.0	

Current smoker	19.8	13.8	16.3	
Physical activity, (%)	28.7	26.2	22.7	0.001
HBP, (%)	61.6	80.5	80.8	<0.001
CKD, (%)	11.8	23.6	25.2	<0.001
COPD, (%)	9.3	12.6	12.8	<0.001
Cancer, (%)	10.8	17.8	17.0	<0.001
CVD, (%)	20.0	35.3	26.9	<0.001
Diabetes, (%)	37.1	46.4	48.2	<0.001
Hyperlipidemia, (%)	71.0	85.8	88.0	<0.001

The data were adjusted for survey weights from the NHANES.

The data are presented as the means \pm SDs or percentages.

We considered two-sided p-values less than 0.05 as statistically significant.

Abbreviations: PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

Table 2 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n=8,856)							
Nonusers	21.42	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	33.60	1.35 (1.12 to 1.62)	<0.001	1.31 (0.99 to 1.74)	0.06	1.25 (1.00 to 1.55)	0.05
Lipid-lowering drugs other than statins	35.11	1.36 (0.78 to 2.37)	0.28	1.00 (0.49 to 2.02)	1.00	1.23 (0.73 to 2.09)	0.44
ASM/Wt (n=8,839)							
Nonusers	10.85	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	14.11	1.86 (1.62 to 2.13)	<0.001	1.23 (0.99 to 1.54)	0.06	1.14 (0.97 to 1.34)	0.11
Lipid-lowering drugs other than statins	14.19	1.99 (1.33 to 2.97)	<0.001	0.93 (0.53 to 1.62)	0.79	0.92 (0.62 to 1.37)	0.67
ASM/Ht ² (n=8,803)							
Nonusers	5.50	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	6.54	1.20 (0.95 to 1.52)	0.12	1.11 (0.77 to 1.60)	0.56	0.87 (0.64 to 1.18)	0.38
Lipid-lowering drugs other than statins	4.17	0.75 (0.41 to 1.36)	0.34	0.83 (0.31 to 2.25)	0.71	0.99 (0.47 to 2.09)	0.97
		β (95% CI)	<i>P</i>	B (95% CI)	<i>P</i>	B (95% CI)	<i>P</i>
Max HGS* (n=4,340)							
Nonusers	—	Ref.		Ref.		Ref.	
Statin users		-3.01 (-3.97 to -2.06)	<0.001	-0.35 (-1.11 to 0.41)	0.36	-0.13 (-0.66 to 0.40)	0.64
Lipid-lowering drugs other than statins		-3.79 (-5.95 to -1.63)	<0.001	-2.07 (-3.99 to -0.14)	0.04	-0.90 (-2.41 to 0.61)	0.24

Relative grip strength* (n=4,230)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.23 (-0.30 to -0.17)	<0.001	-0.01 (-0.06 to 0.04)	0.66	-0.01 (-0.04 to 0.03)	0.77
Lipid-lowering drugs other than statins		-0.34 (-0.49 to -0.19)	<0.001	-0.08 (-0.20 to 0.05)	0.23	-0.07 (-0.18 to 0.03)	0.17
Combined HGS* (n=4,275)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-5.9 (-7.86 to -3.93)	<0.001	-0.61 (-2.18 to 0.96)	0.44	-0.32 (-1.32 to 0.67)	0.53
Lipid-lowering drugs other than statins		-6.82 (-10.88 to -2.76)	<0.001	-2.78 (-6.25 to 0.69)	0.11	-2.03 (-4.88 to 0.82)	0.16
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n=8,806)							
Nonusers	5.10	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	6.22	1.36 (1.13 to 1.63)	<0.001	1.32 (1.00 to 1.75)	0.05	1.26 (1.00 to 1.56)	0.05
Lipid-lowering drugs other than statins	4.17	1.37 (0.79 to 2.39)	0.26	1.01 (0.50 to 2.03)	0.99	1.21 (0.72 to 2.05)	0.47
ASM and BMI definition (n=19,259)							
Nonusers	10.80	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.20	0.76 (0.47 to 1.23)	0.27	0.92 (0.51 to 1.66)	0.78	0.98 (0.65 to 1.47)	0.92
Lipid-lowering drugs other than statins	3.20	0.30 (0.08 to 1.16)	0.08	0.38 (0.09 to 1.60)	0.18	0.74 (0.23 to 2.44)	0.62
LDH* (n=21,908)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		2.55 (1.32 to 3.78)	<0.001	-0.55 (-1.81 to 0.71)	0.39	-0.57 (-1.72 to 0.58)	0.33

Lipid-lowering drugs other than statins		-0.42 (-3.71 to 2.88)	0.80	-2.77 (-6.35 to 0.81)	0.13	-0.28 (-3.31 to 2.75)	0.86
---	--	-----------------------	------	-----------------------	------	-----------------------	------

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal mass index; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table 3 Odds ratios of musculoskeletal pain for statin users compared to nonusers

	Prevalence, %	Crude		Adjusted		After matching*	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Any Region (n=5,136)							
Nonusers	69.68	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	27.78	1.15 (0.96 to 1.38)	0.12	1.15 (0.88 to 1.50)	0.30	1.09 (0.91 to 1.31)	0.36
Lipid-lowering drugs other than statins	2.24	1.08 (0.64 to 1.82)	0.76	1.10 (0.59 to 2.04)	0.75	1.04 (0.67 to 1.61)	0.85
Neck/Upper Back (n=5,136)							
Nonusers	74.02	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	21.83	0.74 (0.56 to 0.97)	0.03	0.96 (0.64 to 1.44)	0.84	0.94 (0.67 to 1.32)	0.73
Lipid-lowering drugs other than statins	4.15	1.52 (0.87 to 2.66)	0.14	2.17 (1.07 to 4.39)	0.03	2.19 (1.19 to 4.00)	0.01
Upper Extremities (n=5,136)							
Nonusers	69.33	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	28.01	1.13 (0.92 to 1.38)	0.23	1.11 (0.81 to 1.51)	0.50	1.13 (0.93 to 1.39)	0.22
Lipid-lowering drugs other than statins	2.66	1.16 (0.69 to 1.94)	0.56	1.27 (0.68 to 2.38)	0.44	1.25 (0.79 to 1.98)	0.33
Lower Back (n=5,136)							
Nonusers	69.78	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	28.26	1.03 (0.82 to 1.29)	0.82	1.05 (0.76 to 1.45)	0.75	1.05 (0.79 to 1.39)	0.74
Lipid-lowering drugs other than statins	1.96	0.66 (0.29 to 1.48)	0.31	0.61 (0.24 to 1.54)	0.28	0.74 (0.37 to 1.50)	0.41
Lower Extremities (n=5,136)							
Nonusers	68.81	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	28.53	1.17 (0.95 to 1.45)	0.14	1.12 (0.83 to 1.51)	0.44	1.08 (0.84 to 1.41)	0.54

Lipid-lowering drugs other than statins	2.66	1.22 (0.66 to 2.23)	0.52	1.09 (0.54 to 2.22)	0.80	1.01 (0.55 to 1.83)	0.99
---	------	---------------------	------	---------------------	------	---------------------	------

Abbreviations: OR, odds ratio; CI, confidence interval.

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

*Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table 4 The causal relationship between statins and sarcopenia-related traits based on two-sample Mendelian randomization analysis

Outcome	SNPs	MR method	Beta/OR	95%CI	P-value
Appendicular lean mass	11	IVW	-0.060	-0.153, 0.033	0.208
		MR Egger	-0.019	-0.191, 0.153	0.834
		Weighted median	-0.023	-0.056, 0.010	0.173
	4	MR PRESOO	-0.016	-0.057, 0.025	0.488
Hand grip strength (right)	11	IVW	-0.014	-0.039, 0.012	0.289
		MR Egger	-0.003	-0.050, 0.043	0.892
		Weighted median	-0.010	-0.031, 0.011	0.339
	8	MR PRESOO	0.003	-0.017, 0.023	0.776
Hand grip strength (left)	11	IVW	-0.216	-0.044, 0.001	0.059
		MR Egger	-0.004	-0.044, 0.036	0.847
		Weighted median	-0.013	-0.031, 0.006	0.171
	10	MR PRESOO	-0.021	-0.041, 0.002	0.058
Low hand grip strength	11	IVW	1.042	0.889, 1.221	0.614
		MR Egger	1.025	0.759, 1.384	0.875
		Weighted median	1.028	0.839, 1.259	0.792
		MR PRESOO	1.069	0.917, 1.247	0.411
Walking pace	11	IVW	0.001	-0.010, 0.011	0.939
		MR Egger	0.007	-0.012, 0.026	0.497
		Weighted median	-0.002	-0.016, 0.011	0.748
		MR PRESOO	0.003	-0.007, 0.012	0.649
Lactate dehydrogenase	8	IVW	-0.080	-0.213, 0.053	0.238
		MR Egger	0.035	-0.230, 0.230	0.804
		Weighted median	0.003	-0.082, 0.087	0.952
	6	MR PRESOO	-0.030	-0.100, 0.040	0.437

Abbreviations: SNP, Single nucleotide polymorphism; IVW, Inverse variance weighted; MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier.

We considered two-sided p-values less than 0.05 as statistically significant.

Supplemental tables

Table S1 Details of studies and datasets used in the study

Trait	Sample size (cases/controls)	Datatype	Unit	Ancestry	Consortium/ First Author	PMID or GWAS ID
Statins	290,385 (73,475/216,910)	Binary	/	European	UK Biobank	31015401
Appendicular lean mass	450,243	Continuous	kg	European	UK Biobank	33097823
Hand grip strength (right)	461,089	Continuous	SD	European	MRC-IEU	ukb-b-10215
Hand grip strength (left)	461,026	Continuous	SD	European	MRC-IEU	ukb-b-7478
Low hand grip strength	121,055 (6,734/114,321)	Binary	/	European	Garan Jones	33510174
Walking pace	459,915	Continuous	km/s	European	MRC-IEU	ukb-b-4711
Lactate dehydrogenase	126,319	Continuous	SD	East Asian	Ishigaki K	29403010

Abbreviations: SD, Standard Deviation; PMID, PubMed Unique Identifier; GWAS ID, Genome-Wide Association Study Identifier; MRC-IEU, Medical Research Council Integrative Epidemiology Unit.

Table S2 SNPs are used as instrumental variables for Statins (P-value < 5×10⁻⁸)

Traits	SNP	Chr	Position	Effect allele	another allele	Beta	SE	P-value	F-statistic
Statins-ALM/HGS (right)/	rs113911544	1	55706403	G	A	0.085085202	0.014373915	3.20E-09	35.0395019
HGS (left)/LHGS/Walking	rs11591147	1	55505647	T	G	-0.362323999	0.021494841	9.40E-64	284.1356506
pace	rs1260326	2	27730940	T	C	0.059920058	0.005712328	9.70E-26	110.0317897
	rs12725767	1	6676040	G	A	0.035128029	0.005856082	2.00E-09	35.98266012
	rs12740374	1	109817590	T	G	-0.156618273	0.006742468	2.30E-119	539.5691038
	rs1367117	2	21263900	A	G	0.105726091	0.005900949	8.70E-72	321.0115277
	rs4299376	2	44072576	G	T	0.086690463	0.005971001	9.20E-48	210.7892007
	rs4541244	2	58917535	T	C	-0.034275082	0.005711376	2.00E-09	36.01434333
	rs570530	1	234866776	A	G	-0.032541516	0.005613812	6.80E-09	33.60159042
	rs693668	1	55521109	G	A	-0.048941477	0.005866453	7.30E-17	69.5989924
	rs79598313	1	27284913	T	C	0.146636976	0.018408443	1.60E-15	63.45310484
Statins-LDH	rs113911544	1	55706403	G	A	0.085085202	0.014373915	3.20E-09	35.0395019
	rs1260326	2	27730940	T	C	0.059920058	0.005712328	9.70E-26	110.0317897
	rs12725767	1	6676040	G	A	0.035128029	0.005856082	2.00E-09	35.98266012
	rs12740374	1	109817590	T	G	-0.156618273	0.006742468	2.30E-119	539.5691038
	rs1367117	2	21263900	A	G	0.105726091	0.005900949	8.70E-72	321.0115277
	rs4541244	2	58917535	T	C	-0.034275082	0.005711376	2.00E-09	36.01434333
	rs570530	1	234866776	A	G	-0.032541516	0.005613812	6.80E-09	33.60159042
	rs693668	1	55521109	G	A	-0.048941477	0.005866453	7.30E-17	69.5989924
	rs7534572	1	62999675	C	G	-0.074218207	0.005852643	7.50E-37	160.8114059

Abbreviations: SNP, Single nucleotide polymorphism, MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier. ALM, Appendicular

Lean Muscle; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

Table S3 Definition of statins and lipid-lowering drugs

Generic drug code	Drug name
Statin drugs	
d00280	lovastatin
d00348	pravastatin
d00746	simvastatin
d03183	fluvastatin
d04105	atorvastatin
d04140	cerivastatin
d04787	lovastatin; niacin
d04851	rosuvastatin
d05048	amlodipine; atorvastatin
d05348	ezetimibe; simvastatin
d07110	niacin; simvastatin
d07637	pitavastatin
d07805	simvastatin; sitagliptin
d08383	evolocumab
Lipid-lowering drugs other than statins	
c00019	antihyperlipidemic agents - unspecified
c00173	hmg-coa reductase inhibitors - unspecified
d00193	cholestyramine
d00196	clofibrate
d00245	gemfibrozil
d00353	probucol
d00744	colestipol
d04286	fenofibrate
d04695	colesevelam
d04824	ezetimibe
d07371	fenofibric acid
d07891	icosapent
d08374	alirocumab
h00036	bezafibrate

Table S4 Characteristics of cardiovascular disease, diabetes, or hyperlipidemia patients with Statin use or nonuse after matching

	After matching		
	Non-use (5,249)	Statin drug use (5,429)	Standardized difference
Age, (year)	62.6 ± 0.2	64.7 ± 0.1	<0.001
Male, (%)	50.9	52.4	<0.001
Race/ethnicity, (%)			
Hispanic-Mexican	13.3	11.8	<0.001
Other Ethnicity	17.5	16.5	<0.001
Non-Hispanic White	47.0	51.3	<0.001
Non-Hispanic Black	22.2	20.4	<0.001
Education status, (%)			<0.001
Less than high school	29.6	28.5	
High school	23.6	24.3	
More than high school	46.8	47.2	
Marital status, (%)			<0.001
Married	57.2	59.1	
Never married	10.9	9.0	
Other	32.0	31.9	
PIR, (%)			<0.001
< 1.3	30.0	27.8	
1.3-3.5	38.5	39.5	
> 3.5	31.5	32.7	

BMI, kg/m ²			<0.001
18.5-25	20.4	18.2	
25-30	33.5	36.2	
≥ 30	46.1	45.7	
Alcohols status, (%)			<0.001
= 0, g/d	42.5	43.7	
< 5, g/d	40.0	39.2	
5-30, g/d	15.1	15.5	
> 30, g/d	2.3	1.6	
Smoking status, (%)			<0.001
Never smoking	49.0	47.4	
Former smoker	34.6	38.1	
Current smoker	16.4	14.5	
Moderate exercise, (%)	26.2	26.4	<0.001
HBP, (%)	76.6	79.2	<0.001
CKD, (%)	20.0	23.0	<0.001
COPD, (%)	12.1	12.6	<0.001
Cancer, (%)	15.6	17.1	<0.001
CVD, (%)	27.7	33.0	<0.001
Diabetes, (%)	43.9	45.1	<0.001
Hyperlipidemia, (%)	42.9	45.5	<0.001

Data were adjusted for survey weights of NHANES.

Data are presented as means \pm SD or percent.

We considered two-sided p-values less than 0.05 as statistically significant.

Abbreviations: PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular diseases; CKD, Chronic Kidney Disease; COPD, Chronic Obstructive Pulmonary Disease.

Table S5 The association between statin users and skeletal muscle-related phenotypes compared with nonusers by stepwise regression analysis

	ASM/BMI (n=8,856)		ASM/Ht ² and bf Sarcopenic Obesity (n=8,806)		Max HGS (n=4,340)		Relative HGS (n=4,230)		Combined HGS (n=4,275)		Neck/Upper (n=5,136)	Back
	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	β (95% CI)	<i>P</i>	β (95% CI)	<i>P</i>	β (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Unadjusted	1.35 (1.12 to 1.62)	< 0.001	1.36 (1.13 to 1.63)	< 0.001	-3.01 (-3.97 to -2.06)	< 0.001	-0.23 (-0.30 to -0.17)	< 0.001	-5.90 (-7.86 to -3.93)	< 0.001	0.74 (0.56 to 0.97)	0.03
Age adjustment	1.01 (0.82 to 1.23)	0.96	1.01 (0.83 to 1.23)	0.91	0.67 (-0.22 to 1.56)	0.14	-0.02 (-0.10 to 0.05)	0.5	1.31 (-0.50 to 3.11)	0.15	0.83 (0.61 to 1.12)	0.21
+ Sex	1.24 (1.00 to 1.55)	0.05	1.25 (1.01 to 1.56)	0.05	0.10 (-0.64 to 0.84)	0.78	-0.06 (-0.12 to -0.01)	0.03	0.24 (-1.26 to 1.74)	0.75	0.85 (0.63 to 1.14)	0.27
+ Race/ ethnicity	1.29 (1.03 to 1.62)	0.03	1.30 (1.04 to 1.63)	0.02	-0.09 (-0.81 to 0.63)	0.80	-0.07 (-0.13 to -0.02)	0.01	-0.14 (-1.61 to 1.33)	0.84	0.83 (0.61 to 1.11)	0.21
+Education level	1.29 (1.02 to 1.62)	0.03	1.29 (1.03 to 1.63)	0.03	-0.09 (-0.83 to 0.66)	0.82	-0.07 (-0.13 to -0.02)	0.01	-0.14 (-1.64 to 1.35)	0.85	0.83 (0.61 to 1.12)	0.21
+Marital status	1.28 (1.02 to 1.62)	0.03	1.29 (1.03 to 1.63)	0.03	-0.16 (-0.90 to 0.57)	0.65	-0.08 (-0.14 to -0.02)	0.01	-0.30 (-1.78 to 1.18)	0.68	0.82 (0.61 to 1.12)	0.2
+ PIR	1.31 (1.02 to 1.69)	0.03	1.32 (1.03 to 1.70)	0.03	-0.28 (-1.02 to 0.45)	0.44	-0.09 (-0.15 to -0.04)	< 0.001	-0.48 (-1.98 to 1.01)	0.51	0.86 (0.61 to 1.21)	0.37
+ BMI	-	-	-	-	-0.55 (-1.24 to 0.13)	0.11	-0.04 (-0.08 to 0.01)	0.08	-1.05 (-2.42 to 0.31)	0.13	0.88 (0.63 to 1.25)	0.48
+ Alcohols statuses	1.33 (1.03 to 1.72)	0.03	1.34 (1.04 to 1.73)	0.03	-0.49 (-1.22 to 0.23)	0.18	-0.04 (-0.08 to 0.01)	0.10	-0.90 (-2.30 to 0.51)	0.2	0.82 (0.60 to 1.12)	0.21
+ Smoking status	1.34 (1.03 to 1.73)	0.03	1.35 (1.04 to 1.74)	0.02	-0.49 (-1.23 to 0.24)	0.18	-0.04 (-0.08 to 0.01)	0.10	-0.90 (-2.31 to 0.52)	0.21	0.82 (0.60 to 1.12)	0.2
+ Physical activity	1.35 (1.04 to 1.74)	0.02	1.36 (1.05 to 1.75)	0.02	-0.50 (-1.27 to 0.28)	0.2	-0.04 (-0.09 to 0.01)	0.13	-0.91 (-2.40 to 0.58)	0.22	0.81 (0.59 to 1.11)	0.19

+ HBP	1.31 (1.01 to 1.71)	0.04	1.32 (1.02 to 1.72)	0.04	-0.54 (-1.32 to 0.24)	0.17	-0.04 (-0.08 to 0.01)	0.15	-0.97 (-2.48 to 0.54)	0.20	0.82 (0.59 to 1.13)	0.21
+ CVD	1.31 (0.99 to 1.72)	0.06	1.32 (1.00 to 1.74)	0.05	-0.33 (-1.09 to 0.44)	0.39	-0.02 (-0.07 to 0.03)	0.37	-0.63 (-2.14 to 0.88)	0.40	0.81 (0.56 to 1.18)	0.27
+ Diabetes	1.28 (0.97 to 1.69)	0.08	1.29 (0.98 to 1.71)	0.07	-0.25 (-1.04 to 0.54)	0.52	-0.01 (-0.06 to 0.04)	0.62	-0.48 (-2.02 to 1.07)	0.53	0.82 (0.56 to 1.19)	0.28
+ Hyperlipidemia	1.32 (0.99 to 1.75)	0.06	1.33 (1.00 to 1.77)	0.05	-0.26 (-1.05 to 0.53)	0.50	-0.01 (-0.06 to 0.04)	0.71	-0.44 (-2.02 to 1.14)	0.57	0.84 (0.56 to 1.24)	0.36
+ CKD	1.33 (0.99 to 1.78)	0.06	1.34 (1.00 to 1.80)	0.05	-0.31 (-1.11 to 0.5)	0.44	-0.01 (-0.06 to 0.04)	0.76	-0.51 (-2.12 to 1.10)	0.52	0.82 (0.58 to 1.17)	0.26
+ COPD	1.32 (0.98 to 1.76)	0.07	1.33 (0.99 to 1.78)	0.06	-0.31 (-1.11 to 0.49)	0.43	-0.01 (-0.06 to 0.04)	0.74	-0.53 (-2.13 to 1.08)	0.51	0.83 (0.58 to 1.19)	0.29
+ Cancer	1.32 (0.98 to 1.76)	0.07	1.33 (0.99 to 1.78)	0.06	-0.32 (-1.12 to 0.48)	0.42	-0.01 (-0.06 to 0.04)	0.72	-0.55 (-2.14 to 1.05)	0.49	0.85 (0.59 to 1.24)	0.39

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; HGS, Hand grip strength; BMI, body mass index; Wt, weight; Ht, height; PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women.

Table S6 The results of sensitivity analysis for two-sample Mendelian randomization analysis of the causal relationships between Statins and sarcopenia-related traits

Outcome	No. of IVs	Heterogeneity		MR-Egger pleiotropy test			MR-PRESSO
		Cochran's <i>Q</i>	<i>P</i> -value	intercept	SE	<i>P</i> -value	Global Test <i>P</i> -value
Appendicular lean mass	11	346.6756844	2.02E-68	-0.0042237	0.00746	0.585	<0.001
Hand grip strength (right)	11	40.71459187	1.27E-05	-0.0010619	0.00202	0.612	<0.001
Hand grip strength (left)	11	32.39685682	<0.001	-0.0018087	0.00172	0.321	<0.001
Low hand grip strength	11	10.56373443	0.393	0.00164006	0.01293	0.902	0.463
Walking pace	8	8.438255201	0.586	-0.0006592	0.00082	0.443	0.622
Lactate dehydrogenase	11	38.72767287	2.20E-06	-0.0082974	0.00844	0.363	<0.001

Abbreviations: MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier.

We considered two-sided *p*-values less than 0.05 as statistically significant.

Table S7 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among the population over 65 years old

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 2,367)							
Nonusers	35.05	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	43.20	0.86 (0.65 to 1.13)	0.27	1.04 (0.73 to 1.49)	0.81	1.11 (0.80 to 1.55)	0.52
Lipid-lowering drugs other than statins	34.23	1.19 (0.53 to 2.67)	0.68	1.02 (0.43 to 2.40)	0.97	1.31 (0.58 to 2.97)	0.51
ASM/Wt (n= 2,408)							
Nonusers	24.01	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	21.34	1.41 (1.12 to 1.77)	< 0.001	1.17 (0.83 to 1.63)	0.36	1.16 (0.90 to 1.50)	0.25
Lipid-lowering drugs other than statins	27.26	0.96 (0.52 to 1.80)	0.91	0.68 (0.29 to 1.59)	0.36	0.87 (0.45 to 1.70)	0.69
ASM/Ht ² (n= 2,430)							
Nonusers	15.26	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	12.60	0.80(0.60 to 1.06)	0.12	0.84 (0.55 to 1.27)	0.39	0.74 (0.50 to 1.10)	0.13
Lipid-lowering drugs other than statins	7.08	0.42 (0.19 to 0.95)	0.04	0.34 (0.15 to 0.78)	0.01	0.57 (0.20 to 1.57)	0.28
Max HGS* (n= 1,590)							
Nonusers	—	Ref.		Ref.		Ref.	
Statin users		0.54 (-0.81 to 1.88)	0.42	-0.22 (-0.94 to 0.51)	0.55	0.14 (-0.63 to 0.91)	0.72
Lipid-lowering drugs other than statins		-0.30 (-3.42 to 2.83)	0.85	-0.32 (-2.20 to 1.56)	0.73	0.10 (-2.21 to 2.40)	0.94
Relative HGS* (n= 1,532)							
Nonusers	—	Ref.		Ref.		Ref.	

Statin users		-0.01 (-0.1 to 0.08)	0.81	-0.02 (-0.07 to 0.03)	0.41	0.02 (-0.04 to 0.07)	0.52
Lipid-lowering drugs other than statins		-0.02 (-0.23 to 0.19)	0.86	0.03 (-0.11 to 0.17)	0.64	-0.03 (-0.19 to 0.13)	0.73
Combined HGS* (n= 1,560)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		0.86 (-1.70 to 3.42)	0.50	-0.58 (-1.88 to 0.72)	0.37	-0.06 (-1.56 to 1.44)	0.94
Lipid-lowering drugs other than statins		0.15 (-6.25 to 6.55)	0.96	0.09 (-3.28 to 3.46)	0.96	-1.24 (-5.70 to 3.22)	0.59
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n= 2,369)							
Nonusers	14.68	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	12.60	0.87 (0.66 to 1.14)	0.29	1.06 (0.74 to 1.52)	0.74	1.15 (0.83 to 1.59)	0.41
Lipid-lowering drugs other than statins	7.08	1.20 (0.53 to 2.69)	0.66	1.03 (0.44 to 2.44)	0.95	1.36 (0.6 to 3.07)	0.46
ASM and BMI definition (n= 7,839)							
Nonusers	14.80	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.10	0.54 (0.29 to 1.00)	0.05	0.74 (0.33 to 1.67)	0.47	0.83 (0.48 to 1.46)	0.53
Lipid-lowering drugs other than statins	4.60	0.31 (0.05 to 1.92)	0.21	0.42 (0.06 to 2.81)	0.37	0.91 (0.21 to 4.04)	0.91
LDH* (n= 8,954)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-2.34 (-4.15 to -0.54)	0.01	-0.73 (-2.65 to 1.19)	0.45	0.04 (-1.58 to 1.66)	0.96
Lipid-lowering drugs other than statins		-2.97 (-8.28 to 2.35)	0.27	-1.81 (-7.51 to 3.89)	0.53	-0.44 (-4.76 to 3.89)	0.84
Musculoskeletal Pain Symptoms							
Any Region (n= 2,312)							

Nonusers	33.74	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	35.99	1.10 (0.86 to 1.42)	0.43	1.13 (0.82 to 1.55)	0.44	0.99 (0.77 to 1.27)	0.91
Lipid-lowering drugs other than statins	32.47	0.94 (0.51 to 1.76)	0.85	0.92 (0.44 to 1.91)	0.82	1.19 (0.64 to 2.18)	0.58
Neck/Upper Back (n= 2,312)							
Nonusers	7.01	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	6.02	0.85 (0.58 to 1.25)	0.40	0.77 (0.48 to 1.24)	0.27	0.74 (0.45 to 1.22)	0.23
Lipid-lowering drugs other than statins	11.68	1.75 (0.84 to 3.66)	0.13	1.83 (0.92 to 3.63)	0.08	1.80 (0.69 to 4.68)	0.23
Upper Extremities (n= 2,312)							
Nonusers	23.40	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	25.68	1.13 (0.84 to 1.52)	0.41	1.23 (0.85 to 1.80)	0.27	1.08 (0.82 to 1.42)	0.58
Lipid-lowering drugs other than statins	25.76	1.14 (0.54 to 2.37)	0.73	1.24 (0.59 to 2.63)	0.56	1.58 (0.83 to 3.01)	0.16
Lower Back (n= 2,312)							
Nonusers	7.46	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	9.74	1.34 (0.90 to 1.99)	0.15	1.49 (0.92 to 2.42)	0.10	1.07 (0.70 to 1.63)	0.75
Lipid-lowering drugs other than statins	6.04	0.80 (0.28 to 2.29)	0.67	1.11 (0.36 to 3.44)	0.85	0.88 (0.30 to 2.62)	0.82
Lower Extremities (n= 2,312)							
Nonusers	12.92	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.49	1.05 (0.74 to 1.50)	0.78	0.91 (0.63 to 1.34)	0.64	0.88 (0.61 to 1.29)	0.52
Lipid-lowering drugs other than statins	10.23	0.77 (0.31 to 1.88)	0.56	0.74 (0.24 to 2.33)	0.60	0.96 (0.38 to 2.39)	0.93

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal mass index; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school,

High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohol status (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S8 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with diabetes

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 3,136)							
Nonusers	31.76	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	45.27	1.02 (0.71 to 1.45)	0.92	1.57 (0.94 to 2.61)	0.09	1.29 (0.85 to 1.97)	0.23
Lipid-lowering drugs other than statins	34.44	1.05 (0.51 to 2.18)	0.90	1.11 (0.40 to 3.05)	0.84	1.20 (0.43 to 3.38)	0.73
ASM/Wt (n= 3,153)							
Nonusers	14.26	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	16.43	1.34 (1.04 to 1.73)	0.03	0.88 (0.63 to 1.23)	0.45	0.96 (0.72 to 1.28)	0.76
Lipid-lowering drugs other than statins	13.05	1.67 (0.78 to 3.56)	0.18	0.72 (0.32 to 1.62)	0.43	0.81 (0.40 to 1.66)	0.57
ASM/Ht ² (n= 3,169)							
Nonusers	4.79	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	4.75	0.76 (0.49 to 1.17)	0.21	0.46 (0.27 to 0.80)	0.01	0.55 (0.32 to 0.93)	0.03
Lipid-lowering drugs other than statins	2.37	0.58 (0.24 to 1.41)	0.22	0.50 (0.19 to 1.37)	0.18	0.61 (0.16 to 2.31)	0.47
Max HGS* (n= 1,746)							
Nonusers	—	Ref.		Ref.		Ref.	
Statin users		-0.14 (-2.01 to 1.73)	0.88	-0.59 (-1.83 to 0.65)	0.34	-0.50 (-1.76 to 0.75)	0.43
Lipid-lowering drugs other than statins		-6.13 (-9.45 to -2.82)	< 0.001	-3.86 (-6.95 to -0.77)	0.02	-3.43 (-7.85 to 1.00)	0.13
Relative HGS* (n= 1,685)							
Nonusers	—	Ref.		Ref.		Ref.	
Statin users		-0.09 (-0.23 to 0.05)	0.21	-0.03 (-0.14 to 0.08)	0.54	-0.07 (-0.16 to 0.02)	0.12

Lipid-lowering drugs other than statins		-0.60 (-0.86 to -0.34)	< 0.001	-0.13 (-0.36 to 0.11)	0.29	-0.47 (-0.79 to -0.15)	< 0.001
Combined HGS* (n= 1,711)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.27 (-4.14 to 3.59)	0.89	-0.86 (-3.41 to 1.70)	0.50	-1.18 (-3.50 to 1.14)	0.32
Lipid-lowering drugs other than statins		-9.71 (-16.59 to -2.82)	0.01	-4.87 (-9.87 to 0.13)	0.06	-11.85 (-20.39 to -3.32)	0.01
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n= 3,139)							
Nonusers	4.35	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	4.36	1.02 (0.72 to 1.46)	0.90	1.58 (0.95 to 2.66)	0.08	1.52 (1.00 to 2.30)	0.05
Lipid-lowering drugs other than statins	2.37	1.06 (0.51 to 2.20)	0.87	1.12 (0.40 to 3.09)	0.83	1.47 (0.52 to 4.15)	0.46
ASM and BMI definition (n= 7,473)							
Nonusers	10.71	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	7.73	0.59 (0.27 to 1.27)	0.18	1.05 (0.47 to 2.34)	0.91	1.41 (0.67 to 2.96)	0.36
Lipid-lowering drugs other than statins	4.68	0.46 (0.06 to 3.50)	0.45	0.47 (0.06 to 3.92)	0.49	1.05 (0.13 to 8.72)	0.96
LDH* (n= 8,973)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		1.11 (-1.48 to 3.71)	0.40	0.39 (-2.22 to 2.99)	0.77	-0.75 (-3.27 to 1.78)	0.56
Lipid-lowering drugs other than statins		-0.06 (-5.38 to 5.25)	0.98	-1.58 (-7.05 to 3.89)	0.57	1.90 (-5.21 to 9.01)	0.60
Musculoskeletal Pain Symptoms							
Any Region (n= 1,843)							
Nonusers	37.86	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	51.70	0.84 (0.63 to 1.11)	0.21	0.88 (0.64 to 1.21)	0.43	0.82 (0.60 to 1.11)	0.20
Lipid-lowering drugs other than statins	46.79	0.60 (0.24 to 1.49)	0.26	0.37 (0.13 to 1.05)	0.06	0.53 (0.24 to 1.16)	0.11

Neck/Upper Back (n= 1,843)							
Nonusers	8.30	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	8.51	0.54 (0.36 to 0.82)	0.01	0.77 (0.46 to 1.27)	0.29	0.71 (0.42 to 1.20)	0.20
Lipid-lowering drugs other than statins	19.42	0.85 (0.30 to 2.37)	0.74	0.53 (0.12 to 2.33)	0.39	1.05 (0.35 to 3.17)	0.94
Upper Extremities (n= 1,843)							
Nonusers	25.81	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	36.91	0.84 (0.62 to 1.15)	0.27	0.94 (0.64 to 1.36)	0.72	0.86 (0.62 to 1.19)	0.36
Lipid-lowering drugs other than statins	32.53	0.64 (0.22 to 1.85)	0.40	0.52 (0.17 to 1.53)	0.23	0.71 (0.31 to 1.61)	0.42
Lower Back (n= 1,843)							
Nonusers	14.52	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	13.15	0.66 (0.46 to 0.94)	0.02	0.75 (0.46 to 1.22)	0.23	0.77 (0.51 to 1.18)	0.23
Lipid-lowering drugs other than statins	12.89	0.54 (0.16 to 1.76)	0.30	0.57 (0.16 to 2.05)	0.38	0.71 (0.25 to 2.00)	0.52
Lower Extremities (n= 1,843)							
Nonusers	15.33	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	23.06	0.89 (0.61 to 1.30)	0.53	1.05 (0.66 to 1.67)	0.83	0.90 (0.61 to 1.34)	0.61
Lipid-lowering drugs other than statins	20.80	0.67 (0.22 to 2.01)	0.46	0.61 (0.20 to 1.84)	0.37	0.52 (0.18 to 1.48)	0.22

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S9 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with cardiovascular disease

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 1,641)							
Nonusers	33.76	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	40.61	1.02 (0.71 to 1.45)	0.92	1.57 (0.94 to 2.61)	0.09	1.29 (0.85 to 1.97)	0.23
Lipid-lowering drugs other than statins	45.97	1.05 (0.51 to 2.18)	0.90	1.11 (0.40 to 3.05)	0.84	1.20 (0.43 to 3.38)	0.73
ASM/Wt (n= 1,671)							
Nonusers	15.67	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	15.92	1.34 (1.04 to 1.73)	0.03	0.88 (0.63 to 1.23)	0.45	0.96 (0.72 to 1.28)	0.76
Lipid-lowering drugs other than statins	16.32	1.67 (0.78 to 3.56)	0.18	0.72 (0.32 to 1.62)	0.43	0.81 (0.40 to 1.66)	0.57
ASM/Ht ² (n= 1,676)							
Nonusers	10.92	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.51	0.76 (0.49 to 1.17)	0.21	0.46 (0.27 to 0.8)	0.01	0.55 (0.32 to 0.93)	0.03
Lipid-lowering drugs other than statins	6.61	0.58 (0.24 to 1.41)	0.22	0.50 (0.19 to 1.37)	0.18	0.61 (0.16 to 2.31)	0.47
Max HGS* (n= 996)							
Nonusers	—	Ref.		Ref.		Ref.	
Statin users		-0.14 (-2.01 to 1.73)	0.88	-0.59 (-1.83 to 0.65)	0.34	-0.50 (-1.76 to 0.75)	0.43
Lipid-lowering drugs other than statins		-6.13 (-9.45 to -2.82)	< 0.001	-3.86 (-6.95 to -0.77)	0.02	-3.43 (-7.85 to 1.00)	0.13
Relative HGS* (n= 947)							
Nonusers	—	Ref.		Ref.		Ref.	

Statin users		-0.09 (-0.23 to 0.05)	0.21	-0.03 (-0.14 to 0.08)	0.54	-0.07 (-0.16 to 0.02)	0.12
Lipid-lowering drugs other than statins		-0.60 (-0.86 to -0.34)	< 0.001	-0.13 (-0.36 to 0.11)	0.29	-0.47 (-0.79 to -0.15)	< 0.001
Combined HGS* (n= 968)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.27 (-4.14 to 3.59)	0.89	-0.86 (-3.41 to 1.7)	0.50	-1.18 (-3.50 to 1.14)	0.32
Lipid-lowering drugs other than statins		-9.71 (-16.59 to -2.82)	0.01	-4.87 (-9.87 to 0.13)	0.06	-11.85 (-20.39 to -3.32)	0.01
Sarcopenic Obesity							
ASM/Ht2 and Body Fat Percent Definition (n= 1,643)							
Nonusers	10.14	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	7.14	1.02 (0.72 to 1.46)	0.90	1.58 (0.95 to 2.66)	0.08	1.52 (1.00 to 2.30)	0.05
Lipid-lowering drugs other than statins	6.61	1.06 (0.51 to 2.20)	0.87	1.12 (0.40 to 3.09)	0.83	1.47 (0.52 to 4.15)	0.46
ASM and BMI definition (n= 4,725)							
Nonusers	49.18	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	44.73	0.59 (0.27 to 1.27)	0.18	1.05 (0.47 to 2.34)	0.91	1.41 (0.67 to 2.96)	0.36
Lipid-lowering drugs other than statins	36.72	0.46 (0.06 to 3.50)	0.45	0.47 (0.06 to 3.92)	0.49	1.05 (0.13 to 8.72)	0.96
LDH* (n= 5,340)							
Nonusers		Ref.		Ref.		Ref.	
Statin users		1.11 (-1.48 to 3.71)	0.40	0.39 (-2.22 to 2.99)	0.77	-0.75 (-3.27 to 1.78)	0.56
Lipid-lowering drugs other than statins		-0.06 (-5.38 to 5.25)	0.98	-1.58 (-7.05 to 3.89)	0.57	1.90 (-5.21 to 9.01)	0.60
Musculoskeletal Pain Symptoms							
Any Region (n= 1,158)							
Nonusers	49.18	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	44.73	0.84 (0.63 to 1.11)	0.21	0.88 (0.64 to 1.21)	0.43	0.82 (0.60 to 1.11)	0.20

Lipid-lowering drugs other than statins	36.72	0.60 (0.24 to 1.49)	0.26	0.37 (0.13 to 1.05)	0.06	0.53 (0.24 to 1.16)	0.11
Neck/Upper Back (n= 1,158)							
Nonusers	16.46	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	9.68	0.54 (0.36 to 0.82)	0.01	0.77 (0.46 to 1.27)	0.29	0.71 (0.42 to 1.20)	0.20
Lipid-lowering drugs other than statins	14.29	0.85 (0.30 to 2.37)	0.74	0.53 (0.12 to 2.33)	0.39	1.05 (0.35 to 3.17)	0.94
Upper Extremities (n= 1,158)							
Nonusers	34.93	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	31.13	0.84 (0.62 to 1.15)	0.27	0.94 (0.64 to 1.36)	0.72	0.86 (0.62 to 1.19)	0.36
Lipid-lowering drugs other than statins	25.48	0.64 (0.22 to 1.85)	0.40	0.52 (0.17 to 1.53)	0.23	0.71 (0.31 to 1.61)	0.42
Lower Back (n= 1,158)							
Nonusers	20.31	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	14.39	0.66 (0.46 to 0.94)	0.02	0.75 (0.46 to 1.22)	0.23	0.77 (0.51 to 1.18)	0.23
Lipid-lowering drugs other than statins	12.07	0.54 (0.16 to 1.76)	0.30	0.57 (0.16 to 2.05)	0.38	0.71 (0.25 to 2.00)	0.52
Lower Extremities (n= 1,158)							
Nonusers	23.02	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	21	0.89 (0.61 to 1.30)	0.53	1.05 (0.66 to 1.67)	0.83	0.90 (0.61 to 1.34)	0.61
Lipid-lowering drugs other than statins	16.71	0.67 (0.22 to 2.01)	0.46	0.61 (0.20 to 1.84)	0.37	0.52 (0.18 to 1.48)	0.22

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are $<29.76\%$ in men or $<22.31\%$ in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin

Table S10 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with hyperlipidemia

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 6,627)							
Nonusers	18.39	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	32.33	1.43 (1.19 to 1.72)	< 0.001	1.15 (0.85 to 1.56)	0.37	1.13 (0.88 to 1.45)	0.36
Lipid-lowering drugs other than statins	35.10	1.58 (0.90 to 2.79)	0.11	1.08 (0.51 to 2.28)	0.85	1.26 (0.72 to 2.20)	0.42
ASM/Wt (n= 6,638)							
Nonusers	10.11	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.90	2.12 (1.83 to 2.46)	< 0.001	1.20 (0.94 to 1.54)	0.15	1.08 (0.89 to 1.31)	0.45
Lipid-lowering drugs other than statins	15.12	2.40 (1.57 to 3.68)	< 0.001	0.98 (0.54 to 1.79)	0.95	0.88 (0.57 to 1.36)	0.58
ASM/Ht2 (n= 6,640)							
Nonusers	5.10	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	6.26	1.24 (0.97 to 1.60)	0.09	1.21 (0.83 to 1.77)	0.31	0.96 (0.68 to 1.37)	0.83
Lipid-lowering drugs other than statins	4.16	0.81 (0.42 to 1.55)	0.51	1.19 (0.41 to 3.47)	0.75	1.30 (0.59 to 2.88)	0.52
Max HGS* (n= 3,407)							
Nonusers	—	Ref.		Ref.		Ref.	
Statin users		-3.38 (-4.40 to -2.36)	< 0.001	-0.10 (-1.02 to 0.83)	0.83	0.10 (-0.50 to 0.70)	0.75
Lipid-lowering drugs other than statins		-3.93 (-6.21 to -1.65)	< 0.001	-2.04 (-4.21 to 0.12)	0.06	-0.81 (-2.37 to 0.75)	0.31
Relative HGS* (n= 3,329)							
Nonusers	—	Ref.		Ref.		Ref.	

Statin users		-0.29 (-0.37 to -0.21)	< 0.001	-0.01 (-0.08 to 0.06)	0.76	0.01 (-0.03 to 0.05)	0.56
Lipid-lowering drugs other than statins		-0.37 (-0.54 to -0.21)	< 0.001	-0.11 (-0.25 to 0.04)	0.13	-0.07 (-0.18 to 0.03)	0.17
Combined HGS* (n= 3,362)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-6.46 (-8.59 to -4.34)	< 0.001	0.03 (-1.84 to 1.90)	0.98	0.43 (-0.69 to 1.54)	0.45
Lipid-lowering drugs other than statins		-6.93 (-11.24 to -2.63)	< 0.001	-2.59 (-6.43 to 1.24)	0.18	-1.81 (-4.69 to 1.06)	0.22
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n= 6,627)							
Nonusers	4.75	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	5.97	1.44 (1.20 to 1.73)	< 0.001	1.17 (0.86 to 1.58)	0.32	1.13 (0.88 to 1.45)	0.35
Lipid-lowering drugs other than statins	4.16	1.60 (0.91 to 2.81)	0.11	1.09 (0.51 to 2.31)	0.82	1.24 (0.71 to 2.16)	0.45
ASM and BMI definition (n= 14,406)							
Nonusers	9.50	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	9.30	0.98 (0.58 to 1.64)	0.93	0.93 (0.48 to 1.78)	0.82	1.02 (0.64 to 1.63)	0.94
Lipid-lowering drugs other than statins	3.60	0.38 (0.09 to 1.51)	0.17	0.43 (0.10 to 1.86)	0.25	0.78 (0.23 to 2.64)	0.69
LDH* (n= 16,274)							
Nonusers		Ref.		Ref.		Ref.	
Statin users		3.27 (2.00 to 4.54)	< 0.001	-0.36 (-1.80 to 1.08)	0.62	-0.17 (-1.48 to 1.15)	0.80
Lipid-lowering drugs other than statins		1.37 (-2.32 to 5.06)	0.47	-1.04 (-5.00 to 2.92)	0.6	0.85 (-2.31 to 4.01)	0.60
Musculoskeletal Pain Symptoms							
Any Region (n= 3,741)							
Nonusers	39.06	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	43.01	1.18 (0.98 to 1.42)	0.09	1.15 (0.87 to 1.52)	0.30	1.11 (0.89 to 1.38)	0.35

Lipid-lowering drugs other than statins	39.83	1.03 (0.63 to 1.71)	0.90	1.20 (0.64 to 2.25)	0.57	1.13 (0.70 to 1.81)	0.61
Neck/Upper Back (n= 3,741)							
Nonusers	10.95	1.00 (Ref.)				1.00 (Ref.)	
Statin users	8.39	0.74 (0.54 to 1.03)	0.08	1.03 (0.65 to 1.62)	0.89	1.05 (0.70 to 1.56)	0.83
Lipid-lowering drugs other than statins	15.59	1.50 (0.80 to 2.84)	0.20	2.57 (1.18 to 5.57)	0.02	2.62 (1.36 to 5.08)	< 0.001
Upper Extremities (n= 3,741)							
Nonusers	26.92	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	29.46	1.13 (0.92 to 1.39)	0.23	1.10 (0.82 to 1.47)	0.53	1.11 (0.88 to 1.41)	0.39
Lipid-lowering drugs other than statins	28.95	1.11 (0.67 to 1.83)	0.69	1.27 (0.71 to 2.27)	0.41	1.26 (0.77 to 2.07)	0.36
Lower Back (n= 3,741)							
Nonusers	11.73	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.19	1.14 (0.88 to 1.48)	0.30	1.15 (0.80 to 1.66)	0.43	1.22 (0.87 to 1.71)	0.24
Lipid-lowering drugs other than statins	5.19	0.41 (0.17 to 1.03)	0.06	0.50 (0.18 to 1.44)	0.19	0.76 (0.35 to 1.68)	0.50
Lower Extremities (n= 3,741)							
Nonusers	15.10	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	18.17	1.25 (0.99 to 1.57)	0.06	1.14 (0.78 to 1.66)	0.50	1.14 (0.84 to 1.55)	0.41
Lipid-lowering drugs other than statins	15.29	1.01 (0.56 to 1.84)	0.96	1.06 (0.51 to 2.19)	0.88	1.03 (0.53 to 1.99)	0.93

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are $<7 \text{ kg/m}^2$ in men or $<5.5 \text{ kg/m}^2$ in women

ASM/Wt cutoffs are $<29.76\%$ in men or $<22.31\%$ in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S11 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 10,412)							
Nonusers	19.08	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	35.88	1.78 (1.44 to 2.19)	< 0.001	1.33 (0.97 to 1.82)	0.08	1.25 (0.99 to 1.59)	0.06
Lipid-lowering drugs other than statins	38.03	1.81 (1.01 to 3.23)	0.05	1.11 (0.55 to 2.26)	0.77	1.52 (0.85 to 2.71)	0.16
ASM/Wt (n= 10,459)							
Nonusers	8.30	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.84	2.37 (2.04 to 2.76)	< 0.001	1.24 (0.97 to 1.58)	0.09	1.22 (1.02 to 1.47)	0.03
Lipid-lowering drugs other than statins	14.07	2.60 (1.67 to 4.06)	< 0.001	0.96 (0.54 to 1.71)	0.89	1.06 (0.68 to 1.65)	0.79
ASM/Ht2 (n= 10,474)							
Nonusers	5.92	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	7.20	1.23 (0.94 to 1.62)	0.13	1.19 (0.80 to 1.75)	0.38	0.94 (0.66 to 1.33)	0.72
Lipid-lowering drugs other than statins	5.31	0.89 (0.50 to 1.58)	0.69	0.78 (0.32 to 1.88)	0.58	1.29 (0.56 to 2.99)	0.55
Max HGS* (n= 4,526)							
	—						

Nonusers		Ref.		Ref.		Ref.	
Statin users		-4.53 (-5.43 to -3.63)	< 0.001	-0.61 (-1.19 to -0.04)	0.04	-0.45 (-1.04 to 0.14)	0.14
Lipid-lowering drugs other than statins		-5.78 (-8.22 to -3.33)	< 0.001	-2.20 (-4.08 to -0.31)	0.02	-1.17 (-2.88 to 0.54)	0.18
Relative HGS* (n= 4,410)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.39 (-0.46 to -0.32)	< 0.001	-0.03 (-0.07 to 0.02)	0.24	-0.03 (-0.07 to 0.01)	0.15
Lipid-lowering drugs other than statins		-0.64 (-0.8 to -0.48)	< 0.001	-0.1 (-0.24 to 0.04)	0.15	-0.09 (-0.21 to 0.03)	0.13
Combined HGS* (n= 4,461)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-8.91 (-10.66 to -7.17)	< 0.001	-1.29 (-2.44 to -0.14)	0.03	-1.06 (-2.17 to 0.05)	0.06
Lipid-lowering drugs other than statins		-11.34 (-15.92 to -6.76)	< 0.001	-4.02 (-7.06 to -0.99)	0.01	-2.33 (-5.47 to 0.81)	0.15
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n= 10,415)							
Nonusers	5.08	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	

Statin users	6.77	1.78 (1.44 to 2.20)	< 0.001	1.33 (0.97 to 1.83)	0.07	1.23 (0.96 to 1.57)	0.10
Lipid-lowering drugs other than statins	4.28	1.82 (1.02 to 3.24)	0.04	1.12 (0.55 to 2.27)	0.76	1.51 (0.83 to 2.73)	0.18
ASM and BMI definition (n= 21,553)							
Nonusers	7.90	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.50	1.09 (0.62 to 1.90)	0.77	1.18 (0.58 to 2.41)	0.64	0.85 (0.53 to 1.34)	0.47
Lipid-lowering drugs other than statins	5.00	0.63 (0.17 to 2.33)	0.49	0.56 (0.13 to 2.49)	0.45	0.86 (0.26 to 2.90)	0.81
LDH* (n= 24,501)							
Nonusers	—	Ref.		Ref.		Ref.	
Statin users		4.64 (3.36 to 5.93)	< 0.001	-0.73 (-2.10 to 0.64)	0.30	-0.28 (-1.79 to 1.22)	0.71
Lipid-lowering drugs other than statins		4.01 (0.18 to 7.84)	0.04	-1.44 (-5.43 to 2.55)	0.48	-0.62 (-4.69 to 3.46)	0.77
Musculoskeletal Pain Symptoms							
Any Region (n= 6,226)							
Nonusers	33.04	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	44.40	1.62 (1.33 to 1.97)	< 0.001	1.22 (0.96 to 1.54)	0.11	1.10 (0.89 to 1.35)	0.38
Lipid-lowering drugs other than statins	37.35	1.21 (0.71 to 2.05)	0.48	0.88 (0.44 to 1.77)	0.72	0.93 (0.57 to 1.52)	0.77
Neck/Upper Back (n= 6,226)							
Nonusers	9.02	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.40	0.93 (0.75 to 1.15)	0.47	0.94 (0.66 to 1.34)	0.73	0.89 (0.61 to 1.30)	0.54

Lipid-lowering drugs other than statins	14.41	1.70 (0.90 to 3.19)	0.10	1.57 (0.68 to 3.60)	0.28	1.82 (0.90 to 3.65)	0.09
Upper Extremities (n= 6,226)							
Nonusers	21.49	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	30.08	1.57 (1.26 to 1.96)	< 0.001	1.14 (0.83 to 1.59)	0.40	1.14 (0.91 to 1.43)	0.25
Lipid-lowering drugs other than statins	27.77	1.40 (0.77 to 2.55)	0.26	1.15 (0.57 to 2.30)	0.69	1.25 (0.75 to 2.09)	0.39
Lower Back (n= 6,226)							
Nonusers	11.22	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.20	1.20 (0.93 to 1.55)	0.15	1.05 (0.75 to 1.47)	0.76	1.10 (0.80 to 1.51)	0.54
Lipid-lowering drugs other than statins	10.26	0.90 (0.41 to 2.00)	0.80	0.66 (0.26 to 1.69)	0.38	0.75 (0.34 to 1.65)	0.48
Lower Extremities (n= 6,226)							
Nonusers	12.79	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	18.98	1.60 (1.25 to 2.04)	< 0.001	1.22 (0.89 to 1.68)	0.20	1.07 (0.80 to 1.42)	0.65
Lipid-lowering drugs other than statins	19.74	1.68 (0.87 to 3.22)	0.12	1.14 (0.51 to 2.53)	0.74	1.05 (0.55 to 2.03)	0.88

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3,

1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women


ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Figure and tables

Figure 1 Flow of study



Abbreviations: NHANES, National Health and Nutrition Examination Survey; CVD, cardiovascular disease; HLP, hyperlipidemia; SNP, Single Nucleotide Polymorphism; LDH, Lactate Dehydrogenase.

A: Flow of study.

B: Two-sample Mendelian randomization study design.

Arrows represent associations.

Dashed lines with “X” in the middle represent genetic variants applied as instrumental variables

for Statins that should not be associated with potential confounding factors and do not exert an effect on sarcopenia-related traits and LDH via other pathways in assumptions 2 and 3, respectively.

Abbreviations: SNP, Single nucleotide polymorphism; IVW, Inverse variance weighted; MR-PRESSO, MR-pleiotropy residual sum and outlier; LDH, Lactic dehydrogenase.

Table 1 Baseline characteristics of patients with cardiovascular disease, diabetes, or hyperlipidemia

	Statin drug use			
	Nonuse (13,474)	Statin drugs (8,481)	Lipid-lowering drugs other than statins(n=594)	p
Age, (year)	55.4 ± 0.1	65.7 ± 0.1	63.3 ± 0.5	<0.001
Male, (%)	48.2	53.5	52.2	<0.001
Race/ethnicity, (%)				
Hispanic-Mexican	17.8	11.4	14.5	<0.001
Other Ethnicity	18.2	16.2	18.0	<0.001
Non-Hispanic White	42.2	52.3	54.0	<0.001
Non-Hispanic Black	21.8	20.2	13.5	<0.001
Education status, (%)				<0.001
Less than high school	29.9	28.2	30.6	
High school	22.1	24.9	23.6	
More than high school	48.1	46.9	45.8	
Marital status, (%)				<0.001
Married	56.2	59.9	62.3	
Never married	16.2	8.3	8.9	
other	27.6	31.8	28.8	
PIR, (%)				<0.001
< 1.3	31.5	27.4	30.6	
1.3-3.5	37.8	39.7	38.7	
> 3.5	30.7	32.9	30.8	
BMI, kg/m ²				0.003
18.5-25	21.3	18.1	18.4	
25-30	34.5	36.2	33.9	
≥ 30	44.3	45.7	47.7	
Alcohols status, (%)				<0.001

=0, g/d	38.5	44.2	45.3	
< 5, g/d	42.5	39.1	40.4	
5-30, g/d	16.3	15.1	13.0	
> 30, g/d	2.7	1.7	1.3	
Smoking status, (%)				<0.001
Never smoking	52.0	46.8	46.6	
Former smoker	28.2	39.4	37.0	
Current smoker	19.8	13.8	16.3	
Physical activity, (%)	28.7	26.2	22.7	0.001
HBP, (%)	61.6	80.5	80.8	<0.001
CKD, (%)	11.8	23.6	25.2	<0.001
COPD, (%)	9.3	12.6	12.8	<0.001
Cancer, (%)	10.8	17.8	17.0	<0.001
CVD, (%)	20.0	35.3	26.9	<0.001
Diabetes, (%)	37.1	46.4	48.2	<0.001
Hyperlipidemia, (%)	71.0	85.8	88.0	<0.001

The data were adjusted for survey weights from the NHANES.

The data are presented as the means \pm SDs or percentages.

We considered two-sided p-values less than 0.05 as statistically significant.

Abbreviations: PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

Table 2 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n=8,856)							
Nonusers	21.42	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	33.60	1.35 (1.12 to 1.62)	<0.001	1.31 (0.99 to 1.74)	0.06	1.25 (1.00 to 1.55)	0.05
Lipid-lowering drugs other than statins	35.11	1.36 (0.78 to 2.37)	0.28	1.00 (0.49 to 2.02)	1.00	1.23 (0.73 to 2.09)	0.44
ASM/Wt (n=8,839)							
Nonusers	10.85	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	14.11	1.86 (1.62 to 2.13)	<0.001	1.23 (0.99 to 1.54)	0.06	1.14 (0.97 to 1.34)	0.11
Lipid-lowering drugs other than statins	14.19	1.99 (1.33 to 2.97)	<0.001	0.93 (0.53 to 1.62)	0.79	0.92 (0.62 to 1.37)	0.67
ASM/Ht ² (n=8,803)							
Nonusers	5.50	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	6.54	1.20 (0.95 to 1.52)	0.12	1.11 (0.77 to 1.60)	0.56	0.87 (0.64 to 1.18)	0.38
Lipid-lowering drugs other than statins	4.17	0.75 (0.41 to 1.36)	0.34	0.83 (0.31 to 2.25)	0.71	0.99 (0.47 to 2.09)	0.97
		β (95% CI)	<i>P</i>	B (95% CI)	<i>P</i>	B (95% CI)	<i>P</i>

Max HGS* (n=4,340)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-3.01 (-3.97 to -2.06)	<0.001	-0.35 (-1.11 to 0.41)	0.36	-0.13 (-0.66 to 0.40)	0.64
Lipid-lowering drugs other than statins		-3.79 (-5.95 to -1.63)	<0.001	-2.07 (-3.99 to -0.14)	0.04	-0.90 (-2.41 to 0.61)	0.24
Relative grip strength* (n=4,230)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.23 (-0.30 to -0.17)	<0.001	-0.01 (-0.06 to 0.04)	0.66	-0.01 (-0.04 to 0.03)	0.77
Lipid-lowering drugs other than statins		-0.34 (-0.49 to -0.19)	<0.001	-0.08 (-0.20 to 0.05)	0.23	-0.07 (-0.18 to 0.03)	0.17
Combined HGS* (n=4,275)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-5.9 (-7.86 to -3.93)	<0.001	-0.61 (-2.18 to 0.96)	0.44	-0.32 (-1.32 to 0.67)	0.53
Lipid-lowering drugs other than statins		-6.82 (-10.88 to -2.76)	<0.001	-2.78 (-6.25 to 0.69)	0.11	-2.03 (-4.88 to 0.82)	0.16
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n=8,806)							
Nonusers	5.10	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	

Statin users	6.22	1.36 (1.13 to 1.63)	<0.001	1.32 (1.00 to 1.75)	0.05	1.26 (1.00 to 1.56)	0.05
Lipid-lowering drugs other than statins	4.17	1.37 (0.79 to 2.39)	0.26	1.01 (0.50 to 2.03)	0.99	1.21 (0.72 to 2.05)	0.47
ASM and BMI definition (n=19,259)							
Nonusers	10.80	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.20	0.76 (0.47 to 1.23)	0.27	0.92 (0.51 to 1.66)	0.78	0.98 (0.65 to 1.47)	0.92
Lipid-lowering drugs other than statins	3.20	0.30 (0.08 to 1.16)	0.08	0.38 (0.09 to 1.60)	0.18	0.74 (0.23 to 2.44)	0.62
LDH* (n=21,908)							
Nonusers	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		2.55 (1.32 to 3.78)	<0.001	-0.55 (-1.81 to 0.71)	0.39	-0.57 (-1.72 to 0.58)	0.33
Lipid-lowering drugs other than statins		-0.42 (-3.71 to 2.88)	0.80	-2.77 (-6.35 to 0.81)	0.13	-0.28 (-3.31 to 2.75)	0.86

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal mass index; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No),

chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are $<29.76\%$ in men or $<22.31\%$ in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table 3 Odds ratios of musculoskeletal pain for statin users compared to nonusers

	Prevalence, %	Crude		Adjusted		After matching*	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Any Region (n=5,136)							
Nonusers	69.68	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	27.78	1.15 (0.96 to 1.38)	0.12	1.15 (0.88 to 1.50)	0.30	1.09 (0.91 to 1.31)	0.36
Lipid-lowering drugs other than statins	2.24	1.08 (0.64 to 1.82)	0.76	1.10 (0.59 to 2.04)	0.75	1.04 (0.67 to 1.61)	0.85
Neck/Upper Back (n=5,136)							
Nonusers	74.02	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	21.83	0.74 (0.56 to 0.97)	0.03	0.96 (0.64 to 1.44)	0.84	0.94 (0.67 to 1.32)	0.73
Lipid-lowering drugs other than statins	4.15	1.52 (0.87 to 2.66)	0.14	2.17 (1.07 to 4.39)	0.03	2.19 (1.19 to 4.00)	0.01
Upper Extremities (n=5,136)							
Nonusers	69.33	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	28.01	1.13 (0.92 to 1.38)	0.23	1.11 (0.81 to 1.51)	0.50	1.13 (0.93 to 1.39)	0.22
Lipid-lowering drugs other than statins	2.66	1.16 (0.69 to 1.94)	0.56	1.27 (0.68 to 2.38)	0.44	1.25 (0.79 to 1.98)	0.33
Lower Back (n=5,136)							
Nonusers	69.78	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	

Statin users	28.26	1.03 (0.82 to 1.29)	0.82	1.05 (0.76 to 1.45)	0.75	1.05 (0.79 to 1.39)	0.74
Lipid-lowering drugs other than statins	1.96	0.66 (0.29 to 1.48)	0.31	0.61 (0.24 to 1.54)	0.28	0.74 (0.37 to 1.50)	0.41
Lower Extremities (n=5,136)							
Nonusers	68.81	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	28.53	1.17 (0.95 to 1.45)	0.14	1.12 (0.83 to 1.51)	0.44	1.08 (0.84 to 1.41)	0.54
Lipid-lowering drugs other than statins	2.66	1.22 (0.66 to 2.23)	0.52	1.09 (0.54 to 2.22)	0.80	1.01 (0.55 to 1.83)	0.99

Abbreviations: OR, odds ratio; CI, confidence interval.

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

*Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table 4 The causal relationship between statins and sarcopenia-related traits based on two-sample Mendelian randomization analysis

Outcome	SNPs	MR method	Beta/OR	95%CI	P-value
Appendicular lean mass	11	IVW	-0.060	-0.153, 0.033	0.208
		MR Egger	-0.019	-0.191, 0.153	0.834
		Weighted median	-0.023	-0.056, 0.010	0.173
	4	MR PRESOO	-0.016	-0.057, 0.025	0.488
Hand grip strength (right)	11	IVW	-0.014	-0.039, 0.012	0.289
		MR Egger	-0.003	-0.050, 0.043	0.892
		Weighted median	-0.010	-0.031, 0.011	0.339
	8	MR PRESOO	0.003	-0.017, 0.023	0.776
Hand grip strength (left)	11	IVW	-0.216	-0.044, 0.001	0.059
		MR Egger	-0.004	-0.044, 0.036	0.847
		Weighted median	-0.013	-0.031, 0.006	0.171
	10	MR PRESOO	-0.021	-0.041, 0.002	0.058
Low hand grip strength	11	IVW	1.042	0.889, 1.221	0.614
		MR Egger	1.025	0.759, 1.384	0.875
		Weighted median	1.028	0.839, 1.259	0.792
		MR PRESOO	1.069	0.917, 1.247	0.411
Walking pace	11	IVW	0.001	-0.010, 0.011	0.939
		MR Egger	0.007	-0.012, 0.026	0.497
		Weighted median	-0.002	-0.016, 0.011	0.748
		MR PRESOO	0.003	-0.007, 0.012	0.649
Lactate dehydrogenase	8	IVW	-0.080	-0.213, 0.053	0.238
		MR Egger	0.035	-0.230, 0.230	0.804
		Weighted median	0.003	-0.082, 0.087	0.952
	6	MR PRESOO	-0.030	-0.100, 0.040	0.437

Abbreviations: SNP, Single nucleotide polymorphism; IVW, Inverse variance weighted; MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier.

We considered two-sided p-values less than 0.05 as statistically significant.

Supplemental tables

Table S1 Details of studies and datasets used in the study

Trait	Sample size (cases/controls)	Datatype	Unit	Ancestry	Consortium/ First Author	PMID or GWAS ID
Statins	290,385 (73,475/216,910)	Binary	/	European	UK Biobank	31015401
Appendicular lean mass	450,243	Continuous	kg	European	UK Biobank	33097823
Hand grip strength (right)	461,089	Continuous	SD	European	MRC-IEU	ukb-b-10215
Hand grip strength (left)	461,026	Continuous	SD	European	MRC-IEU	ukb-b-7478
Low hand grip strength	121,055 (6,734/114,321)	Binary	/	European	Garan Jones	33510174
Walking pace	459,915	Continuous	km/s	European	MRC-IEU	ukb-b-4711
Lactate dehydrogenase	126,319	Continuous	SD	East Asian	Ishigaki K	29403010

Abbreviations: SD, Standard Deviation; PMID, PubMed Unique Identifier; GWAS ID, Genome-Wide Association Study Identifier; MRC-IEU, Medical Research Council Integrative Epidemiology Unit.

Table S2 SNPs are used as instrumental variables for Statins (P-value < 5×10⁻⁸)

Traits	SNP	Chr	Position	Effect allele	another allele	Beta	SE	P-value	F-statistic
Statins-ALM/HGS (right)/	rs113911544	1	55706403	G	A	0.085085202	0.014373915	3.20E-09	35.0395019
HGS (left)/LHGS/Walking	rs11591147	1	55505647	T	G	-0.362323999	0.021494841	9.40E-64	284.1356506
pace	rs1260326	2	27730940	T	C	0.059920058	0.005712328	9.70E-26	110.0317897
	rs12725767	1	6676040	G	A	0.035128029	0.005856082	2.00E-09	35.98266012
	rs12740374	1	109817590	T	G	-0.156618273	0.006742468	2.30E-119	539.5691038
	rs1367117	2	21263900	A	G	0.105726091	0.005900949	8.70E-72	321.0115277
	rs4299376	2	44072576	G	T	0.086690463	0.005971001	9.20E-48	210.7892007
	rs4541244	2	58917535	T	C	-0.034275082	0.005711376	2.00E-09	36.01434333
	rs570530	1	234866776	A	G	-0.032541516	0.005613812	6.80E-09	33.60159042
	rs693668	1	55521109	G	A	-0.048941477	0.005866453	7.30E-17	69.5989924
	rs79598313	1	27284913	T	C	0.146636976	0.018408443	1.60E-15	63.45310484
Statins-LDH	rs113911544	1	55706403	G	A	0.085085202	0.014373915	3.20E-09	35.0395019
	rs1260326	2	27730940	T	C	0.059920058	0.005712328	9.70E-26	110.0317897
	rs12725767	1	6676040	G	A	0.035128029	0.005856082	2.00E-09	35.98266012
	rs12740374	1	109817590	T	G	-0.156618273	0.006742468	2.30E-119	539.5691038

	rs1367117	2	21263900	A	G	0.105726091	0.005900949	8.70E-72	321.0115277
	rs4541244	2	58917535	T	C	-0.034275082	0.005711376	2.00E-09	36.01434333
	rs570530	1	234866776	A	G	-0.032541516	0.005613812	6.80E-09	33.60159042
	rs693668	1	55521109	G	A	-0.048941477	0.005866453	7.30E-17	69.5989924
	rs7534572	1	62999675	C	G	-0.074218207	0.005852643	7.50E-37	160.8114059

Abbreviations: SNP, Single nucleotide polymorphism, MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier. ALM, Appendicular

Lean Muscle; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

Table S3 Definition of statins and lipid-lowering drugs

Generic drug code	Drug name
Statin drugs	
d00280	lovastatin
d00348	pravastatin
d00746	simvastatin
d03183	fluvastatin
d04105	atorvastatin
d04140	cerivastatin
d04787	lovastatin; niacin
d04851	rosuvastatin
d05048	amlodipine; atorvastatin
d05348	ezetimibe; simvastatin
d07110	niacin; simvastatin
d07637	pitavastatin
d07805	simvastatin; sitagliptin
d08383	evolcumab
Lipid-lowering drugs other than statins	
c00019	antihyperlipidemic agents - unspecified
c00173	hmg-coa reductase inhibitors - unspecified
d00193	cholestyramine
d00196	clofibrate
d00245	gemfibrozil
d00353	probucol
d00744	colestipol
d04286	fenofibrate
d04695	colesevelam
d04824	ezetimibe
d07371	fenofibric acid

d07891	icosapent
d08374	alirocumab
h00036	bezafibrate

Table S4 Characteristics of cardiovascular disease, diabetes, or hyperlipidemia patients with Statin use or nonuse after matching

	After matching		
	Non-use (5,249)	Statin drug use (5,429)	Standardized difference
Age, (year)	62.6 ± 0.2	64.7 ± 0.1	<0.001
Male, (%)	50.9	52.4	<0.001
Race/ethnicity, (%)			
Hispanic-Mexican	13.3	11.8	<0.001
Other Ethnicity	17.5	16.5	<0.001
Non-Hispanic White	47.0	51.3	<0.001
Non-Hispanic Black	22.2	20.4	<0.001
Education status, (%)			<0.001
Less than high school	29.6	28.5	
High school	23.6	24.3	
More than high school	46.8	47.2	
Marital status, (%)			<0.001
Married	57.2	59.1	
Never married	10.9	9.0	

Other	32.0	31.9	
PIR, (%)			<0.001
< 1.3	30.0	27.8	
1.3-3.5	38.5	39.5	
> 3.5	31.5	32.7	
BMI, kg/m ²			<0.001
18.5-25	20.4	18.2	
25-30	33.5	36.2	
≥ 30	46.1	45.7	
Alcohols status, (%)			<0.001
= 0, g/d	42.5	43.7	
< 5, g/d	40.0	39.2	
5-30, g/d	15.1	15.5	
> 30, g/d	2.3	1.6	
Smoking status, (%)			<0.001
Never smoking	49.0	47.4	
Former smoker	34.6	38.1	

Current smoker	16.4	14.5	
Moderate exercise, (%)	26.2	26.4	<0.001
HBP, (%)	76.6	79.2	<0.001
CKD, (%)	20.0	23.0	<0.001
COPD, (%)	12.1	12.6	<0.001
Cancer, (%)	15.6	17.1	<0.001
CVD, (%)	27.7	33.0	<0.001
Diabetes, (%)	43.9	45.1	<0.001
Hyperlipidemia, (%)	42.9	45.5	<0.001

Data were adjusted for survey weights of NHANES.

Data are presented as means \pm SD or percent.

We considered two-sided p-values less than 0.05 as statistically significant.

Abbreviations: PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular diseases; CKD, Chronic Kidney Disease; COPD, Chronic Obstructive Pulmonary Disease.

Table S5 The association between statin users and skeletal muscle-related phenotypes compared with nonusers by stepwise regression analysis

	ASM/BMI (n=8,856)		ASM/Ht ² and bf Sarcopenic Obesity (n=8,806)		Max HGS (n=4,340)		Relative HGS (n=4,230)		Combined HGS (n=4,275)		Neck/Upper	Back
	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	β (95% CI)	<i>P</i>	β (95% CI)	<i>P</i>	β (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Unadjusted	1.35 (1.12 to 1.62)	< 0.001	1.36 (1.13 to 1.63)	< 0.001	-3.01 (-3.97 to -2.06)	< 0.001	-0.23 (-0.30 to -0.17)	< 0.001	-5.90 (-7.86 to -3.93)	< 0.001	0.74 (0.56 to 0.97)	0.03
Age adjustment	1.01 (0.82 to 1.23)	0.96	1.01 (0.83 to 1.23)	0.91	0.67 (-0.22 to 1.56)	0.14	-0.02 (-0.10 to 0.05)	0.5	1.31 (-0.50 to 3.11)	0.15	0.83 (0.61 to 1.12)	0.21
+ Sex	1.24 (1.00 to 1.55)	0.05	1.25 (1.01 to 1.56)	0.05	0.10 (-0.64 to 0.84)	0.78	-0.06 (-0.12 to -0.01)	0.03	0.24 (-1.26 to 1.74)	0.75	0.85 (0.63 to 1.14)	0.27
+ Race/ ethnicity	1.29 (1.03 to 1.62)	0.03	1.30 (1.04 to 1.63)	0.02	-0.09 (-0.81 to 0.63)	0.80	-0.07 (-0.13 to -0.02)	0.01	-0.14 (-1.61 to 1.33)	0.84	0.83 (0.61 to 1.11)	0.21
+Education level	1.29 (1.02 to 1.62)	0.03	1.29 (1.03 to 1.63)	0.03	-0.09 (-0.83 to 0.66)	0.82	-0.07 (-0.13 to -0.02)	0.01	-0.14 (-1.64 to 1.35)	0.85	0.83 (0.61 to 1.12)	0.21
+Marital status	1.28 (1.02 to 1.62)	0.03	1.29 (1.03 to 1.63)	0.03	-0.16 (-0.90 to 0.57)	0.65	-0.08 (-0.14 to -0.02)	0.01	-0.30 (-1.78 to 1.18)	0.68	0.82 (0.61 to 1.12)	0.2
+ PIR	1.31 (1.02 to 1.69)	0.03	1.32 (1.03 to 1.70)	0.03	-0.28 (-1.02 to 0.45)	0.44	-0.09 (-0.15 to -0.04)	< 0.001	-0.48 (-1.98 to 1.01)	0.51	0.86 (0.61 to 1.21)	0.37
+ BMI	-	-	-	-	-0.55 (-1.24 to 0.13)	0.11	-0.04 (-0.08 to 0.01)	0.08	-1.05 (-2.42 to 0.31)	0.13	0.88 (0.63 to 1.25)	0.48
+ Alcohols statuses	1.33 (1.03 to 1.72)	0.03	1.34 (1.04 to 1.73)	0.03	-0.49 (-1.22 to 0.23)	0.18	-0.04 (-0.08 to 0.01)	0.10	-0.90 (-2.30 to 0.51)	0.2	0.82 (0.60 to 1.12)	0.21
+ Smoking status	1.34 (1.03 to 1.73)	0.03	1.35 (1.04 to 1.74)	0.02	-0.49 (-1.23 to 0.24)	0.18	-0.04 (-0.08 to 0.01)	0.10	-0.90 (-2.31 to 0.52)	0.21	0.82 (0.60 to 1.12)	0.2
+ Physical activity	1.35 (1.04 to 1.74)	0.02	1.36 (1.05 to 1.75)	0.02	-0.50 (-1.27 to 0.28)	0.2	-0.04 (-0.09 to 0.01)	0.13	-0.91 (-2.40 to 0.58)	0.22	0.81 (0.59 to 1.11)	0.19

+ HBP	1.31 (1.01 to 1.71)	0.04	1.32 (1.02 to 1.72)	0.04	-0.54 (-1.32 to 0.24)	0.17	-0.04 (-0.08 to 0.01)	0.15	-0.97 (-2.48 to 0.54)	0.20	0.82 (0.59 to 1.13)	0.21
+ CVD	1.31 (0.99 to 1.72)	0.06	1.32 (1.00 to 1.74)	0.05	-0.33 (-1.09 to 0.44)	0.39	-0.02 (-0.07 to 0.03)	0.37	-0.63 (-2.14 to 0.88)	0.40	0.81 (0.56 to 1.18)	0.27
+ Diabetes	1.28 (0.97 to 1.69)	0.08	1.29 (0.98 to 1.71)	0.07	-0.25 (-1.04 to 0.54)	0.52	-0.01 (-0.06 to 0.04)	0.62	-0.48 (-2.02 to 1.07)	0.53	0.82 (0.56 to 1.19)	0.28
+ Hyperlipidemia	1.32 (0.99 to 1.75)	0.06	1.33 (1.00 to 1.77)	0.05	-0.26 (-1.05 to 0.53)	0.50	-0.01 (-0.06 to 0.04)	0.71	-0.44 (-2.02 to 1.14)	0.57	0.84 (0.56 to 1.24)	0.36
+ CKD	1.33 (0.99 to 1.78)	0.06	1.34 (1.00 to 1.80)	0.05	-0.31 (-1.11 to 0.5)	0.44	-0.01 (-0.06 to 0.04)	0.76	-0.51 (-2.12 to 1.10)	0.52	0.82 (0.58 to 1.17)	0.26
+ COPD	1.32 (0.98 to 1.76)	0.07	1.33 (0.99 to 1.78)	0.06	-0.31 (-1.11 to 0.49)	0.43	-0.01 (-0.06 to 0.04)	0.74	-0.53 (-2.13 to 1.08)	0.51	0.83 (0.58 to 1.19)	0.29
+ Cancer	1.32 (0.98 to 1.76)	0.07	1.33 (0.99 to 1.78)	0.06	-0.32 (-1.12 to 0.48)	0.42	-0.01 (-0.06 to 0.04)	0.72	-0.55 (-2.14 to 1.05)	0.49	0.85 (0.59 to 1.24)	0.39

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; HGS, Hand grip strength; BMI, body mass index; Wt, weight; Ht, height; PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women.

Table S6 The results of sensitivity analysis for two-sample Mendelian randomization analysis of the causal relationships between Statins and sarcopenia-related traits

Outcome	No. of IVs	Heterogeneity		MR-Egger pleiotropy test			MR-PRESSO
		Cochran's <i>Q</i>	<i>P</i> -value	intercept	SE	<i>P</i> -value	Global Test <i>P</i> -value
Appendicular lean mass	11	346.6756844	2.02E-68	-0.0042237	0.00746	0.585	<0.001
Hand grip strength (right)	11	40.71459187	1.27E-05	-0.0010619	0.00202	0.612	<0.001
Hand grip strength (left)	11	32.39685682	<0.001	-0.0018087	0.00172	0.321	<0.001
Low hand grip strength	11	10.56373443	0.393	0.00164006	0.01293	0.902	0.463
Walking pace	8	8.438255201	0.586	-0.0006592	0.00082	0.443	0.622
Lactate dehydrogenase	11	38.72767287	2.20E-06	-0.0082974	0.00844	0.363	<0.001

Abbreviations: MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier.

We considered two-sided *p*-values less than 0.05 as statistically significant.

Table S7 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among the population over 65 years old

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 2,367)							
Nonusers	35.05	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	43.20	0.86 (0.65 to 1.13)	0.27	1.04 (0.73 to 1.49)	0.81	1.11 (0.80 to 1.55)	0.52
Lipid-lowering drugs other than statins	34.23	1.19 (0.53 to 2.67)	0.68	1.02 (0.43 to 2.40)	0.97	1.31 (0.58 to 2.97)	0.51
ASM/Wt (n= 2,408)							
Nonusers	24.01	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	21.34	1.41 (1.12 to 1.77)	< 0.001	1.17 (0.83 to 1.63)	0.36	1.16 (0.90 to 1.50)	0.25
Lipid-lowering drugs other than statins	27.26	0.96 (0.52 to 1.80)	0.91	0.68 (0.29 to 1.59)	0.36	0.87 (0.45 to 1.70)	0.69
ASM/Ht ² (n= 2,430)							
Nonusers	15.26	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	12.60	0.80(0.60 to 1.06)	0.12	0.84 (0.55 to 1.27)	0.39	0.74 (0.50 to 1.10)	0.13
Lipid-lowering drugs other than statins	7.08	0.42 (0.19 to 0.95)	0.04	0.34 (0.15 to 0.78)	0.01	0.57 (0.20 to 1.57)	0.28
Max HGS* (n= 1,590)							
	—						

Nonusers		Ref.		Ref.		Ref.	
Statin users		0.54 (-0.81 to 1.88)	0.42	-0.22 (-0.94 to 0.51)	0.55	0.14 (-0.63 to 0.91)	0.72
Lipid-lowering drugs other than statins		-0.30 (-3.42 to 2.83)	0.85	-0.32 (-2.20 to 1.56)	0.73	0.10 (-2.21 to 2.40)	0.94
Relative HGS* (n= 1,532)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.01 (-0.1 to 0.08)	0.81	-0.02 (-0.07 to 0.03)	0.41	0.02 (-0.04 to 0.07)	0.52
Lipid-lowering drugs other than statins		-0.02 (-0.23 to 0.19)	0.86	0.03 (-0.11 to 0.17)	0.64	-0.03 (-0.19 to 0.13)	0.73
Combined HGS* (n= 1,560)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		0.86 (-1.70 to 3.42)	0.50	-0.58 (-1.88 to 0.72)	0.37	-0.06 (-1.56 to 1.44)	0.94
Lipid-lowering drugs other than statins		0.15 (-6.25 to 6.55)	0.96	0.09 (-3.28 to 3.46)	0.96	-1.24 (-5.70 to 3.22)	0.59
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n= 2,369)							
Nonusers	14.68	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	12.60	0.87 (0.66 to 1.14)	0.29	1.06 (0.74 to 1.52)	0.74	1.15 (0.83 to 1.59)	0.41
Lipid-lowering drugs other than statins	7.08	1.20 (0.53 to 2.69)	0.66	1.03 (0.44 to 2.44)	0.95	1.36 (0.6 to 3.07)	0.46

ASM and BMI definition (n= 7,839)							
Nonusers	14.80	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.10	0.54 (0.29 to 1.00)	0.05	0.74 (0.33 to 1.67)	0.47	0.83 (0.48 to 1.46)	0.53
Lipid-lowering drugs other than statins	4.60	0.31 (0.05 to 1.92)	0.21	0.42 (0.06 to 2.81)	0.37	0.91 (0.21 to 4.04)	0.91
LDH* (n= 8,954)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-2.34 (-4.15 to -0.54)	0.01	-0.73 (-2.65 to 1.19)	0.45	0.04 (-1.58 to 1.66)	0.96
Lipid-lowering drugs other than statins		-2.97 (-8.28 to 2.35)	0.27	-1.81 (-7.51 to 3.89)	0.53	-0.44 (-4.76 to 3.89)	0.84
Musculoskeletal Pain Symptoms							
Any Region (n= 2,312)							
Nonusers	33.74	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	35.99	1.10 (0.86 to 1.42)	0.43	1.13 (0.82 to 1.55)	0.44	0.99 (0.77 to 1.27)	0.91
Lipid-lowering drugs other than statins	32.47	0.94 (0.51 to 1.76)	0.85	0.92 (0.44 to 1.91)	0.82	1.19 (0.64 to 2.18)	0.58
Neck/Upper Back (n= 2,312)							
Nonusers	7.01	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	6.02	0.85 (0.58 to 1.25)	0.40	0.77 (0.48 to 1.24)	0.27	0.74 (0.45 to 1.22)	0.23
Lipid-lowering drugs other than statins	11.68	1.75 (0.84 to 3.66)	0.13	1.83 (0.92 to 3.63)	0.08	1.80 (0.69 to 4.68)	0.23

Upper Extremities (n= 2,312)							
Nonusers	23.40	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	25.68	1.13 (0.84 to 1.52)	0.41	1.23 (0.85 to 1.80)	0.27	1.08 (0.82 to 1.42)	0.58
Lipid-lowering drugs other than statins	25.76	1.14 (0.54 to 2.37)	0.73	1.24 (0.59 to 2.63)	0.56	1.58 (0.83 to 3.01)	0.16
Lower Back (n= 2,312)							
Nonusers	7.46	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	9.74	1.34 (0.90 to 1.99)	0.15	1.49 (0.92 to 2.42)	0.10	1.07 (0.70 to 1.63)	0.75
Lipid-lowering drugs other than statins	6.04	0.80 (0.28 to 2.29)	0.67	1.11 (0.36 to 3.44)	0.85	0.88 (0.30 to 2.62)	0.82
Lower Extremities (n= 2,312)							
Nonusers	12.92	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.49	1.05 (0.74 to 1.50)	0.78	0.91 (0.63 to 1.34)	0.64	0.88 (0.61 to 1.29)	0.52
Lipid-lowering drugs other than statins	10.23	0.77 (0.31 to 1.88)	0.56	0.74 (0.24 to 2.33)	0.60	0.96 (0.38 to 2.39)	0.93

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal mass index; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are $<29.76\%$ in men or $<22.31\%$ in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S8 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with diabetes

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 3,136)							
Nonusers	31.76	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	45.27	1.02 (0.71 to 1.45)	0.92	1.57 (0.94 to 2.61)	0.09	1.29 (0.85 to 1.97)	0.23
Lipid-lowering drugs other than statins	34.44	1.05 (0.51 to 2.18)	0.90	1.11 (0.40 to 3.05)	0.84	1.20 (0.43 to 3.38)	0.73
ASM/Wt (n= 3,153)							
Nonusers	14.26	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	16.43	1.34 (1.04 to 1.73)	0.03	0.88 (0.63 to 1.23)	0.45	0.96 (0.72 to 1.28)	0.76
Lipid-lowering drugs other than statins	13.05	1.67 (0.78 to 3.56)	0.18	0.72 (0.32 to 1.62)	0.43	0.81 (0.40 to 1.66)	0.57
ASM/Ht ² (n= 3,169)							
Nonusers	4.79	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	4.75	0.76 (0.49 to 1.17)	0.21	0.46 (0.27 to 0.80)	0.01	0.55 (0.32 to 0.93)	0.03
Lipid-lowering drugs other than statins	2.37	0.58 (0.24 to 1.41)	0.22	0.50 (0.19 to 1.37)	0.18	0.61 (0.16 to 2.31)	0.47
Max HGS* (n= 1,746)							
Nonusers	—	Ref.		Ref.		Ref.	

Statin users		-0.14 (-2.01 to 1.73)	0.88	-0.59 (-1.83 to 0.65)	0.34	-0.50 (-1.76 to 0.75)	0.43
Lipid-lowering drugs other than statins		-6.13 (-9.45 to -2.82)	< 0.001	-3.86 (-6.95 to -0.77)	0.02	-3.43 (-7.85 to 1.00)	0.13
Relative HGS* (n= 1,685)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.09 (-0.23 to 0.05)	0.21	-0.03 (-0.14 to 0.08)	0.54	-0.07 (-0.16 to 0.02)	0.12
Lipid-lowering drugs other than statins		-0.60 (-0.86 to -0.34)	< 0.001	-0.13 (-0.36 to 0.11)	0.29	-0.47 (-0.79 to -0.15)	< 0.001
Combined HGS* (n= 1,711)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.27 (-4.14 to 3.59)	0.89	-0.86 (-3.41 to 1.70)	0.50	-1.18 (-3.50 to 1.14)	0.32
Lipid-lowering drugs other than statins		-9.71 (-16.59 to -2.82)	0.01	-4.87 (-9.87 to 0.13)	0.06	-11.85 (-20.39 to -3.32)	0.01
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n= 3,139)							
Nonusers	4.35	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	4.36	1.02 (0.72 to 1.46)	0.90	1.58 (0.95 to 2.66)	0.08	1.52 (1.00 to 2.30)	0.05
Lipid-lowering drugs other than statins	2.37	1.06 (0.51 to 2.20)	0.87	1.12 (0.40 to 3.09)	0.83	1.47 (0.52 to 4.15)	0.46
ASM and BMI definition (n= 7,473)							
Nonusers	10.71	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	7.73	0.59 (0.27 to 1.27)	0.18	1.05 (0.47 to 2.34)	0.91	1.41 (0.67 to 2.96)	0.36

Lipid-lowering drugs other than statins	4.68	0.46 (0.06 to 3.50)	0.45	0.47 (0.06 to 3.92)	0.49	1.05 (0.13 to 8.72)	0.96
LDH* (n= 8,973)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		1.11 (-1.48 to 3.71)	0.40	0.39 (-2.22 to 2.99)	0.77	-0.75 (-3.27 to 1.78)	0.56
Lipid-lowering drugs other than statins		-0.06 (-5.38 to 5.25)	0.98	-1.58 (-7.05 to 3.89)	0.57	1.90 (-5.21 to 9.01)	0.60
Musculoskeletal Pain Symptoms							
Any Region (n= 1,843)							
Nonusers	37.86	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	51.70	0.84 (0.63 to 1.11)	0.21	0.88 (0.64 to 1.21)	0.43	0.82 (0.60 to 1.11)	0.20
Lipid-lowering drugs other than statins	46.79	0.60 (0.24 to 1.49)	0.26	0.37 (0.13 to 1.05)	0.06	0.53 (0.24 to 1.16)	0.11
Neck/Upper Back (n= 1,843)							
Nonusers	8.30	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	8.51	0.54 (0.36 to 0.82)	0.01	0.77 (0.46 to 1.27)	0.29	0.71 (0.42 to 1.20)	0.20
Lipid-lowering drugs other than statins	19.42	0.85 (0.30 to 2.37)	0.74	0.53 (0.12 to 2.33)	0.39	1.05 (0.35 to 3.17)	0.94
Upper Extremities (n= 1,843)							
Nonusers	25.81	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	36.91	0.84 (0.62 to 1.15)	0.27	0.94 (0.64 to 1.36)	0.72	0.86 (0.62 to 1.19)	0.36
Lipid-lowering drugs other than statins	32.53	0.64 (0.22 to 1.85)	0.40	0.52 (0.17 to 1.53)	0.23	0.71 (0.31 to 1.61)	0.42
Lower Back (n= 1,843)							

Nonusers	14.52	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	13.15	0.66 (0.46 to 0.94)	0.02	0.75 (0.46 to 1.22)	0.23	0.77 (0.51 to 1.18)	0.23
Lipid-lowering drugs other than statins	12.89	0.54 (0.16 to 1.76)	0.30	0.57 (0.16 to 2.05)	0.38	0.71 (0.25 to 2.00)	0.52
Lower Extremities (n= 1,843)							
Nonusers	15.33	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	23.06	0.89 (0.61 to 1.30)	0.53	1.05 (0.66 to 1.67)	0.83	0.90 (0.61 to 1.34)	0.61
Lipid-lowering drugs other than statins	20.80	0.67 (0.22 to 2.01)	0.46	0.61 (0.20 to 1.84)	0.37	0.52 (0.18 to 1.48)	0.22

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S9 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with cardiovascular disease

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 1,641)							
Nonusers	33.76	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	40.61	1.02 (0.71 to 1.45)	0.92	1.57 (0.94 to 2.61)	0.09	1.29 (0.85 to 1.97)	0.23
Lipid-lowering drugs other than statins	45.97	1.05 (0.51 to 2.18)	0.90	1.11 (0.40 to 3.05)	0.84	1.20 (0.43 to 3.38)	0.73
ASM/Wt (n= 1,671)							
Nonusers	15.67	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	15.92	1.34 (1.04 to 1.73)	0.03	0.88 (0.63 to 1.23)	0.45	0.96 (0.72 to 1.28)	0.76
Lipid-lowering drugs other than statins	16.32	1.67 (0.78 to 3.56)	0.18	0.72 (0.32 to 1.62)	0.43	0.81 (0.40 to 1.66)	0.57
ASM/Ht ² (n= 1,676)							
Nonusers	10.92	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.51	0.76 (0.49 to 1.17)	0.21	0.46 (0.27 to 0.8)	0.01	0.55 (0.32 to 0.93)	0.03
Lipid-lowering drugs other than statins	6.61	0.58 (0.24 to 1.41)	0.22	0.50 (0.19 to 1.37)	0.18	0.61 (0.16 to 2.31)	0.47
Max HGS* (n= 996)							
Nonusers	—	Ref.		Ref.		Ref.	

Statin users		-0.14 (-2.01 to 1.73)	0.88	-0.59 (-1.83 to 0.65)	0.34	-0.50 (-1.76 to 0.75)	0.43
Lipid-lowering drugs other than statins		-6.13 (-9.45 to -2.82)	< 0.001	-3.86 (-6.95 to -0.77)	0.02	-3.43 (-7.85 to 1.00)	0.13
Relative HGS* (n= 947)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.09 (-0.23 to 0.05)	0.21	-0.03 (-0.14 to 0.08)	0.54	-0.07 (-0.16 to 0.02)	0.12
Lipid-lowering drugs other than statins		-0.60 (-0.86 to -0.34)	< 0.001	-0.13 (-0.36 to 0.11)	0.29	-0.47 (-0.79 to -0.15)	< 0.001
Combined HGS* (n= 968)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.27 (-4.14 to 3.59)	0.89	-0.86 (-3.41 to 1.7)	0.50	-1.18 (-3.50 to 1.14)	0.32
Lipid-lowering drugs other than statins		-9.71 (-16.59 to -2.82)	0.01	-4.87 (-9.87 to 0.13)	0.06	-11.85 (-20.39 to -3.32)	0.01
Sarcopenic Obesity							
ASM/Ht2 and Body Fat Percent Definition (n= 1,643)							
Nonusers	10.14	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	7.14	1.02 (0.72 to 1.46)	0.90	1.58 (0.95 to 2.66)	0.08	1.52 (1.00 to 2.30)	0.05
Lipid-lowering drugs other than statins	6.61	1.06 (0.51 to 2.20)	0.87	1.12 (0.40 to 3.09)	0.83	1.47 (0.52 to 4.15)	0.46
ASM and BMI definition (n= 4,725)							
Nonusers	49.18	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	44.73	0.59 (0.27 to 1.27)	0.18	1.05 (0.47 to 2.34)	0.91	1.41 (0.67 to 2.96)	0.36

Lipid-lowering drugs other than statins	36.72	0.46 (0.06 to 3.50)	0.45	0.47 (0.06 to 3.92)	0.49	1.05 (0.13 to 8.72)	0.96
LDH* (n= 5,340)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		1.11 (-1.48 to 3.71)	0.40	0.39 (-2.22 to 2.99)	0.77	-0.75 (-3.27 to 1.78)	0.56
Lipid-lowering drugs other than statins		-0.06 (-5.38 to 5.25)	0.98	-1.58 (-7.05 to 3.89)	0.57	1.90 (-5.21 to 9.01)	0.60
Musculoskeletal Pain Symptoms							
Any Region (n= 1,158)							
Nonusers	49.18	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	44.73	0.84 (0.63 to 1.11)	0.21	0.88 (0.64 to 1.21)	0.43	0.82 (0.60 to 1.11)	0.20
Lipid-lowering drugs other than statins	36.72	0.60 (0.24 to 1.49)	0.26	0.37 (0.13 to 1.05)	0.06	0.53 (0.24 to 1.16)	0.11
Neck/Upper Back (n= 1,158)							
Nonusers	16.46	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	9.68	0.54 (0.36 to 0.82)	0.01	0.77 (0.46 to 1.27)	0.29	0.71 (0.42 to 1.20)	0.20
Lipid-lowering drugs other than statins	14.29	0.85 (0.30 to 2.37)	0.74	0.53 (0.12 to 2.33)	0.39	1.05 (0.35 to 3.17)	0.94
Upper Extremities (n= 1,158)							
Nonusers	34.93	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	31.13	0.84 (0.62 to 1.15)	0.27	0.94 (0.64 to 1.36)	0.72	0.86 (0.62 to 1.19)	0.36
Lipid-lowering drugs other than statins	25.48	0.64 (0.22 to 1.85)	0.40	0.52 (0.17 to 1.53)	0.23	0.71 (0.31 to 1.61)	0.42
Lower Back (n= 1,158)							

Nonusers	20.31	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	14.39	0.66 (0.46 to 0.94)	0.02	0.75 (0.46 to 1.22)	0.23	0.77 (0.51 to 1.18)	0.23
Lipid-lowering drugs other than statins	12.07	0.54 (0.16 to 1.76)	0.30	0.57 (0.16 to 2.05)	0.38	0.71 (0.25 to 2.00)	0.52
Lower Extremities (n= 1,158)							
Nonusers	23.02	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	21	0.89 (0.61 to 1.30)	0.53	1.05 (0.66 to 1.67)	0.83	0.90 (0.61 to 1.34)	0.61
Lipid-lowering drugs other than statins	16.71	0.67 (0.22 to 2.01)	0.46	0.61 (0.20 to 1.84)	0.37	0.52 (0.18 to 1.48)	0.22

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohol status (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin

Table S10 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with hyperlipidemia

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 6,627)							
Nonusers	18.39	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	32.33	1.43 (1.19 to 1.72)	< 0.001	1.15 (0.85 to 1.56)	0.37	1.13 (0.88 to 1.45)	0.36
Lipid-lowering drugs other than statins	35.10	1.58 (0.90 to 2.79)	0.11	1.08 (0.51 to 2.28)	0.85	1.26 (0.72 to 2.20)	0.42
ASM/Wt (n= 6,638)							
Nonusers	10.11	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.90	2.12 (1.83 to 2.46)	< 0.001	1.20 (0.94 to 1.54)	0.15	1.08 (0.89 to 1.31)	0.45
Lipid-lowering drugs other than statins	15.12	2.40 (1.57 to 3.68)	< 0.001	0.98 (0.54 to 1.79)	0.95	0.88 (0.57 to 1.36)	0.58
ASM/Ht2 (n= 6,640)							
Nonusers	5.10	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	6.26	1.24 (0.97 to 1.60)	0.09	1.21 (0.83 to 1.77)	0.31	0.96 (0.68 to 1.37)	0.83
Lipid-lowering drugs other than statins	4.16	0.81 (0.42 to 1.55)	0.51	1.19 (0.41 to 3.47)	0.75	1.30 (0.59 to 2.88)	0.52
Max HGS* (n= 3,407)							
Nonusers	—	Ref.		Ref.		Ref.	

Statin users		-3.38 (-4.40 to -2.36)	< 0.001	-0.10 (-1.02 to 0.83)	0.83	0.10 (-0.50 to 0.70)	0.75
Lipid-lowering drugs other than statins		-3.93 (-6.21 to -1.65)	< 0.001	-2.04 (-4.21 to 0.12)	0.06	-0.81 (-2.37 to 0.75)	0.31
Relative HGS* (n= 3,329)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.29 (-0.37 to -0.21)	< 0.001	-0.01 (-0.08 to 0.06)	0.76	0.01 (-0.03 to 0.05)	0.56
Lipid-lowering drugs other than statins		-0.37 (-0.54 to -0.21)	< 0.001	-0.11 (-0.25 to 0.04)	0.13	-0.07 (-0.18 to 0.03)	0.17
Combined HGS* (n= 3,362)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-6.46 (-8.59 to -4.34)	< 0.001	0.03 (-1.84 to 1.90)	0.98	0.43 (-0.69 to 1.54)	0.45
Lipid-lowering drugs other than statins		-6.93 (-11.24 to -2.63)	< 0.001	-2.59 (-6.43 to 1.24)	0.18	-1.81 (-4.69 to 1.06)	0.22
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n= 6,627)							
Nonusers	4.75	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	5.97	1.44 (1.20 to 1.73)	< 0.001	1.17 (0.86 to 1.58)	0.32	1.13 (0.88 to 1.45)	0.35
Lipid-lowering drugs other than statins	4.16	1.60 (0.91 to 2.81)	0.11	1.09 (0.51 to 2.31)	0.82	1.24 (0.71 to 2.16)	0.45
ASM and BMI definition (n= 14,406)							
Nonusers	9.50	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	

Statin users	9.30	0.98 (0.58 to 1.64)	0.93	0.93 (0.48 to 1.78)	0.82	1.02 (0.64 to 1.63)	0.94
Lipid-lowering drugs other than statins	3.60	0.38 (0.09 to 1.51)	0.17	0.43 (0.10 to 1.86)	0.25	0.78 (0.23 to 2.64)	0.69
LDH* (n= 16,274)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		3.27 (2.00 to 4.54)	< 0.001	-0.36 (-1.80 to 1.08)	0.62	-0.17 (-1.48 to 1.15)	0.80
Lipid-lowering drugs other than statins		1.37 (-2.32 to 5.06)	0.47	-1.04 (-5.00 to 2.92)	0.6	0.85 (-2.31 to 4.01)	0.60
Musculoskeletal Pain Symptoms							
Any Region (n= 3,741)							
Nonusers	39.06	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	43.01	1.18 (0.98 to 1.42)	0.09	1.15 (0.87 to 1.52)	0.30	1.11 (0.89 to 1.38)	0.35
Lipid-lowering drugs other than statins	39.83	1.03 (0.63 to 1.71)	0.90	1.20 (0.64 to 2.25)	0.57	1.13 (0.70 to 1.81)	0.61
Neck/Upper Back (n= 3,741)							
Nonusers	10.95	1.00 (Ref.)				1.00 (Ref.)	
Statin users	8.39	0.74 (0.54 to 1.03)	0.08	1.03 (0.65 to 1.62)	0.89	1.05 (0.70 to 1.56)	0.83
Lipid-lowering drugs other than statins	15.59	1.50 (0.80 to 2.84)	0.20	2.57 (1.18 to 5.57)	0.02	2.62 (1.36 to 5.08)	< 0.001
Upper Extremities (n= 3,741)							
Nonusers	26.92	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	

Statin users	29.46	1.13 (0.92 to 1.39)	0.23	1.10 (0.82 to 1.47)	0.53	1.11 (0.88 to 1.41)	0.39
Lipid-lowering drugs other than statins	28.95	1.11 (0.67 to 1.83)	0.69	1.27 (0.71 to 2.27)	0.41	1.26 (0.77 to 2.07)	0.36
Lower Back (n= 3,741)							
Nonusers	11.73	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.19	1.14 (0.88 to 1.48)	0.30	1.15 (0.80 to 1.66)	0.43	1.22 (0.87 to 1.71)	0.24
Lipid-lowering drugs other than statins	5.19	0.41 (0.17 to 1.03)	0.06	0.50 (0.18 to 1.44)	0.19	0.76 (0.35 to 1.68)	0.50
Lower Extremities (n= 3,741)							
Nonusers	15.10	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	18.17	1.25 (0.99 to 1.57)	0.06	1.14 (0.78 to 1.66)	0.50	1.14 (0.84 to 1.55)	0.41
Lipid-lowering drugs other than statins	15.29	1.01 (0.56 to 1.84)	0.96	1.06 (0.51 to 2.19)	0.88	1.03 (0.53 to 1.99)	0.93

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S11 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 10,412)							
Nonusers	19.08	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	35.88	1.78 (1.44 to 2.19)	< 0.001	1.33 (0.97 to 1.82)	0.08	1.25 (0.99 to 1.59)	0.06
Lipid-lowering drugs other than statins	38.03	1.81 (1.01 to 3.23)	0.05	1.11 (0.55 to 2.26)	0.77	1.52 (0.85 to 2.71)	0.16
ASM/Wt (n= 10,459)							
Nonusers	8.30	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.84	2.37 (2.04 to 2.76)	< 0.001	1.24 (0.97 to 1.58)	0.09	1.22 (1.02 to 1.47)	0.03
Lipid-lowering drugs other than statins	14.07	2.60 (1.67 to 4.06)	< 0.001	0.96 (0.54 to 1.71)	0.89	1.06 (0.68 to 1.65)	0.79
ASM/Ht2 (n= 10,474)							
Nonusers	5.92	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	

Statin users	7.20	1.23 (0.94 to 1.62)	0.13	1.19 (0.80 to 1.75)	0.38	0.94 (0.66 to 1.33)	0.72
Lipid-lowering drugs other than statins	5.31	0.89 (0.50 to 1.58)	0.69	0.78 (0.32 to 1.88)	0.58	1.29 (0.56 to 2.99)	0.55
Max HGS* (n= 4,526)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-4.53 (-5.43 to -3.63)	< 0.001	-0.61 (-1.19 to -0.04)	0.04	-0.45 (-1.04 to 0.14)	0.14
Lipid-lowering drugs other than statins		-5.78 (-8.22 to -3.33)	< 0.001	-2.20 (-4.08 to -0.31)	0.02	-1.17 (-2.88 to 0.54)	0.18
Relative HGS* (n= 4,410)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.39 (-0.46 to -0.32)	< 0.001	-0.03 (-0.07 to 0.02)	0.24	-0.03 (-0.07 to 0.01)	0.15
Lipid-lowering drugs other than statins		-0.64 (-0.8 to -0.48)	< 0.001	-0.1 (-0.24 to 0.04)	0.15	-0.09 (-0.21 to 0.03)	0.13
Combined HGS* (n= 4,461)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-8.91 (-10.66 to -7.17)	< 0.001	-1.29 (-2.44 to -0.14)	0.03	-1.06 (-2.17 to 0.05)	0.06

Lipid-lowering drugs other than statins		-11.34 (-15.92 to -6.76)	< 0.001	-4.02 (-7.06 to -0.99)	0.01	-2.33 (-5.47 to 0.81)	0.15
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n=10,415)							
Nonusers	5.08	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	6.77	1.78 (1.44 to 2.20)	< 0.001	1.33 (0.97 to 1.83)	0.07	1.23 (0.96 to 1.57)	0.10
Lipid-lowering drugs other than statins	4.28	1.82 (1.02 to 3.24)	0.04	1.12 (0.55 to 2.27)	0.76	1.51 (0.83 to 2.73)	0.18
ASM and BMI definition (n= 21,553)							
Nonusers	7.90	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.50	1.09 (0.62 to 1.90)	0.77	1.18 (0.58 to 2.41)	0.64	0.85 (0.53 to 1.34)	0.47
Lipid-lowering drugs other than statins	5.00	0.63 (0.17 to 2.33)	0.49	0.56 (0.13 to 2.49)	0.45	0.86 (0.26 to 2.90)	0.81
LDH* (n= 24,501)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		4.64 (3.36 to 5.93)	< 0.001	-0.73 (-2.10 to 0.64)	0.30	-0.28 (-1.79 to 1.22)	0.71

Lipid-lowering drugs other than statins		4.01 (0.18 to 7.84)	0.04	-1.44 (-5.43 to 2.55)	0.48	-0.62 (-4.69 to 3.46)	0.77
Musculoskeletal Pain Symptoms							
Any Region (n= 6,226)							
Nonusers	33.04	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	44.40	1.62 (1.33 to 1.97)	< 0.001	1.22 (0.96 to 1.54)	0.11	1.10 (0.89 to 1.35)	0.38
Lipid-lowering drugs other than statins	37.35	1.21 (0.71 to 2.05)	0.48	0.88 (0.44 to 1.77)	0.72	0.93 (0.57 to 1.52)	0.77
Neck/Upper Back (n= 6,226)							
Nonusers	9.02	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.40	0.93 (0.75 to 1.15)	0.47	0.94 (0.66 to 1.34)	0.73	0.89 (0.61 to 1.30)	0.54
Lipid-lowering drugs other than statins	14.41	1.70 (0.90 to 3.19)	0.10	1.57 (0.68 to 3.60)	0.28	1.82 (0.90 to 3.65)	0.09
Upper Extremities (n= 6,226)							
Nonusers	21.49	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	30.08	1.57 (1.26 to 1.96)	< 0.001	1.14 (0.83 to 1.59)	0.40	1.14 (0.91 to 1.43)	0.25
Lipid-lowering drugs other than statins	27.77	1.40 (0.77 to 2.55)	0.26	1.15 (0.57 to 2.30)	0.69	1.25 (0.75 to 2.09)	0.39
Lower Back (n= 6,226)							

Nonusers	11.22	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.20	1.20 (0.93 to 1.55)	0.15	1.05 (0.75 to 1.47)	0.76	1.10 (0.80 to 1.51)	0.54
Lipid-lowering drugs other than statins	10.26	0.90 (0.41 to 2.00)	0.80	0.66 (0.26 to 1.69)	0.38	0.75 (0.34 to 1.65)	0.48
Lower Extremities (n= 6,226)							
Nonusers	12.79	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	18.98	1.60 (1.25 to 2.04)	< 0.001	1.22 (0.89 to 1.68)	0.20	1.07 (0.80 to 1.42)	0.65
Lipid-lowering drugs other than statins	19.74	1.68 (0.87 to 3.22)	0.12	1.14 (0.51 to 2.53)	0.74	1.05 (0.55 to 2.03)	0.88

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women


ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Figure and tables

Figure 1 Flow of study



Abbreviations: NHANES, National Health and Nutrition Examination Survey; CVD, cardiovascular disease; HLP, hyperlipidemia; SNP, Single Nucleotide Polymorphism; LDH, Lactate Dehydrogenase.

A: Flow of study.

B: Two-sample Mendelian randomization study design.

Arrows represent associations.

Dashed lines with “X” in the middle represent genetic variants applied as instrumental variables

for Statins that should not be associated with potential confounding factors and do not exert an effect on sarcopenia-related traits and LDH via other pathways in assumptions 2 and 3, respectively.

Abbreviations: SNP, Single nucleotide polymorphism; IVW, Inverse variance weighted; MR-PRESSO, MR-pleiotropy residual sum and outlier; LDH, Lactic dehydrogenase.

Table 1 Baseline characteristics of patients with cardiovascular disease, diabetes, or hyperlipidemia

	Statin drug use			
	Nonuse (13,474)	Statin drugs (8,481)	Lipid-lowering drugs other than statins(n=594)	p
Age, (year)	55.4 ± 0.1	65.7 ± 0.1	63.3 ± 0.5	<0.001
Male, (%)	48.2	53.5	52.2	<0.001
Race/ethnicity, (%)				
Hispanic-Mexican	17.8	11.4	14.5	<0.001
Other Ethnicity	18.2	16.2	18.0	<0.001
Non-Hispanic White	42.2	52.3	54.0	<0.001
Non-Hispanic Black	21.8	20.2	13.5	<0.001
Education status, (%)				<0.001
Less than high school	29.9	28.2	30.6	
High school	22.1	24.9	23.6	
More than high school	48.1	46.9	45.8	
Marital status, (%)				<0.001
Married	56.2	59.9	62.3	
Never married	16.2	8.3	8.9	
other	27.6	31.8	28.8	
PIR, (%)				<0.001
< 1.3	31.5	27.4	30.6	
1.3-3.5	37.8	39.7	38.7	
> 3.5	30.7	32.9	30.8	
BMI, kg/m ²				0.003
18.5-25	21.3	18.1	18.4	
25-30	34.5	36.2	33.9	
≥ 30	44.3	45.7	47.7	
Alcohols status, (%)				<0.001

=0, g/d	38.5	44.2	45.3	
< 5, g/d	42.5	39.1	40.4	
5-30, g/d	16.3	15.1	13.0	
> 30, g/d	2.7	1.7	1.3	
Smoking status, (%)				<0.001
Never smoking	52.0	46.8	46.6	
Former smoker	28.2	39.4	37.0	
Current smoker	19.8	13.8	16.3	
Physical activity, (%)	28.7	26.2	22.7	0.001
HBP, (%)	61.6	80.5	80.8	<0.001
CKD, (%)	11.8	23.6	25.2	<0.001
COPD, (%)	9.3	12.6	12.8	<0.001
Cancer, (%)	10.8	17.8	17.0	<0.001
CVD, (%)	20.0	35.3	26.9	<0.001
Diabetes, (%)	37.1	46.4	48.2	<0.001
Hyperlipidemia, (%)	71.0	85.8	88.0	<0.001

The data were adjusted for survey weights from the NHANES.

The data are presented as the means \pm SDs or percentages.

We considered two-sided p-values less than 0.05 as statistically significant.

Abbreviations: PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

Table 2 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n=8,856)							
Nonusers	21.42	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	33.60	1.35 (1.12 to 1.62)	<0.001	1.31 (0.99 to 1.74)	0.06	1.25 (1.00 to 1.55)	0.05
Lipid-lowering drugs other than statins	35.11	1.36 (0.78 to 2.37)	0.28	1.00 (0.49 to 2.02)	1.00	1.23 (0.73 to 2.09)	0.44
ASM/Wt (n=8,839)							
Nonusers	10.85	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	14.11	1.86 (1.62 to 2.13)	<0.001	1.23 (0.99 to 1.54)	0.06	1.14 (0.97 to 1.34)	0.11
Lipid-lowering drugs other than statins	14.19	1.99 (1.33 to 2.97)	<0.001	0.93 (0.53 to 1.62)	0.79	0.92 (0.62 to 1.37)	0.67
ASM/Ht ² (n=8,803)							
Nonusers	5.50	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	6.54	1.20 (0.95 to 1.52)	0.12	1.11 (0.77 to 1.60)	0.56	0.87 (0.64 to 1.18)	0.38
Lipid-lowering drugs other than statins	4.17	0.75 (0.41 to 1.36)	0.34	0.83 (0.31 to 2.25)	0.71	0.99 (0.47 to 2.09)	0.97
		β (95% CI)	<i>P</i>	B (95% CI)	<i>P</i>	B (95% CI)	<i>P</i>

Max HGS* (n=4,340)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-3.01 (-3.97 to -2.06)	<0.001	-0.35 (-1.11 to 0.41)	0.36	-0.13 (-0.66 to 0.40)	0.64
Lipid-lowering drugs other than statins		-3.79 (-5.95 to -1.63)	<0.001	-2.07 (-3.99 to -0.14)	0.04	-0.90 (-2.41 to 0.61)	0.24
Relative grip strength* (n=4,230)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.23 (-0.30 to -0.17)	<0.001	-0.01 (-0.06 to 0.04)	0.66	-0.01 (-0.04 to 0.03)	0.77
Lipid-lowering drugs other than statins		-0.34 (-0.49 to -0.19)	<0.001	-0.08 (-0.20 to 0.05)	0.23	-0.07 (-0.18 to 0.03)	0.17
Combined HGS* (n=4,275)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-5.9 (-7.86 to -3.93)	<0.001	-0.61 (-2.18 to 0.96)	0.44	-0.32 (-1.32 to 0.67)	0.53
Lipid-lowering drugs other than statins		-6.82 (-10.88 to -2.76)	<0.001	-2.78 (-6.25 to 0.69)	0.11	-2.03 (-4.88 to 0.82)	0.16
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n=8,806)							
Nonusers	5.10	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	

Statin users	6.22	1.36 (1.13 to 1.63)	<0.001	1.32 (1.00 to 1.75)	0.05	1.26 (1.00 to 1.56)	0.05
Lipid-lowering drugs other than statins	4.17	1.37 (0.79 to 2.39)	0.26	1.01 (0.50 to 2.03)	0.99	1.21 (0.72 to 2.05)	0.47
ASM and BMI definition (n=19,259)							
Nonusers	10.80	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.20	0.76 (0.47 to 1.23)	0.27	0.92 (0.51 to 1.66)	0.78	0.98 (0.65 to 1.47)	0.92
Lipid-lowering drugs other than statins	3.20	0.30 (0.08 to 1.16)	0.08	0.38 (0.09 to 1.60)	0.18	0.74 (0.23 to 2.44)	0.62
LDH* (n=21,908)							
Nonusers	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		2.55 (1.32 to 3.78)	<0.001	-0.55 (-1.81 to 0.71)	0.39	-0.57 (-1.72 to 0.58)	0.33
Lipid-lowering drugs other than statins		-0.42 (-3.71 to 2.88)	0.80	-2.77 (-6.35 to 0.81)	0.13	-0.28 (-3.31 to 2.75)	0.86

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal mass index; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No),

chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are $<29.76\%$ in men or $<22.31\%$ in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table 3 Odds ratios of musculoskeletal pain for statin users compared to nonusers

	Prevalence, %	Crude		Adjusted		After matching*	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Any Region (n=5,136)							
Nonusers	69.68	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	27.78	1.15 (0.96 to 1.38)	0.12	1.15 (0.88 to 1.50)	0.30	1.09 (0.91 to 1.31)	0.36
Lipid-lowering drugs other than statins	2.24	1.08 (0.64 to 1.82)	0.76	1.10 (0.59 to 2.04)	0.75	1.04 (0.67 to 1.61)	0.85
Neck/Upper Back (n=5,136)							
Nonusers	74.02	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	21.83	0.74 (0.56 to 0.97)	0.03	0.96 (0.64 to 1.44)	0.84	0.94 (0.67 to 1.32)	0.73
Lipid-lowering drugs other than statins	4.15	1.52 (0.87 to 2.66)	0.14	2.17 (1.07 to 4.39)	0.03	2.19 (1.19 to 4.00)	0.01
Upper Extremities (n=5,136)							
Nonusers	69.33	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	28.01	1.13 (0.92 to 1.38)	0.23	1.11 (0.81 to 1.51)	0.50	1.13 (0.93 to 1.39)	0.22
Lipid-lowering drugs other than statins	2.66	1.16 (0.69 to 1.94)	0.56	1.27 (0.68 to 2.38)	0.44	1.25 (0.79 to 1.98)	0.33
Lower Back (n=5,136)							
Nonusers	69.78	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	

Statin users	28.26	1.03 (0.82 to 1.29)	0.82	1.05 (0.76 to 1.45)	0.75	1.05 (0.79 to 1.39)	0.74
Lipid-lowering drugs other than statins	1.96	0.66 (0.29 to 1.48)	0.31	0.61 (0.24 to 1.54)	0.28	0.74 (0.37 to 1.50)	0.41
Lower Extremities (n=5,136)							
Nonusers	68.81	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	28.53	1.17 (0.95 to 1.45)	0.14	1.12 (0.83 to 1.51)	0.44	1.08 (0.84 to 1.41)	0.54
Lipid-lowering drugs other than statins	2.66	1.22 (0.66 to 2.23)	0.52	1.09 (0.54 to 2.22)	0.80	1.01 (0.55 to 1.83)	0.99

Abbreviations: OR, odds ratio; CI, confidence interval.

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

*Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table 4 The causal relationship between statins and sarcopenia-related traits based on two-sample Mendelian randomization analysis

Outcome	SNPs	MR method	Beta/OR	95%CI	P-value
Appendicular lean mass	11	IVW	-0.060	-0.153, 0.033	0.208
		MR Egger	-0.019	-0.191, 0.153	0.834
		Weighted median	-0.023	-0.056, 0.010	0.173
	4	MR PRESOO	-0.016	-0.057, 0.025	0.488
Hand grip strength (right)	11	IVW	-0.014	-0.039, 0.012	0.289
		MR Egger	-0.003	-0.050, 0.043	0.892
		Weighted median	-0.010	-0.031, 0.011	0.339
	8	MR PRESOO	0.003	-0.017, 0.023	0.776
Hand grip strength (left)	11	IVW	-0.216	-0.044, 0.001	0.059
		MR Egger	-0.004	-0.044, 0.036	0.847
		Weighted median	-0.013	-0.031, 0.006	0.171
	10	MR PRESOO	-0.021	-0.041, 0.002	0.058
Low hand grip strength	11	IVW	1.042	0.889, 1.221	0.614
		MR Egger	1.025	0.759, 1.384	0.875
		Weighted median	1.028	0.839, 1.259	0.792
		MR PRESOO	1.069	0.917, 1.247	0.411
Walking pace	11	IVW	0.001	-0.010, 0.011	0.939
		MR Egger	0.007	-0.012, 0.026	0.497
		Weighted median	-0.002	-0.016, 0.011	0.748
		MR PRESOO	0.003	-0.007, 0.012	0.649
Lactate dehydrogenase	8	IVW	-0.080	-0.213, 0.053	0.238
		MR Egger	0.035	-0.230, 0.230	0.804
		Weighted median	0.003	-0.082, 0.087	0.952
	6	MR PRESOO	-0.030	-0.100, 0.040	0.437

Abbreviations: SNP, Single nucleotide polymorphism; IVW, Inverse variance weighted; MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier.

We considered two-sided p-values less than 0.05 as statistically significant.

Supplemental tables

Table S1 Details of studies and datasets used in the study

Trait	Sample size (cases/controls)	Datatype	Unit	Ancestry	Consortium/ First Author	PMID or GWAS ID
Statins	290,385 (73,475/216,910)	Binary	/	European	UK Biobank	31015401
Appendicular lean mass	450,243	Continuous	kg	European	UK Biobank	33097823
Hand grip strength (right)	461,089	Continuous	SD	European	MRC-IEU	ukb-b-10215
Hand grip strength (left)	461,026	Continuous	SD	European	MRC-IEU	ukb-b-7478
Low hand grip strength	121,055 (6,734/114,321)	Binary	/	European	Garan Jones	33510174
Walking pace	459,915	Continuous	km/s	European	MRC-IEU	ukb-b-4711
Lactate dehydrogenase	126,319	Continuous	SD	East Asian	Ishigaki K	29403010

Abbreviations: SD, Standard Deviation; PMID, PubMed Unique Identifier; GWAS ID, Genome-Wide Association Study Identifier; MRC-IEU, Medical Research Council Integrative Epidemiology Unit.

Table S2 SNPs are used as instrumental variables for Statins (P-value < 5×10⁻⁸)

Traits	SNP	Chr	Position	Effect allele	another allele	Beta	SE	P-value	F-statistic
Statins-ALM/HGS (right)/	rs113911544	1	55706403	G	A	0.085085202	0.014373915	3.20E-09	35.0395019
HGS (left)/LHGS/Walking	rs11591147	1	55505647	T	G	-0.362323999	0.021494841	9.40E-64	284.1356506
pace	rs1260326	2	27730940	T	C	0.059920058	0.005712328	9.70E-26	110.0317897
	rs12725767	1	6676040	G	A	0.035128029	0.005856082	2.00E-09	35.98266012
	rs12740374	1	109817590	T	G	-0.156618273	0.006742468	2.30E-119	539.5691038
	rs1367117	2	21263900	A	G	0.105726091	0.005900949	8.70E-72	321.0115277
	rs4299376	2	44072576	G	T	0.086690463	0.005971001	9.20E-48	210.7892007
	rs4541244	2	58917535	T	C	-0.034275082	0.005711376	2.00E-09	36.01434333
	rs570530	1	234866776	A	G	-0.032541516	0.005613812	6.80E-09	33.60159042
	rs693668	1	55521109	G	A	-0.048941477	0.005866453	7.30E-17	69.5989924
	rs79598313	1	27284913	T	C	0.146636976	0.018408443	1.60E-15	63.45310484
Statins-LDH	rs113911544	1	55706403	G	A	0.085085202	0.014373915	3.20E-09	35.0395019
	rs1260326	2	27730940	T	C	0.059920058	0.005712328	9.70E-26	110.0317897
	rs12725767	1	6676040	G	A	0.035128029	0.005856082	2.00E-09	35.98266012
	rs12740374	1	109817590	T	G	-0.156618273	0.006742468	2.30E-119	539.5691038

	rs1367117	2	21263900	A	G	0.105726091	0.005900949	8.70E-72	321.0115277
	rs4541244	2	58917535	T	C	-0.034275082	0.005711376	2.00E-09	36.01434333
	rs570530	1	234866776	A	G	-0.032541516	0.005613812	6.80E-09	33.60159042
	rs693668	1	55521109	G	A	-0.048941477	0.005866453	7.30E-17	69.5989924
	rs7534572	1	62999675	C	G	-0.074218207	0.005852643	7.50E-37	160.8114059

Abbreviations: SNP, Single nucleotide polymorphism, MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier. ALM, Appendicular

Lean Muscle; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

Table S3 Definition of statins and lipid-lowering drugs

Generic drug code	Drug name
Statin drugs	
d00280	lovastatin
d00348	pravastatin
d00746	simvastatin
d03183	fluvastatin
d04105	atorvastatin
d04140	cerivastatin
d04787	lovastatin; niacin
d04851	rosuvastatin
d05048	amlodipine; atorvastatin
d05348	ezetimibe; simvastatin
d07110	niacin; simvastatin
d07637	pitavastatin
d07805	simvastatin; sitagliptin
d08383	evolcumab
Lipid-lowering drugs other than statins	
c00019	antihyperlipidemic agents - unspecified
c00173	hmg-coa reductase inhibitors - unspecified
d00193	cholestyramine
d00196	clofibrate
d00245	gemfibrozil
d00353	probucol
d00744	colestipol
d04286	fenofibrate
d04695	colesevelam
d04824	ezetimibe
d07371	fenofibric acid

d07891	icosapent
d08374	alirocumab
h00036	bezafibrate

Table S4 Characteristics of cardiovascular disease, diabetes, or hyperlipidemia patients with Statin use or nonuse after matching

	After matching		
	Non-use (5,249)	Statin drug use (5,429)	Standardized difference
Age, (year)	62.6 ± 0.2	64.7 ± 0.1	<0.001
Male, (%)	50.9	52.4	<0.001
Race/ethnicity, (%)			
Hispanic-Mexican	13.3	11.8	<0.001
Other Ethnicity	17.5	16.5	<0.001
Non-Hispanic White	47.0	51.3	<0.001
Non-Hispanic Black	22.2	20.4	<0.001
Education status, (%)			<0.001
Less than high school	29.6	28.5	
High school	23.6	24.3	
More than high school	46.8	47.2	
Marital status, (%)			<0.001
Married	57.2	59.1	
Never married	10.9	9.0	

Other	32.0	31.9	
PIR, (%)			<0.001
< 1.3	30.0	27.8	
1.3-3.5	38.5	39.5	
> 3.5	31.5	32.7	
BMI, kg/m ²			<0.001
18.5-25	20.4	18.2	
25-30	33.5	36.2	
≥ 30	46.1	45.7	
Alcohols status, (%)			<0.001
= 0, g/d	42.5	43.7	
< 5, g/d	40.0	39.2	
5-30, g/d	15.1	15.5	
> 30, g/d	2.3	1.6	
Smoking status, (%)			<0.001
Never smoking	49.0	47.4	
Former smoker	34.6	38.1	

Current smoker	16.4	14.5	
Moderate exercise, (%)	26.2	26.4	<0.001
HBP, (%)	76.6	79.2	<0.001
CKD, (%)	20.0	23.0	<0.001
COPD, (%)	12.1	12.6	<0.001
Cancer, (%)	15.6	17.1	<0.001
CVD, (%)	27.7	33.0	<0.001
Diabetes, (%)	43.9	45.1	<0.001
Hyperlipidemia, (%)	42.9	45.5	<0.001

Data were adjusted for survey weights of NHANES.

Data are presented as means \pm SD or percent.

We considered two-sided p-values less than 0.05 as statistically significant.

Abbreviations: PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular diseases; CKD, Chronic Kidney Disease; COPD, Chronic Obstructive Pulmonary Disease.

Table S5 The association between statin users and skeletal muscle-related phenotypes compared with nonusers by stepwise regression analysis

	ASM/BMI (n=8,856)		ASM/Ht ² and bf Sarcopenic Obesity (n=8,806)		Max HGS (n=4,340)		Relative HGS (n=4,230)		Combined HGS (n=4,275)		Neck/Upper	Back
	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	β (95% CI)	<i>P</i>	β (95% CI)	<i>P</i>	β (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Unadjusted	1.35 (1.12 to 1.62)	< 0.001	1.36 (1.13 to 1.63)	< 0.001	-3.01 (-3.97 to -2.06)	< 0.001	-0.23 (-0.30 to -0.17)	< 0.001	-5.90 (-7.86 to -3.93)	< 0.001	0.74 (0.56 to 0.97)	0.03
Age adjustment	1.01 (0.82 to 1.23)	0.96	1.01 (0.83 to 1.23)	0.91	0.67 (-0.22 to 1.56)	0.14	-0.02 (-0.10 to 0.05)	0.5	1.31 (-0.50 to 3.11)	0.15	0.83 (0.61 to 1.12)	0.21
+ Sex	1.24 (1.00 to 1.55)	0.05	1.25 (1.01 to 1.56)	0.05	0.10 (-0.64 to 0.84)	0.78	-0.06 (-0.12 to -0.01)	0.03	0.24 (-1.26 to 1.74)	0.75	0.85 (0.63 to 1.14)	0.27
+ Race/ ethnicity	1.29 (1.03 to 1.62)	0.03	1.30 (1.04 to 1.63)	0.02	-0.09 (-0.81 to 0.63)	0.80	-0.07 (-0.13 to -0.02)	0.01	-0.14 (-1.61 to 1.33)	0.84	0.83 (0.61 to 1.11)	0.21
+Education level	1.29 (1.02 to 1.62)	0.03	1.29 (1.03 to 1.63)	0.03	-0.09 (-0.83 to 0.66)	0.82	-0.07 (-0.13 to -0.02)	0.01	-0.14 (-1.64 to 1.35)	0.85	0.83 (0.61 to 1.12)	0.21
+Marital status	1.28 (1.02 to 1.62)	0.03	1.29 (1.03 to 1.63)	0.03	-0.16 (-0.90 to 0.57)	0.65	-0.08 (-0.14 to -0.02)	0.01	-0.30 (-1.78 to 1.18)	0.68	0.82 (0.61 to 1.12)	0.2
+ PIR	1.31 (1.02 to 1.69)	0.03	1.32 (1.03 to 1.70)	0.03	-0.28 (-1.02 to 0.45)	0.44	-0.09 (-0.15 to -0.04)	< 0.001	-0.48 (-1.98 to 1.01)	0.51	0.86 (0.61 to 1.21)	0.37
+ BMI	-	-	-	-	-0.55 (-1.24 to 0.13)	0.11	-0.04 (-0.08 to 0.01)	0.08	-1.05 (-2.42 to 0.31)	0.13	0.88 (0.63 to 1.25)	0.48
+ Alcohols statuses	1.33 (1.03 to 1.72)	0.03	1.34 (1.04 to 1.73)	0.03	-0.49 (-1.22 to 0.23)	0.18	-0.04 (-0.08 to 0.01)	0.10	-0.90 (-2.30 to 0.51)	0.2	0.82 (0.60 to 1.12)	0.21
+ Smoking status	1.34 (1.03 to 1.73)	0.03	1.35 (1.04 to 1.74)	0.02	-0.49 (-1.23 to 0.24)	0.18	-0.04 (-0.08 to 0.01)	0.10	-0.90 (-2.31 to 0.52)	0.21	0.82 (0.60 to 1.12)	0.2
+ Physical activity	1.35 (1.04 to 1.74)	0.02	1.36 (1.05 to 1.75)	0.02	-0.50 (-1.27 to 0.28)	0.2	-0.04 (-0.09 to 0.01)	0.13	-0.91 (-2.40 to 0.58)	0.22	0.81 (0.59 to 1.11)	0.19

+ HBP	1.31 (1.01 to 1.71)	0.04	1.32 (1.02 to 1.72)	0.04	-0.54 (-1.32 to 0.24)	0.17	-0.04 (-0.08 to 0.01)	0.15	-0.97 (-2.48 to 0.54)	0.20	0.82 (0.59 to 1.13)	0.21
+ CVD	1.31 (0.99 to 1.72)	0.06	1.32 (1.00 to 1.74)	0.05	-0.33 (-1.09 to 0.44)	0.39	-0.02 (-0.07 to 0.03)	0.37	-0.63 (-2.14 to 0.88)	0.40	0.81 (0.56 to 1.18)	0.27
+ Diabetes	1.28 (0.97 to 1.69)	0.08	1.29 (0.98 to 1.71)	0.07	-0.25 (-1.04 to 0.54)	0.52	-0.01 (-0.06 to 0.04)	0.62	-0.48 (-2.02 to 1.07)	0.53	0.82 (0.56 to 1.19)	0.28
+ Hyperlipidemia	1.32 (0.99 to 1.75)	0.06	1.33 (1.00 to 1.77)	0.05	-0.26 (-1.05 to 0.53)	0.50	-0.01 (-0.06 to 0.04)	0.71	-0.44 (-2.02 to 1.14)	0.57	0.84 (0.56 to 1.24)	0.36
+ CKD	1.33 (0.99 to 1.78)	0.06	1.34 (1.00 to 1.80)	0.05	-0.31 (-1.11 to 0.5)	0.44	-0.01 (-0.06 to 0.04)	0.76	-0.51 (-2.12 to 1.10)	0.52	0.82 (0.58 to 1.17)	0.26
+ COPD	1.32 (0.98 to 1.76)	0.07	1.33 (0.99 to 1.78)	0.06	-0.31 (-1.11 to 0.49)	0.43	-0.01 (-0.06 to 0.04)	0.74	-0.53 (-2.13 to 1.08)	0.51	0.83 (0.58 to 1.19)	0.29
+ Cancer	1.32 (0.98 to 1.76)	0.07	1.33 (0.99 to 1.78)	0.06	-0.32 (-1.12 to 0.48)	0.42	-0.01 (-0.06 to 0.04)	0.72	-0.55 (-2.14 to 1.05)	0.49	0.85 (0.59 to 1.24)	0.39

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; HGS, Hand grip strength; BMI, body mass index; Wt, weight; Ht, height; PIR, Poverty income ratio; BMI, body mass index; HBP, hypertension; CVD, cardiovascular disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease.

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women.

Table S6 The results of sensitivity analysis for two-sample Mendelian randomization analysis of the causal relationships between Statins and sarcopenia-related traits

Outcome	No. of IVs	Heterogeneity		MR-Egger pleiotropy test			MR-PRESSO
		Cochran's <i>Q</i>	<i>P</i> -value	intercept	SE	<i>P</i> -value	Global Test <i>P</i> -value
Appendicular lean mass	11	346.6756844	2.02E-68	-0.0042237	0.00746	0.585	<0.001
Hand grip strength (right)	11	40.71459187	1.27E-05	-0.0010619	0.00202	0.612	<0.001
Hand grip strength (left)	11	32.39685682	<0.001	-0.0018087	0.00172	0.321	<0.001
Low hand grip strength	11	10.56373443	0.393	0.00164006	0.01293	0.902	0.463
Walking pace	8	8.438255201	0.586	-0.0006592	0.00082	0.443	0.622
Lactate dehydrogenase	11	38.72767287	2.20E-06	-0.0082974	0.00844	0.363	<0.001

Abbreviations: MR-Egger pleiotropy test, Mendelian Randomization-Egger pleiotropy test; MR-PRESSO, MR-pleiotropy residual sum and outlier.

We considered two-sided *p*-values less than 0.05 as statistically significant.

Table S7 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among the population over 65 years old

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 2,367)							
Nonusers	35.05	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	43.20	0.86 (0.65 to 1.13)	0.27	1.04 (0.73 to 1.49)	0.81	1.11 (0.80 to 1.55)	0.52
Lipid-lowering drugs other than statins	34.23	1.19 (0.53 to 2.67)	0.68	1.02 (0.43 to 2.40)	0.97	1.31 (0.58 to 2.97)	0.51
ASM/Wt (n= 2,408)							
Nonusers	24.01	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	21.34	1.41 (1.12 to 1.77)	< 0.001	1.17 (0.83 to 1.63)	0.36	1.16 (0.90 to 1.50)	0.25
Lipid-lowering drugs other than statins	27.26	0.96 (0.52 to 1.80)	0.91	0.68 (0.29 to 1.59)	0.36	0.87 (0.45 to 1.70)	0.69
ASM/Ht ² (n= 2,430)							
Nonusers	15.26	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	12.60	0.80(0.60 to 1.06)	0.12	0.84 (0.55 to 1.27)	0.39	0.74 (0.50 to 1.10)	0.13
Lipid-lowering drugs other than statins	7.08	0.42 (0.19 to 0.95)	0.04	0.34 (0.15 to 0.78)	0.01	0.57 (0.20 to 1.57)	0.28
Max HGS* (n= 1,590)							
	—						

Nonusers		Ref.		Ref.		Ref.	
Statin users		0.54 (-0.81 to 1.88)	0.42	-0.22 (-0.94 to 0.51)	0.55	0.14 (-0.63 to 0.91)	0.72
Lipid-lowering drugs other than statins		-0.30 (-3.42 to 2.83)	0.85	-0.32 (-2.20 to 1.56)	0.73	0.10 (-2.21 to 2.40)	0.94
Relative HGS* (n= 1,532)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.01 (-0.1 to 0.08)	0.81	-0.02 (-0.07 to 0.03)	0.41	0.02 (-0.04 to 0.07)	0.52
Lipid-lowering drugs other than statins		-0.02 (-0.23 to 0.19)	0.86	0.03 (-0.11 to 0.17)	0.64	-0.03 (-0.19 to 0.13)	0.73
Combined HGS* (n= 1,560)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		0.86 (-1.70 to 3.42)	0.50	-0.58 (-1.88 to 0.72)	0.37	-0.06 (-1.56 to 1.44)	0.94
Lipid-lowering drugs other than statins		0.15 (-6.25 to 6.55)	0.96	0.09 (-3.28 to 3.46)	0.96	-1.24 (-5.70 to 3.22)	0.59
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n= 2,369)							
Nonusers	14.68	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	12.60	0.87 (0.66 to 1.14)	0.29	1.06 (0.74 to 1.52)	0.74	1.15 (0.83 to 1.59)	0.41
Lipid-lowering drugs other than statins	7.08	1.20 (0.53 to 2.69)	0.66	1.03 (0.44 to 2.44)	0.95	1.36 (0.6 to 3.07)	0.46

ASM and BMI definition (n= 7,839)							
Nonusers	14.80	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.10	0.54 (0.29 to 1.00)	0.05	0.74 (0.33 to 1.67)	0.47	0.83 (0.48 to 1.46)	0.53
Lipid-lowering drugs other than statins	4.60	0.31 (0.05 to 1.92)	0.21	0.42 (0.06 to 2.81)	0.37	0.91 (0.21 to 4.04)	0.91
LDH* (n= 8,954)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-2.34 (-4.15 to -0.54)	0.01	-0.73 (-2.65 to 1.19)	0.45	0.04 (-1.58 to 1.66)	0.96
Lipid-lowering drugs other than statins		-2.97 (-8.28 to 2.35)	0.27	-1.81 (-7.51 to 3.89)	0.53	-0.44 (-4.76 to 3.89)	0.84
Musculoskeletal Pain Symptoms							
Any Region (n= 2,312)							
Nonusers	33.74	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	35.99	1.10 (0.86 to 1.42)	0.43	1.13 (0.82 to 1.55)	0.44	0.99 (0.77 to 1.27)	0.91
Lipid-lowering drugs other than statins	32.47	0.94 (0.51 to 1.76)	0.85	0.92 (0.44 to 1.91)	0.82	1.19 (0.64 to 2.18)	0.58
Neck/Upper Back (n= 2,312)							
Nonusers	7.01	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	6.02	0.85 (0.58 to 1.25)	0.40	0.77 (0.48 to 1.24)	0.27	0.74 (0.45 to 1.22)	0.23
Lipid-lowering drugs other than statins	11.68	1.75 (0.84 to 3.66)	0.13	1.83 (0.92 to 3.63)	0.08	1.80 (0.69 to 4.68)	0.23

Upper Extremities (n= 2,312)							
Nonusers	23.40	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	25.68	1.13 (0.84 to 1.52)	0.41	1.23 (0.85 to 1.80)	0.27	1.08 (0.82 to 1.42)	0.58
Lipid-lowering drugs other than statins	25.76	1.14 (0.54 to 2.37)	0.73	1.24 (0.59 to 2.63)	0.56	1.58 (0.83 to 3.01)	0.16
Lower Back (n= 2,312)							
Nonusers	7.46	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	9.74	1.34 (0.90 to 1.99)	0.15	1.49 (0.92 to 2.42)	0.10	1.07 (0.70 to 1.63)	0.75
Lipid-lowering drugs other than statins	6.04	0.80 (0.28 to 2.29)	0.67	1.11 (0.36 to 3.44)	0.85	0.88 (0.30 to 2.62)	0.82
Lower Extremities (n= 2,312)							
Nonusers	12.92	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.49	1.05 (0.74 to 1.50)	0.78	0.91 (0.63 to 1.34)	0.64	0.88 (0.61 to 1.29)	0.52
Lipid-lowering drugs other than statins	10.23	0.77 (0.31 to 1.88)	0.56	0.74 (0.24 to 2.33)	0.60	0.96 (0.38 to 2.39)	0.93

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; ASMI, appendicular skeletal mass index; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S8 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with diabetes

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 3,136)							
Nonusers	31.76	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	45.27	1.02 (0.71 to 1.45)	0.92	1.57 (0.94 to 2.61)	0.09	1.29 (0.85 to 1.97)	0.23
Lipid-lowering drugs other than statins	34.44	1.05 (0.51 to 2.18)	0.90	1.11 (0.40 to 3.05)	0.84	1.20 (0.43 to 3.38)	0.73
ASM/Wt (n= 3,153)							
Nonusers	14.26	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	16.43	1.34 (1.04 to 1.73)	0.03	0.88 (0.63 to 1.23)	0.45	0.96 (0.72 to 1.28)	0.76
Lipid-lowering drugs other than statins	13.05	1.67 (0.78 to 3.56)	0.18	0.72 (0.32 to 1.62)	0.43	0.81 (0.40 to 1.66)	0.57
ASM/Ht ² (n= 3,169)							
Nonusers	4.79	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	4.75	0.76 (0.49 to 1.17)	0.21	0.46 (0.27 to 0.80)	0.01	0.55 (0.32 to 0.93)	0.03
Lipid-lowering drugs other than statins	2.37	0.58 (0.24 to 1.41)	0.22	0.50 (0.19 to 1.37)	0.18	0.61 (0.16 to 2.31)	0.47
Max HGS* (n= 1,746)							
Nonusers	—	Ref.		Ref.		Ref.	

Statin users		-0.14 (-2.01 to 1.73)	0.88	-0.59 (-1.83 to 0.65)	0.34	-0.50 (-1.76 to 0.75)	0.43
Lipid-lowering drugs other than statins		-6.13 (-9.45 to -2.82)	< 0.001	-3.86 (-6.95 to -0.77)	0.02	-3.43 (-7.85 to 1.00)	0.13
Relative HGS* (n= 1,685)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.09 (-0.23 to 0.05)	0.21	-0.03 (-0.14 to 0.08)	0.54	-0.07 (-0.16 to 0.02)	0.12
Lipid-lowering drugs other than statins		-0.60 (-0.86 to -0.34)	< 0.001	-0.13 (-0.36 to 0.11)	0.29	-0.47 (-0.79 to -0.15)	< 0.001
Combined HGS* (n= 1,711)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.27 (-4.14 to 3.59)	0.89	-0.86 (-3.41 to 1.70)	0.50	-1.18 (-3.50 to 1.14)	0.32
Lipid-lowering drugs other than statins		-9.71 (-16.59 to -2.82)	0.01	-4.87 (-9.87 to 0.13)	0.06	-11.85 (-20.39 to -3.32)	0.01
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n= 3,139)							
Nonusers	4.35	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	4.36	1.02 (0.72 to 1.46)	0.90	1.58 (0.95 to 2.66)	0.08	1.52 (1.00 to 2.30)	0.05
Lipid-lowering drugs other than statins	2.37	1.06 (0.51 to 2.20)	0.87	1.12 (0.40 to 3.09)	0.83	1.47 (0.52 to 4.15)	0.46
ASM and BMI definition (n= 7,473)							
Nonusers	10.71	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	7.73	0.59 (0.27 to 1.27)	0.18	1.05 (0.47 to 2.34)	0.91	1.41 (0.67 to 2.96)	0.36

Lipid-lowering drugs other than statins	4.68	0.46 (0.06 to 3.50)	0.45	0.47 (0.06 to 3.92)	0.49	1.05 (0.13 to 8.72)	0.96
LDH* (n= 8,973)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		1.11 (-1.48 to 3.71)	0.40	0.39 (-2.22 to 2.99)	0.77	-0.75 (-3.27 to 1.78)	0.56
Lipid-lowering drugs other than statins		-0.06 (-5.38 to 5.25)	0.98	-1.58 (-7.05 to 3.89)	0.57	1.90 (-5.21 to 9.01)	0.60
Musculoskeletal Pain Symptoms							
Any Region (n= 1,843)							
Nonusers	37.86	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	51.70	0.84 (0.63 to 1.11)	0.21	0.88 (0.64 to 1.21)	0.43	0.82 (0.60 to 1.11)	0.20
Lipid-lowering drugs other than statins	46.79	0.60 (0.24 to 1.49)	0.26	0.37 (0.13 to 1.05)	0.06	0.53 (0.24 to 1.16)	0.11
Neck/Upper Back (n= 1,843)							
Nonusers	8.30	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	8.51	0.54 (0.36 to 0.82)	0.01	0.77 (0.46 to 1.27)	0.29	0.71 (0.42 to 1.20)	0.20
Lipid-lowering drugs other than statins	19.42	0.85 (0.30 to 2.37)	0.74	0.53 (0.12 to 2.33)	0.39	1.05 (0.35 to 3.17)	0.94
Upper Extremities (n= 1,843)							
Nonusers	25.81	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	36.91	0.84 (0.62 to 1.15)	0.27	0.94 (0.64 to 1.36)	0.72	0.86 (0.62 to 1.19)	0.36
Lipid-lowering drugs other than statins	32.53	0.64 (0.22 to 1.85)	0.40	0.52 (0.17 to 1.53)	0.23	0.71 (0.31 to 1.61)	0.42
Lower Back (n= 1,843)							

Nonusers	14.52	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	13.15	0.66 (0.46 to 0.94)	0.02	0.75 (0.46 to 1.22)	0.23	0.77 (0.51 to 1.18)	0.23
Lipid-lowering drugs other than statins	12.89	0.54 (0.16 to 1.76)	0.30	0.57 (0.16 to 2.05)	0.38	0.71 (0.25 to 2.00)	0.52
Lower Extremities (n= 1,843)							
Nonusers	15.33	1.00(Ref.)		1.00(Ref.)		1.00(Ref.)	
Statin users	23.06	0.89 (0.61 to 1.30)	0.53	1.05 (0.66 to 1.67)	0.83	0.90 (0.61 to 1.34)	0.61
Lipid-lowering drugs other than statins	20.80	0.67 (0.22 to 2.01)	0.46	0.61 (0.20 to 1.84)	0.37	0.52 (0.18 to 1.48)	0.22

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S9 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with cardiovascular disease

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 1,641)							
Nonusers	33.76	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	40.61	1.02 (0.71 to 1.45)	0.92	1.57 (0.94 to 2.61)	0.09	1.29 (0.85 to 1.97)	0.23
Lipid-lowering drugs other than statins	45.97	1.05 (0.51 to 2.18)	0.90	1.11 (0.40 to 3.05)	0.84	1.20 (0.43 to 3.38)	0.73
ASM/Wt (n= 1,671)							
Nonusers	15.67	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	15.92	1.34 (1.04 to 1.73)	0.03	0.88 (0.63 to 1.23)	0.45	0.96 (0.72 to 1.28)	0.76
Lipid-lowering drugs other than statins	16.32	1.67 (0.78 to 3.56)	0.18	0.72 (0.32 to 1.62)	0.43	0.81 (0.40 to 1.66)	0.57
ASM/Ht ² (n= 1,676)							
Nonusers	10.92	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.51	0.76 (0.49 to 1.17)	0.21	0.46 (0.27 to 0.8)	0.01	0.55 (0.32 to 0.93)	0.03
Lipid-lowering drugs other than statins	6.61	0.58 (0.24 to 1.41)	0.22	0.50 (0.19 to 1.37)	0.18	0.61 (0.16 to 2.31)	0.47
Max HGS* (n= 996)							
Nonusers	—	Ref.		Ref.		Ref.	

Statin users		-0.14 (-2.01 to 1.73)	0.88	-0.59 (-1.83 to 0.65)	0.34	-0.50 (-1.76 to 0.75)	0.43
Lipid-lowering drugs other than statins		-6.13 (-9.45 to -2.82)	< 0.001	-3.86 (-6.95 to -0.77)	0.02	-3.43 (-7.85 to 1.00)	0.13
Relative HGS* (n= 947)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.09 (-0.23 to 0.05)	0.21	-0.03 (-0.14 to 0.08)	0.54	-0.07 (-0.16 to 0.02)	0.12
Lipid-lowering drugs other than statins		-0.60 (-0.86 to -0.34)	< 0.001	-0.13 (-0.36 to 0.11)	0.29	-0.47 (-0.79 to -0.15)	< 0.001
Combined HGS* (n= 968)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.27 (-4.14 to 3.59)	0.89	-0.86 (-3.41 to 1.7)	0.50	-1.18 (-3.50 to 1.14)	0.32
Lipid-lowering drugs other than statins		-9.71 (-16.59 to -2.82)	0.01	-4.87 (-9.87 to 0.13)	0.06	-11.85 (-20.39 to -3.32)	0.01
Sarcopenic Obesity							
ASM/Ht2 and Body Fat Percent Definition (n= 1,643)							
Nonusers	10.14	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	7.14	1.02 (0.72 to 1.46)	0.90	1.58 (0.95 to 2.66)	0.08	1.52 (1.00 to 2.30)	0.05
Lipid-lowering drugs other than statins	6.61	1.06 (0.51 to 2.20)	0.87	1.12 (0.40 to 3.09)	0.83	1.47 (0.52 to 4.15)	0.46
ASM and BMI definition (n= 4,725)							
Nonusers	49.18	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	44.73	0.59 (0.27 to 1.27)	0.18	1.05 (0.47 to 2.34)	0.91	1.41 (0.67 to 2.96)	0.36

Lipid-lowering drugs other than statins	36.72	0.46 (0.06 to 3.50)	0.45	0.47 (0.06 to 3.92)	0.49	1.05 (0.13 to 8.72)	0.96
LDH* (n= 5,340)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		1.11 (-1.48 to 3.71)	0.40	0.39 (-2.22 to 2.99)	0.77	-0.75 (-3.27 to 1.78)	0.56
Lipid-lowering drugs other than statins		-0.06 (-5.38 to 5.25)	0.98	-1.58 (-7.05 to 3.89)	0.57	1.90 (-5.21 to 9.01)	0.60
Musculoskeletal Pain Symptoms							
Any Region (n= 1,158)							
Nonusers	49.18	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	44.73	0.84 (0.63 to 1.11)	0.21	0.88 (0.64 to 1.21)	0.43	0.82 (0.60 to 1.11)	0.20
Lipid-lowering drugs other than statins	36.72	0.60 (0.24 to 1.49)	0.26	0.37 (0.13 to 1.05)	0.06	0.53 (0.24 to 1.16)	0.11
Neck/Upper Back (n= 1,158)							
Nonusers	16.46	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	9.68	0.54 (0.36 to 0.82)	0.01	0.77 (0.46 to 1.27)	0.29	0.71 (0.42 to 1.20)	0.20
Lipid-lowering drugs other than statins	14.29	0.85 (0.30 to 2.37)	0.74	0.53 (0.12 to 2.33)	0.39	1.05 (0.35 to 3.17)	0.94
Upper Extremities (n= 1,158)							
Nonusers	34.93	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	31.13	0.84 (0.62 to 1.15)	0.27	0.94 (0.64 to 1.36)	0.72	0.86 (0.62 to 1.19)	0.36
Lipid-lowering drugs other than statins	25.48	0.64 (0.22 to 1.85)	0.40	0.52 (0.17 to 1.53)	0.23	0.71 (0.31 to 1.61)	0.42
Lower Back (n= 1,158)							

Nonusers	20.31	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	14.39	0.66 (0.46 to 0.94)	0.02	0.75 (0.46 to 1.22)	0.23	0.77 (0.51 to 1.18)	0.23
Lipid-lowering drugs other than statins	12.07	0.54 (0.16 to 1.76)	0.30	0.57 (0.16 to 2.05)	0.38	0.71 (0.25 to 2.00)	0.52
Lower Extremities (n= 1,158)							
Nonusers	23.02	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	21	0.89 (0.61 to 1.30)	0.53	1.05 (0.66 to 1.67)	0.83	0.90 (0.61 to 1.34)	0.61
Lipid-lowering drugs other than statins	16.71	0.67 (0.22 to 2.01)	0.46	0.61 (0.20 to 1.84)	0.37	0.52 (0.18 to 1.48)	0.22

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin

Table S10 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes compared with nonusers among participants with hyperlipidemia

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 6,627)							
Nonusers	18.39	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	32.33	1.43 (1.19 to 1.72)	< 0.001	1.15 (0.85 to 1.56)	0.37	1.13 (0.88 to 1.45)	0.36
Lipid-lowering drugs other than statins	35.10	1.58 (0.90 to 2.79)	0.11	1.08 (0.51 to 2.28)	0.85	1.26 (0.72 to 2.20)	0.42
ASM/Wt (n= 6,638)							
Nonusers	10.11	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.90	2.12 (1.83 to 2.46)	< 0.001	1.20 (0.94 to 1.54)	0.15	1.08 (0.89 to 1.31)	0.45
Lipid-lowering drugs other than statins	15.12	2.40 (1.57 to 3.68)	< 0.001	0.98 (0.54 to 1.79)	0.95	0.88 (0.57 to 1.36)	0.58
ASM/Ht2 (n= 6,640)							
Nonusers	5.10	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	6.26	1.24 (0.97 to 1.60)	0.09	1.21 (0.83 to 1.77)	0.31	0.96 (0.68 to 1.37)	0.83
Lipid-lowering drugs other than statins	4.16	0.81 (0.42 to 1.55)	0.51	1.19 (0.41 to 3.47)	0.75	1.30 (0.59 to 2.88)	0.52
Max HGS* (n= 3,407)							
Nonusers	—	Ref.		Ref.		Ref.	

Statin users		-3.38 (-4.40 to -2.36)	< 0.001	-0.10 (-1.02 to 0.83)	0.83	0.10 (-0.50 to 0.70)	0.75
Lipid-lowering drugs other than statins		-3.93 (-6.21 to -1.65)	< 0.001	-2.04 (-4.21 to 0.12)	0.06	-0.81 (-2.37 to 0.75)	0.31
Relative HGS* (n= 3,329)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.29 (-0.37 to -0.21)	< 0.001	-0.01 (-0.08 to 0.06)	0.76	0.01 (-0.03 to 0.05)	0.56
Lipid-lowering drugs other than statins		-0.37 (-0.54 to -0.21)	< 0.001	-0.11 (-0.25 to 0.04)	0.13	-0.07 (-0.18 to 0.03)	0.17
Combined HGS* (n= 3,362)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-6.46 (-8.59 to -4.34)	< 0.001	0.03 (-1.84 to 1.90)	0.98	0.43 (-0.69 to 1.54)	0.45
Lipid-lowering drugs other than statins		-6.93 (-11.24 to -2.63)	< 0.001	-2.59 (-6.43 to 1.24)	0.18	-1.81 (-4.69 to 1.06)	0.22
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n= 6,627)							
Nonusers	4.75	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	5.97	1.44 (1.20 to 1.73)	< 0.001	1.17 (0.86 to 1.58)	0.32	1.13 (0.88 to 1.45)	0.35
Lipid-lowering drugs other than statins	4.16	1.60 (0.91 to 2.81)	0.11	1.09 (0.51 to 2.31)	0.82	1.24 (0.71 to 2.16)	0.45
ASM and BMI definition (n= 14,406)							
Nonusers	9.50	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	

Statin users	9.30	0.98 (0.58 to 1.64)	0.93	0.93 (0.48 to 1.78)	0.82	1.02 (0.64 to 1.63)	0.94
Lipid-lowering drugs other than statins	3.60	0.38 (0.09 to 1.51)	0.17	0.43 (0.10 to 1.86)	0.25	0.78 (0.23 to 2.64)	0.69
LDH* (n= 16,274)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		3.27 (2.00 to 4.54)	< 0.001	-0.36 (-1.80 to 1.08)	0.62	-0.17 (-1.48 to 1.15)	0.80
Lipid-lowering drugs other than statins		1.37 (-2.32 to 5.06)	0.47	-1.04 (-5.00 to 2.92)	0.6	0.85 (-2.31 to 4.01)	0.60
Musculoskeletal Pain Symptoms							
Any Region (n= 3,741)							
Nonusers	39.06	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	43.01	1.18 (0.98 to 1.42)	0.09	1.15 (0.87 to 1.52)	0.30	1.11 (0.89 to 1.38)	0.35
Lipid-lowering drugs other than statins	39.83	1.03 (0.63 to 1.71)	0.90	1.20 (0.64 to 2.25)	0.57	1.13 (0.70 to 1.81)	0.61
Neck/Upper Back (n= 3,741)							
Nonusers	10.95	1.00 (Ref.)				1.00 (Ref.)	
Statin users	8.39	0.74 (0.54 to 1.03)	0.08	1.03 (0.65 to 1.62)	0.89	1.05 (0.70 to 1.56)	0.83
Lipid-lowering drugs other than statins	15.59	1.50 (0.80 to 2.84)	0.20	2.57 (1.18 to 5.57)	0.02	2.62 (1.36 to 5.08)	< 0.001
Upper Extremities (n= 3,741)							
Nonusers	26.92	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	

Statin users	29.46	1.13 (0.92 to 1.39)	0.23	1.10 (0.82 to 1.47)	0.53	1.11 (0.88 to 1.41)	0.39
Lipid-lowering drugs other than statins	28.95	1.11 (0.67 to 1.83)	0.69	1.27 (0.71 to 2.27)	0.41	1.26 (0.77 to 2.07)	0.36
Lower Back (n= 3,741)							
Nonusers	11.73	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.19	1.14 (0.88 to 1.48)	0.30	1.15 (0.80 to 1.66)	0.43	1.22 (0.87 to 1.71)	0.24
Lipid-lowering drugs other than statins	5.19	0.41 (0.17 to 1.03)	0.06	0.50 (0.18 to 1.44)	0.19	0.76 (0.35 to 1.68)	0.50
Lower Extremities (n= 3,741)							
Nonusers	15.10	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	18.17	1.25 (0.99 to 1.57)	0.06	1.14 (0.78 to 1.66)	0.50	1.14 (0.84 to 1.55)	0.41
Lipid-lowering drugs other than statins	15.29	1.01 (0.56 to 1.84)	0.96	1.06 (0.51 to 2.19)	0.88	1.03 (0.53 to 1.99)	0.93

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are <29.76% in men or <22.31% in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.

Table S11 The association between statin users or lipid-lowering users and skeletal muscle-related phenotypes

	Prevalence, %	Crude		Adjusted		After matching**	
		OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>
Sarcopenic							
ASM/BMI (n= 10,412)							
Nonusers	19.08	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	35.88	1.78 (1.44 to 2.19)	< 0.001	1.33 (0.97 to 1.82)	0.08	1.25 (0.99 to 1.59)	0.06
Lipid-lowering drugs other than statins	38.03	1.81 (1.01 to 3.23)	0.05	1.11 (0.55 to 2.26)	0.77	1.52 (0.85 to 2.71)	0.16
ASM/Wt (n= 10,459)							
Nonusers	8.30	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.84	2.37 (2.04 to 2.76)	< 0.001	1.24 (0.97 to 1.58)	0.09	1.22 (1.02 to 1.47)	0.03
Lipid-lowering drugs other than statins	14.07	2.60 (1.67 to 4.06)	< 0.001	0.96 (0.54 to 1.71)	0.89	1.06 (0.68 to 1.65)	0.79
ASM/Ht2 (n= 10,474)							
Nonusers	5.92	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	

Statin users	7.20	1.23 (0.94 to 1.62)	0.13	1.19 (0.80 to 1.75)	0.38	0.94 (0.66 to 1.33)	0.72
Lipid-lowering drugs other than statins	5.31	0.89 (0.50 to 1.58)	0.69	0.78 (0.32 to 1.88)	0.58	1.29 (0.56 to 2.99)	0.55
Max HGS* (n= 4,526)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-4.53 (-5.43 to -3.63)	< 0.001	-0.61 (-1.19 to -0.04)	0.04	-0.45 (-1.04 to 0.14)	0.14
Lipid-lowering drugs other than statins		-5.78 (-8.22 to -3.33)	< 0.001	-2.20 (-4.08 to -0.31)	0.02	-1.17 (-2.88 to 0.54)	0.18
Relative HGS* (n= 4,410)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-0.39 (-0.46 to -0.32)	< 0.001	-0.03 (-0.07 to 0.02)	0.24	-0.03 (-0.07 to 0.01)	0.15
Lipid-lowering drugs other than statins		-0.64 (-0.8 to -0.48)	< 0.001	-0.1 (-0.24 to 0.04)	0.15	-0.09 (-0.21 to 0.03)	0.13
Combined HGS* (n= 4,461)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		-8.91 (-10.66 to -7.17)	< 0.001	-1.29 (-2.44 to -0.14)	0.03	-1.06 (-2.17 to 0.05)	0.06

Lipid-lowering drugs other than statins		-11.34 (-15.92 to -6.76)	< 0.001	-4.02 (-7.06 to -0.99)	0.01	-2.33 (-5.47 to 0.81)	0.15
Sarcopenic Obesity							
ASM/Ht ² and Body Fat Percent Definition (n=10,415)							
Nonusers	5.08	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	6.77	1.78 (1.44 to 2.20)	< 0.001	1.33 (0.97 to 1.83)	0.07	1.23 (0.96 to 1.57)	0.10
Lipid-lowering drugs other than statins	4.28	1.82 (1.02 to 3.24)	0.04	1.12 (0.55 to 2.27)	0.76	1.51 (0.83 to 2.73)	0.18
ASM and BMI definition (n= 21,553)							
Nonusers	7.90	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.50	1.09 (0.62 to 1.90)	0.77	1.18 (0.58 to 2.41)	0.64	0.85 (0.53 to 1.34)	0.47
Lipid-lowering drugs other than statins	5.00	0.63 (0.17 to 2.33)	0.49	0.56 (0.13 to 2.49)	0.45	0.86 (0.26 to 2.90)	0.81
LDH* (n= 24,501)	—						
Nonusers		Ref.		Ref.		Ref.	
Statin users		4.64 (3.36 to 5.93)	< 0.001	-0.73 (-2.10 to 0.64)	0.30	-0.28 (-1.79 to 1.22)	0.71

Lipid-lowering drugs other than statins		4.01 (0.18 to 7.84)	0.04	-1.44 (-5.43 to 2.55)	0.48	-0.62 (-4.69 to 3.46)	0.77
Musculoskeletal Pain Symptoms							
Any Region (n= 6,226)							
Nonusers	33.04	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	44.40	1.62 (1.33 to 1.97)	< 0.001	1.22 (0.96 to 1.54)	0.11	1.10 (0.89 to 1.35)	0.38
Lipid-lowering drugs other than statins	37.35	1.21 (0.71 to 2.05)	0.48	0.88 (0.44 to 1.77)	0.72	0.93 (0.57 to 1.52)	0.77
Neck/Upper Back (n= 6,226)							
Nonusers	9.02	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	8.40	0.93 (0.75 to 1.15)	0.47	0.94 (0.66 to 1.34)	0.73	0.89 (0.61 to 1.30)	0.54
Lipid-lowering drugs other than statins	14.41	1.70 (0.90 to 3.19)	0.10	1.57 (0.68 to 3.60)	0.28	1.82 (0.90 to 3.65)	0.09
Upper Extremities (n= 6,226)							
Nonusers	21.49	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	30.08	1.57 (1.26 to 1.96)	< 0.001	1.14 (0.83 to 1.59)	0.40	1.14 (0.91 to 1.43)	0.25
Lipid-lowering drugs other than statins	27.77	1.40 (0.77 to 2.55)	0.26	1.15 (0.57 to 2.30)	0.69	1.25 (0.75 to 2.09)	0.39
Lower Back (n= 6,226)							

Nonusers	11.22	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	13.20	1.20 (0.93 to 1.55)	0.15	1.05 (0.75 to 1.47)	0.76	1.10 (0.80 to 1.51)	0.54
Lipid-lowering drugs other than statins	10.26	0.90 (0.41 to 2.00)	0.80	0.66 (0.26 to 1.69)	0.38	0.75 (0.34 to 1.65)	0.48
Lower Extremities (n= 6,226)							
Nonusers	12.79	1.00 (Ref.)		1.00 (Ref.)		1.00 (Ref.)	
Statin users	18.98	1.60 (1.25 to 2.04)	< 0.001	1.22 (0.89 to 1.68)	0.20	1.07 (0.80 to 1.42)	0.65
Lipid-lowering drugs other than statins	19.74	1.68 (0.87 to 3.22)	0.12	1.14 (0.51 to 2.53)	0.74	1.05 (0.55 to 2.03)	0.88

Abbreviations: OR, odds ratio; CI, confidence interval; ASM, appendicular skeletal muscle mass; Wt, weight; Ht, height; HGS, Hand grip strength; LDH, Lactate Dehydrogenase;

We considered two-sided p-values less than 0.05 as statistically significant.

Adjusted model: adjustment for age (continuous), sex(Female, Male), race/ ethnicity (Hispanic-Mexican, Other Ethnicity, Non-Hispanic White, Non-Hispanic Black), and education level (Less than high school, High school, More than high school), marital status (Married, Never married, other), poverty income ratio (<1.3, 1.3-3.5, >3.5), body mass index (18.5-25 kg/m², 25-30 kg/m², ≥30 kg/m²), alcohols statues (=0 g/d, <5 g/d, 5-30 g/d, ≥30 g/d), smoking status (Never smoking, Former smoker, Current smoker), physical activity (Yes, No), hypertension(Yes, No), cardiovascular diseases(Yes, No), diabetes(Yes, No), hyperlipidemia(Yes, No), chronic kidney disease(Yes, No), chronic obstructive pulmonary disease, cancer (Yes, No).

ASM/BMI cutoffs are <0.789 in men and <0.512 in females

ASM/Ht² cutoffs are <7 kg/m² in men or <5.5 kg/m² in women

ASM/Wt cutoffs are $<29.76\%$ in men or $<22.31\%$ in women

*The variables are continuous, and the results are presented as beta coefficients and a 95% confidence interval.

**Propensity score matching with 1: 1 ratio for use or nonuse of statin.